

AD-A263 193



MENTATION PAGE

Form Approved

OMB No. 0704-0188

②

is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Avenue, Suite 1204, Washington, DC 20540.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 15 MAY 1993		3. REPORT TYPE AND DATES COVERED	
4. TITLE AND SUBTITLE THALLIUM TOXICITY: THE PROBLEM; AN ANALYTICAL APPROACH; AN ANTIDOTAL STUDY				5. FUNDING NUMBERS	
6. AUTHOR(S) CPT JAMES P. MULKEY					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) COMPARATIVE TOXICOLOGY LABORATORIES COLLEGE OF VETERINARY MEDICINE KANSAS STATE UNIVERSITY MANHATTAN, KS 66506				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) COMMANDER, US ARMY STUDENT DETACHMENT ATTN: ATZI-TBD FT BENJAMIN HARRISON, IN 46216-5820				10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION/AVAILABILITY STATEMENT <div style="border: 1px solid black; padding: 5px; text-align: center;"> DISTRIBUTION STATEMENT A Approved for public release Distribution Unlimited </div>				12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) Thallium (Tl) is a highly toxic metal that is anthropogenically concentrated in the environment. Tl toxicity and the quantitative analysis of trace levels of Tl in biologic materials by atomic absorption spectroscopy is reviewed; a study designed to evaluate the antidotal efficacy of 2 compounds in the treatment of acute Tl toxicity in rats is documented. Unithiol (2,3-dimercapto-1-propanesulfonic acid, DMPS) and prussian blue (potassium ferric hexacyanoferrate(II), PB), given alone and in combination, were evaluated as antidotes in the treatment of acute thallotoxicosis in male Sprague-Dawley rats. The relative accumulation of Tl in organs was kidney>>heart>liver=brain. PB induced significant decorporation of Tl from all tissues. DMPS failed to significantly decrease the Tl content in any organ, but significantly decreased the Tl content in whole blood. PB+DMPS treatment significantly decreased the Tl content in all organs, but to no greater extent than PB alone. PB and PB+DMPS treatments significantly increased the Tl content of feces, whereas DMPS treatment alone produced little					
14. SUBJECT TERMS Thallium; poison; antidote; chelator; prussian blue; potassium ferric hexacyanoferrate(II); Unithiol; 2,3-dimercapto-1-propanesulfonic acid; rat.				15. NUMBER OF PAGES	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT UNCLASSIFIED	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT		

13. ABSTRACT (CONCLUDED)

effect. This study indicates that PB is a beneficial antidote in the treatment of acute thallotoxicosis in rats. The failure of DMPS to significantly decrease the Tl content in 4 target organs suggests it would not be useful in the treatment of Tl poisoning.

Accession For	
NTIS CR&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

DTIC QUALITY INSPECTED 4

93 4 21 055

253
93-08607



253P8

**THALLIUM TOXICITY:
THE PROBLEM; AN ANALYTICAL APPROACH; AN ANTIDOTAL STUDY**

by

JAMES PATRICK MULKEY

BS, Eastern New Mexico University, 1979

A THESIS

submitted in partial fulfillment of the

requirements for the degree

MASTER OF SCIENCE

Department of Clinical Sciences
College of Veterinary Medicine

**KANSAS STATE UNIVERSITY
Manhattan, KS**

1993

Approved by: *F. H. O'Brien*

Major Professor

ABSTRACT

Thallium (Tl) is a highly toxic metal that is anthropogenically concentrated in the environment. Chapter 1 and 2 review Tl toxicity and the quantitative analysis of trace levels of Tl in biologic materials by atomic absorption spectroscopy (AAS). Chapter 3 documents a study designed to evaluate the antidotal efficacy of 2 compounds in the treatment of acute Tl toxicity in rats. The treatment objective in Tl poisoning is to enhance the metal's elimination from the body without promoting redistribution to target organs, particularly the brain. The therapeutic efficacy of many heavy-metal chelators have been investigated for Tl poisoning; all have some limiting feature. Unithiol (2,3-dimercapto-1-propanesulfonic acid, DMPS) and prussian blue (potassium ferric hexacyanoferrate (II), PB), given alone and in combination, were evaluated as antidotes in the treatment of acute thallotoxicosis in male Sprague-Dawley rats. Animals were poisoned with equivalent doses of 20 mg Tl/kg BW po on day 0, using thallous sulfate. On day 1 (24 h later), antidotal treatments began and were continued through day 4 as follows: 50 mg PB/kg BW po, 2/d; 5 mg DMPS/kg BW ip, 6/d (day 1), 4/d (day 2), 2/d (days 3-4); or their combination. Animals were sacrificed by ip injection of sodium phenobarbital 24 h after the last antidotal treatment (day 5) and tissue samples collected. Thallium concentrations in kidney, liver, heart, brain, whole blood and feces were determined by electrothermal

atomic absorption spectroscopy. The relative accumulation of Tl in organs was kidney>>heart>liver=brain. PB induced significant decorporation of Tl from all tissues. DMPS failed to significantly decrease the Tl content in any organ, but significantly decreased the Tl content in whole blood. PB+DMPS treatment significantly decreased the Tl content in all organs, but to no greater extent than PB alone. PB and PB+DMPS treatments significantly increased the Tl content of feces, whereas DMPS treatment alone produced little effect. This study indicates that PB is a beneficial antidote in the treatment of acute thallotoxicosis in rats. The failure of DMPS to significantly decrease the Tl content in 4 target organs suggests it would not be useful in the treatment of Tl poisoning.

TABLE OF CONTENTS

	PAGE
ACKNOWLEDGEMENTS	vii
INTRODUCTION	viii
 CHAPTER 1. A REVIEW OF THALLIUM TOXICITY	 1
ABSTRACT	2
KEYWORDS	3
CHEMISTRY	4
OCCURRENCE AND DISTRIBUTION	6
PRODUCTION AND USES	7
ABSORPTION, DISTRIBUTION, EXCRETION	8
MOLECULAR BASIS OF THALLIUM TOXICITY	10
ALTERATIONS OF K-DEPENDENT SYSTEMS	10
THALLIUM-SULFHYDRYL GROUP INTERACTIONS	12
OTHER MECHANISMS OF ACTION	13
CLINICAL TOXICOLOGY	16
GASTROINTESTINAL TRACT	17
NERVOUS SYSTEM	17
EYE	18
SKIN	18
HEART	19
KIDNEYS	20
REPRODUCTIVE SYSTEM	20
TERATOGENICITY AND CARCINOGENICITY	21
LABORATORY EVALUATIONS	21

TABLE OF CONTENTS

	PAGE
DIAGNOSIS	22
TREATMENT	24
PROGNOSIS	27
CONCLUSIONS	28
REFERENCES	30
 CHAPTER 2. QUANTITATIVE ANALYSIS OF TRACE LEVELS OF THALLIUM IN BIOLOGIC MATERIALS BY ATOMIC ABSORPTION SPECTROSCOPY	 46
ABSTRACT	47
KEYWORDS	48
THALLIUM	49
NORMAL LEVELS	49
PRODUCTION AND USES	49
ABSORPTION, DISTRIBUTION, EXCRETION	51
TOXICITY	52
ATOMIC ABSORPTION SPECTROSCOPY (AAS)	53
PRINCIPLES AND INSTRUMENTATION	53
FLAME AAS	56
GRAPHITE FURNACE AAS (ELECTROTHERMAL AAS) ...	57
BACKGROUND INTERFERENCE	58
SAMPLE PREPARATION	58
DESTRUCTION OF ORGANIC MATTER	59
SEPARATION AND PRECONCENTRATION	62
STANDARDIZATION	63

TABLE OF CONTENTS

	PAGE
DETERMINATION OF THALLIUM IN BIOLOGIC MATERIALS BY ATOMIC ABSORPTION SPECTROSCOPY	66
FLAME AAS METHODS	67
GRAPHITE FURNACE AAS METHODS	70
CONCLUSIONS	74
REFERENCES	76
 CHAPTER 3. A STUDY OF THE ANTIDOTAL EFFICACY OF 2,3- DIMERCAPTO-1-PROPANESULFONIC ACID AND PRUSSIAN BLUE IN THE TREATMENT OF ACUTE THALLOTOXICOSIS IN RATS	 104
ABSTRACT	105
KEYWORDS	107
INTRODUCTION	108
MATERIALS AND METHODS	112
PROTOCOL	112
SAMPLE COLLECTION	113
THALLIUM ANALYSIS	114
STATISTICAL ANALYSIS	116
RESULTS	117
ORGAN WEIGHT/BODY WEIGHT RATIOS	117
THALLIUM CONTENT - BODY ORGANS	118
THALLIUM CONTENT - BLOOD AND FECES	118
DISCUSSION	119
REFERENCES	123

TABLE OF CONTENTS

	PAGE
APPENDIX A. INDIVIDUAL ANIMAL DATA TABLES	138
WHOLE BODY WEIGHT	139
WEIGHT GAIN	142
ORGAN WEIGHT	145
ORGAN WEIGHT/BODY WEIGHT RATIO	149
THALLIUM CONTENT OF ORGANS, BLOOD AND FECES	153
CLINICAL OBSERVATIONS	156
APPENDIX B. THALLIUM DETERMINATION WORKSHEETS	158
KIDNEY	159
LIVER	172
HEART	185
BRAIN	198
BLOOD	211
FECES	224

LIST OF FIGURES

FIGURE		PAGE
	CHAPTER 1	NONE
	CHAPTER 2	
1	PRINCIPLE OF ATOMIC ABSORPTION SPECTROSCOPY (AAS)	87
2	BASIC FLAME AAS COMPONENTS	88
3	OPTICAL PATHS: SINGLE-BEAM AND DOUBLE-BEAM AAS ...	89
4	PERKIN-ELMER AS-3 AUTOSAMPLER	90
5	PRE-MIX BURNER SCHEMATIC	91
6	PULSE-NEBULIZATION TECHNIQUE	92
7	GRAPHITE FURNACE TUBE WITH L'vov PLATFORM	93
8	CROSS SECTION OF PERKIN-ELMER GRAPHITE FURNACE ...	94
9	BACKGROUND CORRECTION SYSTEM	95
10	LIQUID:LIQUID EXTRACTION OF METAL-LIGAND COMPLEX .	96
11	BATCH EXTRACTION APPARATUS	97
12	AAS CALIBRATION CURVE	98
13	LINEAR RANGE OF AAS CALIBRATION CURVE	99
14	STANDARD ADDITION METHOD CALIBRATION CURVE	100
	CHAPTER 3	
1	BODY WEIGHT AND WEIGHT GAIN	131
2	SURVIVAL RATE	132
3	ORGAN WEIGHT/BODY WEIGHT RATIO	133
4	ORGAN THALLIUM CONCENTRATIONS	134
5	BLOOD AND FECES THALLIUM CONCENTRATIONS	135

LIST OF TABLES

TABLE		PAGE
CHAPTER 1		
1	TOXICITY OF THALLIUM SALTS	44
2	PHYSICAL PROPERTIES OF THALLIUM	45
CHAPTER 2		
1	THALLIUM CONTENT OF CRUSTAL MATERIAL	84
2	ACUTE THALLOTOXICOSIS SYMPTOMS	85
3	SUBACUTE AND CHRONIC THALLOTOXICOSIS SYMPTOMS	86
CHAPTER 3		
1	ANTIDOTAL TREATMENT SCHEDULE	130

ACKNOWLEDGEMENTS

I wish to thank Dr Fred Oehme, whose support, guidance and encouragement made the accomplishment of this work possible. I would also like to thank my other committee members, Drs John Pickrell and Charles Hedgcoth, for their advice and support.

Several individuals should be recognized for their advice and assistance. Sandy Hickman introduced me to AAS and Dr Gary Griffith kept the instrument operational. It was my privilege and good fortune to share an office with Dr Assim Abdel-Mageed. His advice and assistance extended beyond the research project to every facet of graduate education at KSU.

Acknowledgement is due the US Army for granting me a two year sabbatical from regular officer duties so I could earn a masters degree.

I owe a special debt of gratitude to my wife and son, Debbie and Dale, for their patience and understanding during this endeavor. Often, all they saw of their husband and father was his backside -- either hunched over a book or silhouetted by a computer monitor. Their love, affection, and support were a constant source of inspiration to me.

INTRODUCTION

Thallium is a highly toxic metal normally present at trace levels in the environment except when concentrated by human activities. Chapter 1 explores the problem of Tl poisoning in animals and humans. The chemistry relevant to Tl toxicity is presented. The metal's occurrence and distribution and its production and uses are briefly introduced, followed by a discussion of its absorption, distribution and excretion in mammals. The molecular basis of Tl toxicity is reviewed to provide a biochemical and physiological basis for understanding the clinical manifestations of Tl poisoning. A review of the metal's clinical toxicology follows, with emphasis placed on the major effects caused by acute Tl toxicity. Thallotoxicosis often is a diagnostic challenge; clinical clues and laboratory tests useful in diagnosis of Tl poisoning are presented. The management of thallotoxicosis is discussed and treatment options and considerations are presented.

The analytical challenge in toxic-metal antidote studies is the accurate quantification of trace levels of the offending metal in complex biologic matrices (ie, organs, blood, feces, etc). Atomic absorption spectroscopy (AAS) fills this need. Since its introduction by Walsh more than 30 years ago, AAS has matured to become the dominant analytical method for trace level metal analysis in the clinical laboratory.

Chapter 2 discusses the basic principles and instrumentation of AAS. Sample preparation techniques are discussed; destruction of organic matter and liquid-liquid separations are emphasized. The application of flame and graphite furnace (electrothermal) AAS to the determination of Tl in biologic materials is reviewed.

Chapter 3 details my research project, which involved the evaluation of the antidotal efficacy of 2 compounds in the treatment of acute Tl toxicity in rats. The treatment objective in Tl poisoning is to enhance the metal's elimination from the body without promoting redistribution to target organs, particularly the brain. To this end, the therapeutic efficacy of different metal chelators has been investigated in the attempt to find an effective antidote for thallotoxicosis. To date, no chelator has proven to be totally satisfactory.

A metal chelator, Unithiol (2,3-dimercapto-1-propanesulfonic acid, DMPS), and an inorganic dye, prussian blue (potassium ferric hexacyanoferrate(II), PB), given alone and in combination, were evaluated as antidotes in the treatment of acute thallotoxicosis in male Sprague-Dawley rats. Thallium concentrations in kidney, liver, heart, whole blood and feces were determined by electrothermal AAS. This study indicates that PB is a beneficial antidote in the treatment of acute thallotoxicosis in rats. The failure of DMPS to significantly decrease the Tl content in 4 target organs

suggests it would not be useful in the treatment of thallosis.

CHAPTER 1

A REVIEW OF THALLIUM TOXICITY

JP Mulkey and FW Oehme
Comparative Toxicology Laboratories
Kansas State University
Manhattan, KS 66506
(913) 532-4334

(Vet Hum Toxicol, in press)

ABSTRACT

Thallium (Tl) is one of the most toxic of the heavy metals. Its continued use as a rodenticide in many developing countries and its increasing use in an expanding number of new technologies raise concerns about exposure risk to animals and humans. Because Tl and potassium (K) have the same charge and similar ionic radii, Tl follows K distribution pathways and alters a number of K-dependent processes. Possible toxic mechanisms of Tl include ligand formation with protein sulfhydryl groups, inhibition of cellular respiration, interaction with riboflavin and riboflavin-based cofactors, and disruption of calcium homeostasis. The principal clinical features of thallotoxicosis are gastroenteritis, peripheral neuropathy of unknown etiology, and alopecia. The presence of elevated Tl levels in the urine or other biologic materials confirms the diagnosis of Tl poisoning. Treatment with prussian blue (or activated charcoal) will interrupt the enterohepatic cycling of Tl, thus enhancing fecal elimination of the metal. Forced diuresis with potassium loading will increase the renal clearance of Tl, but should be used cautiously because neurologic and cardiovascular symptom may be exacerbated. If recognized and treated early, Tl poisoning carries a favorable prognosis for full recovery.

KEYWORDS: Thallium; poison; treatment; chelator; prussian blue; ferric hexacyanoferrate(II); neuropathy; alopecia.

The toxicity of thallium (Tl) has been known almost since its discovery by Crookes in 1861. While spectroscopically examining the flue dust from a sulfuric acid production plant for tellurium, he noted an unexpected bright green line in the emission spectrum. Crookes attributed the line to a new element which he named "thallium", from the Latin *thallos*, meaning young twig or shoot (1). The following year, Lamy, a contemporary of Crookes, experienced lassitude and weakness while working to isolate the metal. Suspecting Tl to be toxic, he gave thallium sulfate (Tl_2SO_4) to dogs, ducks and hens, all of whom died within a few days (2). Today Tl is recognized as one of the most toxic of the heavy metals (LD_{50} 8-12 mg/kg, man; LD_{50} 30 mg/kg, rats) (3,4). The lethality of Tl salts are listed in Table 1.

CHEMISTRY

Freshly-prepared Tl has metallic luster that soon develops a bluish-grey tinge when exposed to air, the result of oxide build-up on its exposed surface. In the presence of water, the hydroxide is formed. Metallic Tl is soft and malleable, similar to lead in both appearance and physical properties. Some of the element's physical constants are listed in Table 2.

Thallium is located between mercury and lead in the periodic table and is classified along with boron (non-metal),

aluminum, gallium, and indium as a Group IIIA element. The metals of this group are electropositive; as their atomic weights increase, so does their basic character. The monovalent Tl cation (Tl^+) is considered a soft acid (as are cadmium [Cd^{2+}], methylmercury [CH_3Hg^+] and [Hg^{2+}]). Under the Pearson classification of hard and soft acids and bases, hard metals favor interactions with hard bases, and soft metals favor interactions with soft bases (5). Since Tl^+ is considered to be a soft acid, it tends to form stable complexes with soft ligand donors such as sulfur-containing compounds (6).

Salts of the Group IIIA metals are water soluble, but readily hydrolyze at $pH \geq 7$ to form insoluble hydroxides, except for Tl salts (7). Indeed, the high solubility of Tl salts (ie, Tl sulfate, nitrate and acetate) is an important physical property contributing to their marked toxicity in animals and humans.

The electron configuration of Tl is $[Xe]4f^{14}5d^{10}6s^26p$. Its s electrons show a low propensity to be released or covalently bound, so the metal occurs predominantly in the monovalent form. The oxidation potential of the reaction $Tl^+ + 2e^- \rightarrow Tl^{3+}$ is +1.25 V; for $Tl^+ + e^- \rightarrow Tl^0$ it is -0.34 V (8).

Thallium and the alkali metals (potassium [K] and cesium) possess similar ionic radii and electronegativity constants. These properties and its position in the periodic table give Tl a distinct chalcophilic and, occasionally, siderophilic character.

Inorganic Tl(I) compounds are more stable than the Tl(III) analogues in aqueous solution at neutral pH. In contrast, covalent organothallium compounds are stable only in the trivalent form. Tl^{3+} , but not Tl^+ , can be methylated by methyl-vitamin B₁₂ (9). The chemistry of Tl (1) and the Group IIIA metals (10,11) has been reviewed.

OCCURRENCE AND DISTRIBUTION

Thallium is distributed widely, but it is generally present in very low concentration. The crustal abundance of Tl is 0.3 ppm, with higher levels found in granite, shale and manganese nodules. It has also been detected in volcanic rocks, meteorites and in plants. Since Tl and potassium possess similar ionic radii, Tl is concentrated in magmatic potassium minerals such as feldspars and micas. The few Tl minerals that exist contain between 16% and 60% Tl and are quite rare: Crooksite $(Cu,Tl,Ag)_2Se$; lorandite $TlAsS_3$; hutchinsonite $(Tl,Ag)_2S \cdot PbS \cdot 2As_2S_3$; and vrbaite $Tl_2S_3(As,Sb)_2S_3$ (1). Natural Tl concentrations in seawater and freshwater are estimated to be <0.03 ppb (3). Thallium levels in normal humans and animals are <1 ppb in blood and urine and <10 ppb in tissues (4,12).

PRODUCTION AND USES

Thallium is found in pyrites used to make sulfuric acid; the H_2SO_4 production process generates waste residue that yields commercially recoverable levels of the element. Thallium is concentrated in iron, lead, cadmium and copper smelters as flue dust which is further processed to recover commercial quantities of the metal. Annual worldwide Tl production is only ~5 tons (13); recent US production is estimated to be 1500 lbs (682 kg). Thallium is also released to the environment by cement plant emissions and through agricultural use of phosphate fertilizer (14).

A small amount of Tl is used in alloys (anticorrosive), optical lenses (increases refractive index), low-temperature thermometers, dye and pigments (artist paints), semiconductors, superconducting ceramics and films, fiber optic cables, vapor lamps, scintillation counters, portable radiation (γ ray) detection devices, and in organic chemistry (catalyst) (8,15,16).

Mining and smelting, together with sulfuric acid production and coal-burning power plants, are the major iatrogenic sources of Tl in the environment (17,18). Major non-point sources are auto emissions (urban) and phosphate fertilizer (rural), but their contribution to the total environmental burden of the metal has not been fully assessed. The use of Tl in these commercial applications gives rise to

concerns about occupational exposure and environmental pollution (19).

Thallium sulfate (Tl_2SO_4), an odorless and tasteless compound, was once used in the US as an insecticide/rodenticide, but was restricted in 1975 as a consequence of several highly publicized accidental, criminal and suicidal poisonings (2,20). Many developed countries have banned or strictly controlled its use for this purpose (21), yet poisonings still too frequently occur. Its uncontrolled use in developing countries has resulted in a number of accidental human and animal poisonings (22-24).

Thallium was once used to treat syphilis, gonorrhea, tuberculosis, ringworm infestation of the scalp, and as a cosmetic epilant. Safer and more efficacious drugs long ago replaced Tl in the treatment of these conditions. The only medical use of Tl today is as a radioactive contrast agent (^{201}Tl) to image tumors and to visualize the heart in myocardial function tests (25,26).

ABSORPTION, DISTRIBUTION AND EXCRETION

After rapid and complete absorption from the respiratory or gastrointestinal (GI) tract or skin, water-soluble Tl salts are widely distributed to organs and tissues, including the brain, heart, kidney, skeletal muscle and testis, the principal targets of Tl toxicity (27). Since Tl^+ (1.50 Å) and K^+

(1.38 Å) are univalent ions with similar ionic radii, Tl^+ interferes with K^+ -dependent processes and mimics K^+ in its movement and intracellular accumulation in mammals (28). The thallium cation is less rapidly released than the potassium cation (K^+) once it moves into the cell. Because of its large distribution volume and low free plasma concentration, renal excretion of Tl is slow and it may be detected for months after exposure in untreated persons. In mammals, its body clearance is exponential with an estimated half-life of 4 d (29). The kidneys filter Tl into the urine, the salivary glands and liver concentrate Tl in their secretions, and the intestinal mucosal cells actively transport Tl into the lumen of the GI tract, where it can be reabsorbed (enterohepatic circulation) or eliminated in the feces (30,31). In mammals, Tl excretion via the GI tract is twice that of the kidneys. A small amount of the metal is taken up and excreted in hair; its presence near the roots can be seen microscopically within 3-4 d of intoxication. Thallium has been detected in the milk of poisoned female rats, mice, guinea pigs and humans, and a significant fraction of free plasma Tl crosses the placenta barrier (32). Some of the metal is retained in bone and other tissues. (Tl levels increase with time in chronic exposure), which suggests incomplete homeostatic regulation of the metal in the body and accounts for its cumulative toxicity.

MOLECULAR BASIS OF THALLIUM TOXICITY

The toxic effects of Tl have been demonstrated in a wide variety of biological systems, from yeast and bacteria to plants and animals (33-35). Thallium toxicity has been studied extensively in rats, mice, guinea pigs, rabbits, dogs, cats and humans (36-42). In comparing the relative toxicity of heavy metals, Zitko (43) states only methylmercury is more toxic than Tl. Lucky and Venugopal (7) classify Tl as the most toxic cumulative metal cation. Considerable effort has been devoted to better understanding Tl toxicity at the molecular level. The various mechanisms proposed to account for the metal's Tl toxicity are discussed below. While many of these are tenable based on *in vitro* studies or circumstantial evidence, the precise biochemical mechanisms underlying the clinical manifestations of thallotoxicosis are yet to be proven.

Alteration of K-Dependent Processes

Thallium's ability to interfere with a variety of K⁺-dependent processes is thought to play a significant role in its toxicity. The chemical similarities between Tl⁺ and K⁺ explain, in large part, the similar movements exhibited by these 2 ions in cells and tissues. Gehring and Hammond (28) were among the first to propose that Tl⁺ and K⁺ have common cellular targets and receptor sites associated with biological

activity and toxicity. Various K^+ -dependent proteins are known to possess a higher affinity for Tl^+ than for K^+ (44,45). Since Tl^+ alters the activity of these enzymes and membrane transport proteins *in vitro*, they are possible sites of Tl toxicity *in vivo*.

Several studies have explored various Tl -protein interactions. Yeast aldehyde dehydrogenase (YADH) is a critical enzyme in fermentation that catalyzes the NADH-mediated reduction of acetaldehyde to ethanol. At low concentrations, Tl^+ replaces K^+ in the activation of YADH, but at high levels (> 1.0 mM) Tl^+ inhibits it (46).

Pyruvate kinase (PK) is a Mg^{2+} -dependent glycolytic enzyme that catalyzes the transfer of a phosphate group from phosphoenolpyruvate to ADP yielding pyruvate and ATP. It requires K^+ to attain maximum activity. Kaye (47) demonstrated that PK has 50 times greater affinity for Tl^+ than K^+ , and that PK is strongly inhibited by Tl^+ at higher concentrations, possibly due to the formation of a Tl^+ -ADP complex.

Na^+ - K^+ ATPase is responsible for the active transport of monovalent cations across plasma and organelle membranes. This electrogenic antiport is critical for osmotic regulation by cells, the generation of the electrochemical potential gradient responsible for the electrical excitability of nerve cells, and in providing free energy (ATP) for the active transport of metabolites (glucose and amino acids) into some cells. At low levels, Tl^+ has been shown to replace K^+ in the

activation of Na⁺-K⁺ ATPase and to bind the protein with 10-fold higher affinity than K⁺ (28,45). However, at high concentrations, Tl⁺ competitively inhibits Na⁺-K⁺ ATPase (48).

Mitochondria have an abundance of Na⁺-K⁺ ATPase and are particularly susceptible to the effects of Tl (49). Mitochondrial swelling and vacuolization are common electron-microscopic findings in Tl-poisoned neurons (50). Moreover, Tl compromises mitochondrial energy production by inhibiting pyruvate dehydrogenase complex (PDC) and succinate dehydrogenase (SDH) (51). Thus the metal cation blocks the catabolism of carbohydrates and the entry of electrons into the electron transport chain, thereby decreasing ATP generation via oxidative phosphorylation (52). The presence of ketones (acetone, acetoacetate and β -hydroxybutyrate) in the urine and the clinical finding of metabolic acidosis in thallotoxicosis is a consequence of Tl's inhibition of PDC, SDH and other enzymes critical for normal carbohydrate metabolism.

Thallium may also disrupt normal cell metabolism by stimulating enzymes. At low levels, Tl⁺ activates other K⁺-dependent enzymes, such as phosphatase, homoserine dehydrogenase, vitamin B₁₂-dependent diol dehydrogenase, L-threonine dehydratase, and AMP deaminase (34,43).

Thallium-Sulfhydryl Group Interactions

Thallium's chalcophilic character may contribute to its observed toxicity in animals and humans. Thallium has a high

affinity for natural ligands that contain sulfhydryl (-SH) groups. These groups are structurally important in several classes of enzymes, such as hydrolases, oxidoreductases and transferases (ie flavoenzymes, pyridoxal phosphate-dependent enzymes and thiol proteases). They are functionally important constituents of cofactors involved in many enzyme-catalyzed reactions. For example, PDC and SDH both have dithiol-containing lipoamide prosthetic groups that function in transacetylation of metabolites in their enzyme complexes. Thallium-mediated sulfhydryl inactivation may play an important role in the overall toxicity seen in thallotoxicosis.

Thallium's affinity for -SH groups explains some of the clinical effects seen in Tl poisoning. Keratin is the structural protein of hair, horn, nail and feathers. Two of keratin's important physical properties, insolubility and resistance to stretching, are attributable to its large number of cysteine residues (53). These residues cross-link, forming disulfide bonds between adjacent polypeptide chains. Thallium blocks formation of the disulfide bonds in keratin, which is manifested clinically by alopecia and anomalies in nail growth (Mee's lines) (54,55).

Other Mechanisms of Action

Thallium has been shown to adversely affect protein synthesis. Mammalian ribosomes are strictly dependent on K^+ and Mg^{2+} for normal interaction between ribosomal subunits.

Tl⁺ can replace K⁺ causing progressive destabilization and irreversible damage to ribosomes, the 60S subunit being particularly affected (56).

Thallium-induced changes at the molecular level produce alterations in normal physiologic processes. Muscle fiber membranes cannot distinguish between Tl⁺ and K⁺ at low Tl⁺ concentrations, but at higher concentrations they are irreversibly damaged (57). Likewise, Tl⁺ affects the excitability of myocardial cells, the action potentials in nerve fibers, and neuromuscular transmission in a similar way, but to a greater extent, than K⁺.

Interactions between Tl and riboflavin may play a role in the metal's toxicity. Cavanagh (58) has suggested that Tl impairs cell energy metabolism by causing a deficiency of riboflavin and riboflavin-derived cofactors. The observation that Tl salts produce similar pathological effects in nerves, hair, nails and the heart as thiamine deficiency (beriberi) and trivalent arsenic provides circumstantial evidence in support of this theory. Moreover, Tl salts are known to precipitate riboflavin (59); they were once used for this purpose to isolate riboflavin in milk.

Ali et al (60) found that Tl induced alterations in amino acids (glutamic acid, aspartic acid) and neurotransmitters (glutamic acid, dopamine, serotonin) in rat brains exposed acutely or subacutely to the metal ion. Hasan et al (61,62) reported a significant decrease in several enzymes and

neuropathological changes in the hypothalamus and hippocampus after exposure to Tl. Thallium is also known to produce significant increases of lipid peroxidation in the rat brain (63). Its affinity for thiol groups may reduce glutathione levels (64), causing a concomitant increase in membrane-damaging free radicals and peroxides. It is of interest that the antioxidant effect of selenium antagonizes Tl-induced free radical/peroxide generation and counteracts Tl's toxicity *in vivo* (65,66).

The second-messenger cation, calcium (Ca^{2+}), is vital in the regulation of a number of physiologic processes in the cell. Intracellular Ca^{2+} concentration is maintained at a constant low level by the concerted operation of cellular transport and compartmentalization systems. The mitochondria, endoplasmic reticulum and nucleus serve as the principal Ca^{2+} storage sites in the cell, while membrane-bound Ca^{2+} pumps transport the cation out of the cell and into these organelles (67). Several heavy metals are known to cause prolonged elevation of intracellular Ca^{2+} , resulting in Ca^{2+} -induced cytotoxic responses in various tissues (68). Thallium may elevate intracellular Ca^{2+} by 1 or more of the following mechanisms: Inhibiting Na^+-K^+ ATPase and F_0/F_1 -ATP synthase; uncoupling oxidation phosphorylation; or disrupting the normal antioxidant processes in the cell.

Many theories have been proposed to account for Tl's toxicity at the molecular level. It is likely that 1 or more

of them are operative in the cell. This area is of great interest and continues to be fertile ground for further clinical and basic research.

CLINICAL TOXICOLOGY

The symptomatology of thallotoxicosis varies with dose, age and acuteness of intoxication. Curiously, children tend to be less sensitive to Tl than adults (69). A dose of greater than 100 mg (1.4 mg Tl/kg body weight) will produce acute toxicity in adult humans; 500-800 mg is often lethal (8). Smaller doses over longer time periods will produce similar, but milder, symptoms as in acute exposures. Chronic poisoning can produce mild to severe effects depending on the severity of exposure.

Gastroenteritis, polyneuropathy, and hair loss are the dominant clinical features of Tl poisoning. A latent period of hours to 1-2 d may follow acute exposure. Abdominal pain, constipation or diarrhea are common initial complaints, but some individuals experience only nausea and vomiting or itching or a vague dull feeling in the extremities. In high-dose exposure cases, neurologic effects may dominate the clinical picture.

Gastrointestinal Tract

Thallium may cause GI disorders regardless of exposure route. Often, nausea and vomiting occur during the 3-4 d period following intoxication, which may be replaced by severe abdominal pain that is relieved by direct pressure. Signs of enteritis or colitis may be observed; ulceration of the mucosal lining of the colon can ensue, producing GI bleeding (70). Depression of intestinal motility and peristalsis may occur due to possible vagus nerve involvement, resulting in severe constipation.

Nervous System

Neurologic symptoms usually appear in 2-5 d in acute exposure cases, which are characterized by a painful, rapidly progressive peripheral neuropathy that dominates clinically in the second or third week. Sensory disturbances include pain and paresthesias of the lower limbs, numbness in the fingers and toes, with loss of pin-prick and touch sensation (69). Occasionally, hyperesthesia involving the soles of the feet and tibial region occurs; the mere weight of bed sheets on the lower extremities may cause excruciating pain (71). Motor neuropathy is manifested by weakness which is always distal in distribution. The lower body extremities are primarily affected. Upper extremity involvement occurs infrequently and cranial nerve participation is rare. Insomnia, headache, emotional lability (lamentation with a theatrical or hysteri-

cal effect), anxiety, tremor, ataxia, choreoathetosis, and signs of cranial nerve involvement (ptosis, nystagmus, abnormal palatal or vocal cord movements) may develop. Psychosis with paranoia, depression, aggressiveness and hallucinations are not uncommon. In chronic Tl poisoning, ataxia and paresthesia may be the outstanding symptoms. In time, the paresthesia may progress to frank peripheral neuropathy with weakness and atrophy of the associated musculature.

Eye

Retrobulbar neuritis with reduction of vision and central scotoma may occur as a result of Tl intoxication (72). Cataracts, iritis, inflammation of the eyelids, and intraocular hemorrhage have been reported in animals (73). Subnormal or absent retinal electrogenesis may be observed as soon as 2 d post-intoxication, as measured by electroretinography (74).

Skin

Alopecia is the best known effect of chronic Tl poisoning. Epilation begins about 10 d after ingestion; complete hair loss is seen in about 1 mo. This long latent period coincides with the maturation period of the new epithelial cells of the hair papilla, which Tl targets. After a maturation period of 10-14 d, hair loss is evident. Axillary and facial hair, including the inner 1/3 of the eyebrows is

usually spared, which has been attributed to Tl-induced lesions to the sympathetic nervous system (2). However, most evidence supports direct involvement of Tl with the hair follicles as the mechanism of toxicity (54,75,76). Thyresson (54) found a high ^{204}Tl content in active hair follicles, whereas resting follicle uptake of the nuclide was low. Hair loss is usually reversible, but severe poisoning may lead to permanent alopecia. Thallium deposits in hair samples can be observed microscopically as regions of dark brown or black pigmentation near the hair roots 3-5 d post-intoxication. Other observed dermatological effects may include palmar erythema, acne, anhydrosis, and dry scaly skin, which is caused by the metal's toxic effect on sweat and sebaceous glands. Dystrophy of the nails, seen as the appearance of white semilunar bands (Mee's lines), appear 3-4 w after intoxication.

Heart

Cardiac signs, such as sinus tachycardia, irregular pulse, hypertension, and angina-like pain, have been reported during the second week after exposure. While some investigators attribute these signs to vagus nerve involvement, others have noted electrocardiographic changes (nonspecific ST segment abnormalities, flattened or inverted T-wave) that suggest direct myocardial damage (72).

Kidneys

Renal function is usually not grossly impaired, despite the fact that the kidneys accumulate the highest concentration of Tl of any organ. Albuminuria, hematuria, elevated blood urea nitrogen (BUN) or decreased creatinine clearance indicate renal involvement, whereas coproporphyrinuria and uroporphyrinuria reflect liver and muscle damage (71,77). A definitive diagnosis of thallotoxicosis is based on the demonstration of above-normal Tl levels in the urine or other biological specimens.

Reproductive System

Experimental evidence suggests that the reproductive system is highly susceptible to Tl. Decreased libido and impotence in humans, and lower sexual activity in laboratory animals was noted with chronic exposure to the metal. In animals and humans, the testis accumulated high levels of Tl. Moreover, morphological and biochemical changes in the testes and decreased epididymal sperm motility were noted in rats exposed to 10 ppm Tl in drinking water of 2 mo (78). In experiments on embryonic mouse cultures exposed to 1 μ M Tl, only 14% of embryos reached the blastocyst stage of development (79). The human fetus may suffer from transplacental exposure to Tl, as evidenced by skin and nail dystrophy, alopecia and low body weights in newborns of Tl-intoxicated mothers (80).

Teratogenicity and Carcinogenicity

Thallium is teratogenic in chick embryos, causing achondroplasia, leg bone curvature, parrot-beak deformity, microcephaly and decreased fetal size (81). However, teratological investigations in mammals have produced conflicting results (82,83).

Large doses (3 mg/kg $TlCl_3$) of the trivalent Tl cation inhibited tumor growth in Sprague-Dawley rats carrying an ascitic form of Walker 256 carcinoma (84). However, it had no effect on L1210 leukemia cells or other types of solid tumors. Buschke and Peiser (85) found that chronically-exposed rats developed gastric papillomas and inflammatory proliferative lesions in the forestomach, such as hyperkeratosis and epithelial cysts and tufts that extended into the muscularis mucosa. Thallium induced single-stranded DNA breaks in C₃H, B/6 mouse cell cultures, and its mutagenic activity, as measured by dominant lethal testing, was higher than that of mercury chloride (86).

LABORATORY EVALUATIONS

Analysis of urine, feces, hair or saliva for Tl contents should be done to assess the extent of Tl exposure and to monitor treatment. Although a variety of analytical methods can be employed in the determination of Tl, atomic absorption spectroscopy (AAS) is the method of choice in most clinical

laboratories.

Estimates of Tl concentrations in the normal population are 7-15 ng Tl/g hair and ~0.3 µg Tl/L urine. Salivary levels of the metal are ~15 times higher than urinary levels, and thus may serve as a measure of Tl toxicity in people with severe constipation, renal failure or other conditions that prevent collection of standard biological materials (30).

Other laboratory findings in Tl poisoning are nonspecific. Anemia and hemolytic changes are occasionally reported, but the lymphocytosis and eosinophilia sometimes seen are likely due to secondary infection. Elevated liver enzymes may be found, although the metal is not particularly hepatotoxic. Hypokalemia and hypochloremic metabolic acidosis have been observed (2,71). Coproporphyrinuria and uroporphyrinuria may be seen, which may reflect liver and muscle damage (69). Decreased creatinine clearance, elevated BUN, and proteinuria indicate renal function impairment. A slightly elevated cerebrospinal fluid protein level may occasionally be seen, but rarely is it greater than 100 mg% (69).

DIAGNOSIS

The diagnosis of thallotoxicosis is often difficult unless the etiology is well known. The triad of gastroenteritis, peripheral neuropathy of unknown origin, and alopecia should alert the clinician to the possibility of Tl poisoning.

Unfortunately, the diagnosis of Tl poisoning often occurs only after hair loss is observed (3-4 w post-intoxication), thus diminishing the effectiveness of treatment and increasing the likelihood of permanent residual effects. It must be stressed that hair loss does not always occur (70,72,87). Thallium poisoning should be considered any time the patient presents with neurological symptoms of unknown etiology, particularly peripheral neuropathy.

The occurrence of nonspecific symptoms may lead to misdiagnosis, particularly in chronic Tl intoxication. Thallium-induced motor neuropathy must be differentiated from that seen in acute intermittent porphyria or Guillian-Barre' syndrome. Erythema, renal impairment, fever and hair loss may suggest systemic lupus erythematosus, particularly in young females (88).

Routine metal screening tests often are not designed to detect Tl. A Tl mobilization test can be used to confirm poisoning; this entails giving 45 mEq potassium (K) po, then collecting and analyzing urinary excretions during the subsequent 24-h period (89). Care should be taken to insure that urine specimens are collected in a non-metal container and then rapidly acidified to prevent surface adsorption or coprecipitation with other urine constituents. AAS is preferable to colorimetric or spectrophotometric methods because of its high specificity for Tl and its low detection limits (~3 ppm, flame AAS; <1 ppb, graphite furnace AAS) (90).

Additionally, a qualitative test for Tl can be done by microscopically examining hair roots for Tl deposits (black or dark brown pigmentation). In poisoned patients Tl deposits can be found in 95% of scalp hair examined, 50-60% of chest/leg hair, and 30% of eyebrow/eyelid hair (91).

TREATMENT

Estimation of the dose, time elapsed since exposure, and physical status of the patient will aid in determining whether induced vomiting, gastric lavage, supportive care or specific therapy is required, and the priority of these management steps.

In recent acute exposure, ipecac syrup should be given or lavage performed to remove as much Tl as possible from the GI tract. Symptomatic and supportive treatment should be begin immediately, with special attention given to the patient's respiratory and circulatory status.

The treatment objective in Tl poisoning is to enhance the metal's elimination from the body. This is accomplished by inhibiting absorption/reabsorption of the metal from the digestive tract and by mobilizing the Tl from tissue storage sites without exacerbating the patient's symptoms.

Attempts to mobilize Tl by use of chelating agents have yielded negative or marginal results. Ethylenediaminetetraacetic acid and diethylenetriaminepentaacetic acid are

completely ineffective (92,93). Dimercaprol (British anti-Lewisite, BAL) and D-penicillamine failed to enhance Tl excretion in experimental animals (94,95). Dithiocarb (sodium diethyldithiocarbamate, NDDC) chelates Tl *in vivo* and enhances renal excretion, but the lipophilic metal-ligand complex promotes Tl redistribution to the brain, thus exacerbating neurologic symptoms (96). Treatment with dithizone (diphenyldithiocarbazone) yielded equivocal results (97,98) and was found to be goitrogenic and diabetogenic in animal studies.

Potassium increases the urinary excretion of Tl (97) and increases the LD₅₀ of Tl in rats (28). Two possible mechanisms are responsible for increased thalluresis: K blocks tubular reabsorption of Tl, or K mobilizes Tl from intracellular stores thereby raising plasma levels and increasing its availability for filtration by the kidneys. But like NDDC, K may also cause dangerous redistribution of Tl to the central nervous system (99), and thus should be used with caution.

Given orally, prussian blue (potassium ferric hexacyanoferrate(II), PB) absorbs monovalent Tl cations in its crystal lattice, thereby interrupting its enterohepatic circulation. Prussian blue and the Tl-PB complex are not absorbed from the GI tract and are eliminated in the feces. About 7% of PB is degraded to cyanoferrate, which is absorbed and rapidly eliminated in the urine, carrying some bound Tl with it in the process. Prussian blue has a high therapeutic index and is, for all practical purposes, nontoxic (100). It is most

effective when administered within the first 48 h after ingestion, but results from human studies suggest PB has therapeutic utility throughout acute and chronic intoxications.

Prussian blue exists in 2 forms, the so-called insoluble form and the colloidal (soluble) form; the latter form absorbs more Tl. Stevens (101) compared the effectiveness of PB in human trials and found it to enhance fecal elimination of Tl. Since Tl may cause severe constipation, 250 mg PB/kg/d in 4 divided doses should be given in a 15% mannitol solution (50 ml). Prussian blue is not commercially available in the US, but can be obtained from Heyl Chemisch-Pharmazentische Fabrik GmbH & Co (Berlin). Prussian blue is not yet approved for human use by the FDA. Activated charcoal may be used instead of PB, but it is not as effective (100). The recommended dose of activated charcoal is 500 mg/kg/d, given twice daily.

Forced diuresis enhances the elimination of Tl (102) and may be useful in acute intoxication. Hemodialysis, however, is of little benefit once Tl has been sequestered intracellularly unless potassium is given concurrently. For this reason, hemodialysis is only indicated in the initial stages of acute intoxication when Tl plasma levels are relatively high or in the case of renal severe insufficiency/failure (103). Hemofiltration was found ineffective in eliminating Tl (103).

The decorporation of several heavy metals is enhanced by

the concurrent use of 2 or more chelators. In acute Tl-exposed laboratory animals, a chelator-PB combination was shown to produce a synergistic effect that enhanced the overall elimination of the metal from the body. Rios et al (104) demonstrated that the combined administration of D-penicillamine and PB reduced the Tl content in rat target organs more than single administrations of these antidotes, without promoting dangerous redistribution of Tl to brain. The use of chelator-PB combinations to treat thallotoxicosis deserves more research attention.

In summary, acute thallotoxicosis should be treated by gastric lavage/emesis if ingestion was recent, followed by oral PB and laxatives and forced diuresis with K loading. If plasma Tl levels are elevated or if the patient is in renal failure, hemodialysis should be considered.

PROGNOSIS

Thallotoxicosis is a serious illness with high morbidity and mortality whose outcome is hard to estimate. In general, cases with a fulminating onset are rapidly fatal. The longer the patient survives, the better the prognosis for survival, although long-lasting or permanent neurologic sequelae may result. In a follow-up study conducted 4 y after Tl intoxication, Reed (2) found a 58% incidence of chronic neurologic defects involving both the peripheral and central nervous

systems in surviving patients. Severe and presumably permanent deterioration in intellectual function (memory and performance abilities) has been documented in at least 1 case (105). However, if Tl poisoning is recognized and treated early, the chance for full recovery is good.

CONCLUSIONS

Thallium poisoning is a complex and often fatal affliction involving a wide range of organs and tissues. Because of its similarity to potassium, Tl follows K distribution pathways and inhibits a number of K-dependent processes. Several mechanisms have been postulated to account for Tl's toxicity, including ligand formation with sulfhydryl groups of enzymes and transport proteins, inhibition of cellular respiration, interaction with riboflavin and riboflavin-based cofactors, alteration of the activity of K⁺-dependent proteins, and disruption of intracellular calcium homeostasis. The clinical triad of gastroenteritis, peripheral neuropathy of unknown etiology, and alopecia should alert clinicians to the possibility of Tl poisoning. The diagnosis of thallotoxicosis is confirmed by finding elevated Tl concentrations in urine or other biologic materials. Treatment should consist of gastric lavage/emesis to reduce exposure to the metal, PB (or activated charcoal) and laxatives to enhance fecal elimination, and forced diuresis with K loading to increase

renal clearance. If K is given, the patient's status must be monitored carefully because neurologic and cardiovascular symptoms may be exacerbated. Hemodialysis may be useful at the outset if plasma Tl levels are high or in the case of renal failure. A favorable prognosis is justified if the poisoning is recognized and treated early. The longer the exposure to Tl, the greater the risk of permanent neurologic abnormalities.

REFERENCES

1. Lee AG: The Chemistry of Thallium. Elsevier, New York: 1-2, 1971.
2. Reed D, Crawley J, Faro SN et al: Thallotoxicosis. JAMA 183:516-522, 1963.
3. Fergusson JE: The Heavy Elements: Chemistry, Environmental Impact and Health Effects. Pergamon, New York: 18, 275, 1990.
4. Weinig E, Zink P: Quantitative mass spectrometric determination of the normal thallium content in the human body. Arch Toxicol 22:275-281, 1967.
5. Martin BR: Bioinorganic chemistry of metal ion toxicity. In Sigel H ed: Metal Ions in Biological Systems. Vol 20. Concepts on Metal Ion Toxicity. Marcel Dekker, New York 33, 1986.
6. Bugarin MG, Casas JS, Sordo J et al: Thallium(I) interactions in biological fluids: A potentiometric investigation of thallium(I) complex equilibria with some sulphur-containing amino acids. J Inorg Biochem 35:95-105, 1989.
7. Luckey TD, Venugopal B: Metal Toxicity in Mammals. Vol 2. Chemical Toxicity of Metals and Metalloids. Plenum Press, New York: 122-127, 1978.

8. Schoer J: Thallium. In Hutzinger O, ed: The Handbook of Environmental Chemistry. Vol 3. Part C. Anthropogenic Compounds. Springer-Verlag, Berlin: 143-214, 1984.
9. Huber F, Kirchmann H: Biomethylation of Tl(I) compounds. Inorg Chem Acta 29:L249-L250, 1978.
10. Farmer JB, Wade K: Aluminium, gallium, indium and thallium. In Aylett BJ ed: Organometallic Derivatives of the Main Group Elements. Vol 4. MTP International Review of Science. Butterworths, London: 105-140, 1972.
11. Wade K, Banister AJ: The chemistry of aluminium, gallium, indium and thallium. Vol 12. In Bailar JC, Emeleus HJ, Nyholm R et al eds: Comprehensive Inorganic Chemistry. Pergamon, Oxford: 1119-1172, 1973.
12. Geilmann W, Beyermann K, Neeb KH et al: Thallium as a trace element for animals and plants. Biochem Z 333:62, 1960.
13. Adriano DC: Trace Elements in the Terrestrial Environment. Springer Verlag, Berlin: 115, 1986.
14. Schaller KH, Manke G, Raithel HJ et al: Investigations of thallium-exposed workers in cement factories. Int Arch Occup Environ Health 47:223-231, 1980.
15. Betz J, Piehler A, Pechen EV: In situ preparation of high-T_c thallium barium calcium copper oxide thin films by a combination of laser ablation and thermal evaporation. J Appl Phys 71:2478-2479, 1992.

16. Wahlbeck PG, Richards RR, Myers DL: Vaporization reactions of thallium(III) oxide and thallium activities in thallium superconductors. J Chem Phys 95:9122-9127, 1991.
17. Brockhaus A, Dolgner R, Ewers U et al: Excessive thallium absorption among a population living near a thallium emitting cement plant. In Holmstedt B, Lauwerys R, Mercier M et al eds: Mechanisms of Toxicity and Hazard Evaluation. Proceedings of the Second International Congress on Toxicology held in Brussels, Belgium, July 6-11, 1980. Elsevier, Amsterdam: 565-568, 1980.
18. Sabbioni E, Goetz L, Bignoli G: Health and environmental implications of trace metals released from coal-fired power plants: An assessment study of the situation in the European Community. Sci Total Environ 40:141-154, 1984.
19. Hapke HJ: Chronic thallotoxicosis in ruminants and transfer of thallium from feed to edible tissues. In Simon F, Lees P, Semjen G eds: Veterinary Pharmacology, Toxicology and Therapy in Food Producing Animals. Proceedings of the 4th Congress of the European Association for Veterinary Pharmacology and Toxicology held in Budapest, Aug 28-Sept 2, 1988. University of Veterinary Science, Budapest: 359-366, 1990.

20. Munch JC, Ginsberg HM, Nixon CE: The 1932 thallotox-
icosis outbreak in California. JAMA 100:1315-1319, 1933.
21. Aoyama H, Yoshida M, Yamamura Y: Acute poisoning by
intentional ingestion of thallous malonate. Human
Toxicol 5:389-392, 1986.
22. Ben-Assa B: Indirect thallium poisoning in a Bedouin
family. Harefuah 62:378-380, 1982.
23. Zhou D, Lin D: Chronic thallium poisoning in a rural
area of Guizhou Province, China. J Environ Health
48:14-18, 1985.
24. Hakala JE: Thallium poisoning in a dog. Mod Vet Pract
65:783-784, 1984.
25. Bradley-Moore PR, Lebowitz E, Greene MW et al:
Thallium-201 for medical use. Part 2. Biologic
behavior. J Nucl Med 16:156-160, 1975.
26. Atkins HL, Budinger TF, Lebowitz E: Thallium-201 for
medical use. Part 3. Human distribution and physical
imaging properties. J Nucl Med 18:133-140, 1977.
27. Sabbioni E, Marafante E, Rade J et al: Metabolic
patterns of low and toxic doses of thallium in the rat.
In Holmstedt B, Lauwerys R, Mercier M et al: Mechanisms
of Toxicity and Hazard Evaluation. Proceedings of the
Second International Congress on Toxicology held in
Brussels, Belgium, July 6-11, 1980, Elsevier,
Amsterdam: 559-564, 1980.

28. Gehring PJ, Hammond PB: The interrelationship between thallium and potassium in animals. *Pharmacol Exp Ther* 155:187-201, 1967.
29. Rauws AG: Thallium pharmacokinetics and its modification by prussian blue. *Naunyn-Schmiedeberg's Arch Pharmacol* 284:295-306, 1974.
30. Richelmi P, Bono F, Guardia L et al: Salivary levels of thallium in acute human poisoning. *Arch Toxicol* 43:321-325, 1980.
31. Henning CH, Forth W: The excretion of thallium (I)-ions into the gastrointestinal tract in situ of rats. *Arch Toxicol* 49:149-158, 1982.
32. Murphy PH, Beasley CW, Moore WH et al: Thallium-201 in human milk: Observations and radiological consequences. *Health Phys* 56: 539-541, 1989.
33. Heyroth FF: Thallium: A review and summary of medical literature. *Publ Hlth Dep Suppl* 197:1-23, 1947.
34. Smith IC, Carson BL: Trace Metals in the Environment. Volume 1 - Thallium. Ann Arbor Science, Ann Arbor: 45, 1977.
35. Horn EE, Ward JC, Munch JC et al: The effect of thallium on plant growth. *USDA Circ* 409:1-8, 1936.
36. Manzo L, Scelsi R, Moglia A et al: Long-term toxicity of thallium in the rat. In Brown SS, Savory J eds: *Chemical Toxicology and Clinical Chemistry of Metals*. Academic Press, London: 401-405, 1983.

37. Olsen I, Jonsen J: Whole-body autoradiography of ^{204}Tl in embryos, fetuses and placentas of mice. *Toxicology* 23:353-359, 1982.
38. Tackmann W, Kehmann HJ: Refractory period and impulse sequence recorded from the tibial nerves of guinea pigs with acute thallium polyneuropathy. *Z Neurol* 199:105-112, 1971.
39. Talas A, Wellhoner HH: Dose-dependency to Tl^+ kinetics as studied in rabbits. *Arch Toxicol* 53:9-16, 1983.
40. Marmo E, Filippelli A, Scafuro M et al: Effects of thallium sulfate on cardiovascular and respiratory systems of various animals. *Acta Pharmacol Sin* 4:119-122, 1983.
41. Kennedy P, Cavanagh JB: Sensory neuropathy produced in the cat with thallous acetate. *Acta Neuropathol* 39:81-88, 1977.
42. Roby DS, Fein AM, Bennett RH et al: Cardiopulmonary effects of acute thallium poisoning. *Chest* 85:236-240, 1984.
43. Zitko V: Toxicity and pollution potential of thallium. *Sci Total Environ* 4:185-192, 1975.
44. Williams RJP: The biochemistry of sodium, potassium, magnesium, and calcium. *Q Rev Chem Soc* 24:331-365, 1970.

45. Britten JS, Blank M: Thallium activation of the (Na⁺-K⁺)-activated ATPase of rabbit kidney. *Biochim Biophys Acta* 159:160-166, 1968.
46. Bostain KA, Betts GF, Man WK et al: Multiple binding of thallium and rubidium to potassium-activated yeast alcohol dehydrogenase. *Biochem J* 207:73-80, 1982.
47. Kaye JF: Thallium(I) activation of pyruvate kinase. *Arch Biochem Biophys* 143:232-239, 1971.
48. Inturrisi CE: Thallium-induced dephosphorylation of a phosphorylated intermediate of the (sodium + thallium-activated) ATPase. *Biochim Biophys Acta* 178:630-633, 1969.
49. Skulskii IA, Saris N-EL, Savina MV et al: Uptake of thallous ions by mitochondria is stimulated by nonactin but not by respiration alone. *Eur J Biochem* 120:263-266, 1981.
50. Spencer PS, Peterson ER, Madrid RA et al: Effects of thallium salts on neuronal mitochondria in organotypic cord-ganglia-muscle combination cultures. *J Cell Biol* 58:79-85, 1973.
51. Truchant R: The toxicology of thallium. *J Occup Med* 2:334-348, 1960.
52. Melnick RL, Monti LG, Motzkin SM: Uncoupling of mitochondrial oxidative phosphorylation by thallium. *Biochem Biophys Res Commun* 69:68-73, 1976.

53. Voet D, Voet JG: Biochemistry. Wiley & Sons, New York: 158, 1990.
54. Thyresson N: Experimental investigation on thallium poisoning in the rat. Acta Derm Venereol 31:3-27, 1951.
55. Flesch P: Inhibition of keratinizing structures by systemic drugs. Pharmacol Rev 15:653-671, 1963.
56. Hutlin T, Naslund PH: Effects of thallium(I) on the structure and function of mammalian ribosomes. Chem-Biol Interact 8:315-328, 1974.
57. Mullins LJ, Moore RD: The movement of thallium ions in muscle. J Gen Phys 43:759-773, 1960.
58. Cavanagh JB: What have we learnt from Graham Frederick Young? Reflections on the mechanism of thallium neurotoxicity. Neuropathol Appl Neurobiol 17:3-9, 1991.
59. Aliev AM, Gasanov AS: Reaction of some salts of rare and rare earth elements with group B vitamins. Chem Abstr 62:5142g, 1965.
60. Ali SF, Jairaj K, Newport GD et al: Thallium intoxication produces neurochemical alterations in rat brain. Neurotoxicology 11:381-390, 1990.
61. Hasan M, Chandra SV, Bajpai VK et al: Electron microscopic effects of thallium poisoning on the rat hypothalamus and hippocampus: Biochemical changes in the cerebrum. Brain Res Bull 2:255-261, 1977.

62. Hasan M, Chandra SV, Dua PR et al: Biochemical and electrophysiologic effects of thallium poisoning on the rat corpus striatum. *Toxicol Appl Pharmacol* 41:353-359, 1977.
63. Hasan M, Ali SF: Effects of thallium, nickel, and cobalt administration on the lipid peroxidation in different regions of the rat brain. *Toxicol Appl Pharmacol* 57:8-13, 1981.
64. Chandler HA, Scott M: A review of thallium toxicology. *J Roy Nav Med Ser* 72:75-79, 1986.
65. Rusiecki W, Brzezinski J: Influence of sodium selenate on acute thallium poisoning. *Acta Pol Pharm* 23:75-83, 1966.
66. Ganther HE: Biochemistry of selenium. In Zingaro RA, Cooper WC eds: *Selenium*. Van Nostrand Reinhold, New York: 546-614, 1974.
67. Nicotera P, Orrenius S: Ca^{2+} and cell death. *Ann NY Acad Sci* 648:17-27, 1992.
68. Komulainen H, Bondy SC: Increased free intracellular Ca^{2+} by toxic agents: an index of potential neurotoxicity? *Trends Pharmacol Sci* 9:154-156, 1988.
69. Prick JJG: Thallium poisoning. In Vinken PJ, Bruyn GW eds: *Handbook of Clinical Neurology*. Vol 36. *Intoxications of the Nervous System*. North-Holland, New York: 239-278, 1979.

70. Hologgitas J, Ullucci P, Driscoll J et al: Thallium elimination kinetics in acute thallotoxicosis. *J Anal Toxicol* 4:68-73, 1980.
71. Cavanagh JB, Fuller NH, Johnson HRM et al: The effects of thallium salts, with particular reference to the nervous system changes. A report of three cases. *Q J Med* 170:293-319, 1974.
72. Rangel-Guerra R, Martinez HR, Villarreal HJ: Intoxicación por talio. Experiencia con 50 pacientes. *Gac Med Mex* 126:487-494, 1990.
73. Potts AM: Toxic responses of the eye. In Amdur MO, Doull J, Klaassen DC eds: Casarett and Doull's *Toxicology*, 4th ed. Pergamon, New York: 535, 1991.
74. Shamshinova AM, Ivanina TA, Yakovlev AA et al: Electroretinography in the diagnosis of thallium intoxication. *J Hyg Epidemiol Microbiol Immunol* 34:113-121, 1990.
75. Flesch P: Inhibition of keratinizing structures by systemic drugs. *Pharmacol Rev* 15:653-671, 1963.
76. Cavanagh JB, Gregson M: Some effect of a thallium salt on the proliferation of hair follicle cells. *J Pathol* 125:179-191, 1978.
77. Merwe van der CF: The treatment of thallium poisoning: A report of 2 cases. *S Afr Med J* 46:960-961, 1972.
78. Formigli L, Scelsi R, Poggi P et al: Thallium-induced testicular toxicity in the rat. *Environ Res* 40:531-539, 1986.

79. Formigli L, Sabbioni E, Manzo L: Metabolism and toxicity of thallium(I) in the developing rat. *Subst Alc Actions/Misuse* 4:260-264, 1983.
80. Formigli L, Gregotti C, di Nucci A et al: The pollution potential of thallium. In Lekkas TD ed: *Heavy Metals in the Environment*. CEP Consultants, Edinburgh: 15-18, 1985.
81. Hall BK: Thallium-induced achondroplasia in the embryonic chick. *Develop Biol* 28:47-60, 1972.
82. Gibson JE, Sigdestad CP, Becker BA: Placental transport and distribution of thallium-204 sulfate in newborn rats and mice. *Toxicol Appl Pharmacol* 10:408-413, 1967.
83. Gibson JE, Becker BA: Placental transfer, embryo-toxicity and teratogenicity of thallium sulfate in normal and potassium-deficient rats. *Toxicol Appl Pharmacol* 16:120-132, 1970.
84. Adamson RH, Canellos GP, Sieber SM: Studies on the antitumor activity of gallium nitrate (NSC-15200) and other group IIIa metal salts. *Cancer Chemother Rep* 59:599-610, 1975.
85. Buschke A, Peiser B: Epithelial proliferation in the forestomach of rats by the experimental action of thallium. *Z Krebsforsch (Berlin)* 21:11-18, 1923.

86. Zasukhina GD, Vasilyeva IM, Sdirkova NI et al:
Mutagenic effect of thallium and mercury salts on
rodent cells with different repair activities. Mutation
Res 124:163-173, 1983.
87. Bank WJ, Pleasure DE, Suzuki K et al: Thallium
poisoning. Arch Neurol 26:456-464, 1972.
88. Montoya-Cabrera MA, Saucedo-Garcia JM, Escalante-
Galindo P et al: Intoxicación por talio que simuló
lupus eritematoso sistémico en un niño. Gac Med Mex
127:333-336, 1991.
89. Burnett JW: Thallium poisoning. Cutis 46:112-113,
1990.
90. Mulkey JP, Oehme FW: Quantitative analysis of trace
levels of thallium in biologic materials by atomic
absorption spectroscopy. Vet Hum Toxicol, submitted
for publication.
91. Saddique A, Peterson CD: Thallium poisoning: A review.
Vet Hum Toxicol 25:16-22, 1983.
92. Heydlauf H: Tierexperimentelle untersuchungen zur
therapie der thallium vergiftung. KFK Rpt:875-879,
1968.
93. Stock J van der, Schepper J de: The effect of prussian
blue and sodium-ethylenediaminetetraacetic acid on the
faecal and urinary elimination of thallium by the dog.
Res Vet Sci 25:337-342, 1978.

94. Lund A: The effect of various substances on the excretion and toxicity of thallium in the rat. *Acta Pharmacol et Toxicol* 12:260-268, 1956.
95. Heydlauf H: Ferric-cyanoferrate(II): An effective antidote in thallium poisoning. *Eur J Pharmacol* 6:340-344, 1969.
96. Kamerbeek HH, Rauws AG, Ham M ten et al: Dangerous redistribution of thallium by treatment with sodium diethyldithiocarbamate. *Acta Med Scand* 189:149-154, 1971.
97. Chamberlain PH, Stavinocha B, Davis H et al: Thallium poisoning. *Pediatrics* 22:1170-1176, 1958.
98. Paulson G, Vergara G, Young J et al: Thallium intoxication treated with dithizone and hemodialysis. *Arch Int Med* 129:100-107, 1972.
99. Papp JP, Gay PC, Dodson VN et al: Potassium chloride treatment in thallotoxicosis. *Ann Intern Med* 71:119-126, 1969.
100. Lehmann PA, Favari LF: Parameters for the adsorption of thallium ions by activated charcoal and prussian blue. *Clin Toxicol* 22:331-339, 1984.
101. Stevens W, Peteghem C van, Heyndrickx A et al: Eleven cases of thallium intoxication treated with prussian blue. *Int J Clin Pharmacol* 10:1-22, 1974.

102. Nogue S, Mas A, Pares A et al: Acute thallium poisoning: An evaluation of different forms of treatment. J Toxicol Clin Toxicol 19:1015-1021, 1982-83.
103. Wainwright AP, Kox WJ, House IM et al: Clinical features and therapy of acute thallium poisoning. Q J Med 69:939-944, 1988.
104. Rios C, Monroy-Noyola A: D-Penicillamine and prussian blue as antidotes against thallium intoxication in rats. Toxicology 74:69-76, 1992.
105. Thompson DF: Management of thallium poisoning. Clin Toxicol 18:979-990, 1981.
106. Downs WL, Scott JK, Steadman LT et al: Acute and subacute toxicity studies of thallium compounds. Am Ind Hyg Assoc J 21:399-406, 1960.

TABLE 1. TOXICITY OF THALLIUM SALTS.

COMPOUND	ANIMAL	ROUTE DOSE ¹	TOXIC (mg Tl/kg)	DOSE	REF
Tl Acetate	rat	ip	LD ₅₀	23	106
		po	LD ₅₀	32	
	rabbit	iv	LD ₁₀	20	
		ip	LD ₁₀	13	
	guinea	ip	LD ₁₀	7	
	pig	po	LD ₁₀	12	
	dog	po	LD ₁₀	20	
Tl Oxide	rat	ip	LD ₅₀	72	
		po	LD ₅₀	39	
	rabbit	iv	LD ₁₀	39	
		ip	LD ₁₀	60	
	guinea	ip	LD ₁₀	30	
	pig	po	LD ₁₀	5	
	dog	po	LD ₁₀	30	
Tl Nitrate	rat	sc	LD ₁₀	20	34
	mouse	po	LD ₅₀	32.5	
	dog	po	LD ₁₀	45	
Tl Sulfate	rat	po	LD ₅₀	15.8	
	mouse	po	LD ₅₀	29	
	human	po	LD ₁₀	8	

¹ LD₁₀ is the lowest dose producing lethality during 14 d observation period.

TABLE 2. THE PHYSICAL PROPERTIES OF THALLIUM.
 (Adapted from Trump DM: The Integral Scientist,
 Assoc of Shareware Professionals, 1991)

Atomic number	81
Atomic weight	204.3833
Density (g/cm ³ at 20 °C)	11.85
Melting Point (°C)	303.55
Boiling Point (°C)	1456.85
Crystal Structure	
Hexagonal close packed	<230 °C
Body centered cubic	230 - 303.55 °C
Molar Enthalpy of	
Atomization	182.845
Fusion	4.31
Vaporization	166.1
Electron shells	[Xe]4f ¹⁴ 5d ¹⁰ 6s ² 6p
Oxidation states	+1 +3
Atomic radius (pm)	171.0
Ionic radii (pm)	
Tl ⁺	150.0
Tl ³⁺	88.5
Molar Ionization Energy	
(kJ/mol)	
I	589.3
II	1971.0
III	2877.0
Pauling's	
electronegativity	1.8

CHAPTER 2

QUANTITATIVE ANALYSIS OF TRACE LEVELS OF THALLIUM IN BIOLOGIC MATERIALS BY ATOMIC ABSORPTION SPECTROSCOPY

JP Mulkey and FW Oehme
Comparative Toxicology Laboratories
Kansas State University
Manhattan, KS 66506
(913) 532-4334

(*Vet Human Toxicol*, submitted for publication)

ABSTRACT

Thallium is a highly toxic metal (LD_{50} 8-12 mg/kg, man; LD_{50} 30 mg/kg, rat) normally present at trace levels in the environment except when concentrated by human activities. The need for a rapid, specific and sensitive analytical method for thallium determination in the clinical laboratory is met by atomic absorption spectroscopy (AAS). Basic AAS principles and instrumentation are discussed. Sample preparation techniques for trace metal analysis of biological material are presented; the destruction of organic matter and liquid-liquid separations are emphasized. The application of flame AAS and graphite furnace (electrothermal) AAS to the determination of thallium in biologic materials is reviewed.

KEYWORDS: Thallium; flame AAS; graphite furnace AAS; electrothermal AAS; chelate; wet ashing; sodium diethyldithiocarbamic acid; methylisobutylketone.

THALLIUM

The toxicity of thallium and its salts has been known almost since the element's discovery in 1861 by Crookes. Named for the brilliant green spectral line it produces, thallium is recognized as one of the most toxic heavy metals (LD_{50} 8-12 mg/kg, man; LD_{50} 30 mg/kg, rat) (1,2).

Normal Thallium Levels

The crustal abundance of thallium is 0.3 ppm, with higher levels found in granite, shale and manganese nodules (Table 1). Natural thallium concentrations in seawater and freshwater are estimated to be <0.03 ppb (3). Normal thallium levels in humans and animals are <1 ppb in blood and urine and <10 ppb in tissues (4,5).

Production and Uses

Thallium is found in pyrites used to make sulfuric acid; the H_2SO_4 production process generates waste residue that yields commercially recoverable levels of the element. Thallium is concentrated in iron, lead, cadmium and copper smelters as flue dust which is further processed to recover commercial quantities of the metal. Annual worldwide thallium production is only ~5 tons (6); recent US production is estimated to be 1500 lbs. Thallium is also released to the environment by cement plant emissions and through agricultural

use of phosphate fertilizer.

A small amount of thallium is used in alloys (anticorrosive), optical lenses (increases refractive index), low-temperature thermometers, dye and pigments (artist paints), semiconductors and ceramics, vapor lamps, scintillation counters, portable radiation (γ ray) detection devices, and in organic chemistry (catalyst).

Mining and smelting, together with sulfuric acid production and coal-burning power plants, are the major iatrogenic sources of thallium in the environment. Major non-point sources are auto emissions (urban) and phosphate fertilizer (rural) but their contribution to the total environmental burden of the metal has not been fully assessed. The use of thallium in these commercial applications gives rise to concerns about occupational exposure and environmental pollution.

Thallium sulfate (Tl_2SO_4), an odorless and tasteless compound, was once used in the US as an insecticide/rodenticide, but was prohibited 1975 as a consequence of several highly publicized accidental, criminal and suicidal poisonings. Many developed countries have banned or strictly controlled its use for this purpose. However, its continued use in developing countries has resulted in a number of accidental human and animal poisonings (7-9).

Thallium was once used to treat syphilis, gonorrhea, tuberculosis, ringworm infestation of the scalp, and as a

cosmetic epilant. Safer and more efficacious drugs long ago replaced thallium in the treatment of these conditions. The only medical use of thallium today is as a radioactive contrast agent (^{201}Tl) to image tumors and to visualize the heart in myocardial function tests (10,11).

Absorption, Distribution, Excretion

After rapid and complete absorption from the respiratory or gastrointestinal tract or skin, water-soluble thallium salts are widely distributed to organs and tissues, including the brain, heart, kidney, skeletal muscle and testis, the principal targets of thallium toxicity (12). Since Tl^+ (1.50 Å) and K^+ (1.38 Å) are univalent ions with similar ionic radii, Tl^+ interferes with ($\text{Na}^+\text{-K}^+$) ATPase (and other K^+ -dependent enzymes) and mimics K^+ in its movement and intracellular accumulation in mammals (13). Tl^+ is less rapidly released than K^+ once it moves into the cell. Its half-life in rats is estimated to be 4 d (14). Thallium is excreted by the kidney into the urine and is also actively transported by intestinal mucosal cells into the lumen of the gastrointestinal (GI) tract where it can either be reabsorbed (enterohepatic circulation) or excreted in the feces. A small amount of the metal is taken up and excreted in the hair, and its presence near the roots can be seen microscopically within 3-4 d of intoxication. Some thallium is retained in bone and other tissues (Tl levels increase with time in chronic

exposure), which suggests incomplete homeostatic regulation of the metal in the body and accounts for its cumulative toxicity.

Toxicity

The toxic effects of thallium in man and animals have been extensively studied and have been the subject of several reviews (15-17). Acute thallotoxicosis produces a complex clinical picture due to its multiorgan involvement. The predominant symptoms in acute exposure result from the metal's effect on the GI tract, peripheral and central nervous system, cardiovascular system, kidney and skin (Table 2). Subacute and chronic thallotoxicosis may occur in the general population (ie, accidental/intentional food poisoning) or in thallium-exposed workers. Symptoms of subacute and chronic thallium intoxication are similar to acute intoxication, but are less pronounced (Table 3). The symptoms in long-term low-level exposure (ie, industrial emissions and runoff) are poorly understood, but may include partial alopecia and mild neurological disturbances. In humans, maternal exposure produces detectable thallium levels in amniotic fluid and breast milk. Thallium is teratogenic in chick embryos but equivocal effects were observed in rats, mice and cats (18). Thallium may cause deformities in humans if the fetus is exposed during the first trimester (19). It has marked antimitotic activity in rapidly dividing tissues, such as hair

follicles and the testes (15).

ATOMIC ABSORPTION SPECTROSCOPY (AAS)


Many analytical methods have been applied to the determination of thallium in biological materials. Electrochemical methods, such as polarography and anodic stripping voltametry, are sensitive and precise techniques but require significant time and effort in the pretreatment stage to reduce interfering substances in the sample. Neutron activation analysis, isotope dilution mass spectrometry, x-ray fluorescence and inductively coupled plasma mass spectrometry are sensitive specialized techniques not generally suitable for routine thallium analysis in the clinical laboratory setting. Colorimetric methods are relatively insensitive and do not attain the detection limits necessary to determine thallium in chronic exposure cases. Significant improvements in AAS instrumentation and development of many AAS procedures for trace metal analysis have occurred over the past two decades. Today AAS is the dominant method for trace metal analysis of biologic materials because of its speed, specificity, sensitivity and precision.

Principles and Instrumentation

A discussion of AAS principles and instrumentation is presented for readers unfamiliar with the technique. Several

excellent texts are available that treat the subject in greater detail (20-22).

AAS is based on the principle that ground state atoms of a given element will absorb monochromatic light of a given wavelength proportionate to the number of analyte atoms present in the sample (Fig 1). Metallic elements present in a sample are reduced to their ground state by the process of thermal disassociation in a flame or graphite furnace (GF):



Absorption spectrometers have components which fulfill 3 basic requirements (Fig 2). Electromagnetic energy from a spectral source, either a hollow cathode lamp (HCL) or electrodeless discharge lamp (EDL), emits the characteristic spectrum of the element of interest (the analyte) which is passed through the flame or GF to a monochromator (normally a diffraction grating) where the resonance line is isolated. Slits are used to allow only a narrow portion of the spectrum containing the resonance line to reach the detector, a photomultiplier tube. The signal is amplified, processed and recorded so that suitable calculations can be made (Fig 3).

The flame itself emits radiation which may interfere with the analyte's resonance line, so single-beam alternating current (a.c.) instruments have a chopper located between the

lamp and the flame. The chopped light produces an alternating current in the detector. The instrument's electronics are designed to amplify only the a.c. signal, thus flame emission is not measured. In double-beam instruments a rotating half-mirror is used that alternately passes the sample beam and reference beam to the detector (Fig 3). The ratio of the two beams is measured electronically and is converted to an analyte absorbance or a concentration reading. Fluctuations in lamp intensity, detector sensitivity and electronic gain give rise to instrumental noise. Since these fluctuations are measured in both beams in the double-beam system they cancel each other out, producing a more stable, precise signal than the single-beam instrument. Of practical significance, the 30-minute warmup period required for source lamp stabilization in the single-beam system is avoided, since fluctuation in lamp intensity is automatically compensated for with the double-beam system arrangement.

Data processing stations, readout devices and other accessories are available for the AAS. Background correction, pulse-nebulization, peak-area integration and fast recorders are useful in the analysis of biological samples. Autosamplers enhance analytical precision and free personnel to perform other laboratory functions (Fig 4). Computerized work stations allow for the automated collection, processing and reporting of data; dedicated software packages provide graphics useful for the development and assessment of new

analytical procedures and on-line statistical analysis of data to facilitate quality control.

Flame AAS

In flame atomization, the sample solution is drawn by a venturi effect into a spray chamber and the sample mist is mixed with a fuel gas (Fig 5). The aerosol then enters the flame where the analyte is desolvated, dissociated and atomized in rapid succession. Only the smallest droplets ($\leq 10 \mu\text{m}$) reach the flame so much of the sample is wasted (~90%). Two combinations of oxidant-fuel gases are in common use: The air-acetylene flame (2300°C) will atomize about 35 elements; refractory elements require the hotter nitrous oxide-acetylene flame (2900°C). Pulse-nebulization is useful for small samples (Fig 6). A 20-200 μl aliquot is pipetted into a teflon funnel attached to the nebulizer capillary tube; the analyte produces a sharp transient peak that can be quantified. The advantages of flame AAS over GF AAS are its simple optimization requirements, convenience, speed and precision. Disadvantages are the requirement for large sample volumes (3-5 ml) if pulse-nebulization is not available, inefficient use of sample, and its relative lack of sensitivity compared to GF AAS. Because of its advantages, flame AAS should be used whenever sample size and detection limit (DL) are not limiting factors.

Graphite Furnace AAS (Electrothermal AAS)

The graphite furnace's main functional component is a small, cylindrical graphite tube through which the source beam passes. The sample is injected through a hole located on the top of the tube (Fig 7,8). The GF tube is heated by electrical resistance and can attain a temperature of $\sim 3000^{\circ}\text{C}$. The GF has two advantages over flame AAS that make it well suited for the determination of trace elements in biological samples -- it uses small sample volumes (10-50 μl) and it has much lower detection limits for most elements (typically 100-1000 times lower than flame AAS). In the GF mode the GF assembly replaces the burner, and it is controlled by a programmer unit that regulates the furnace as it goes through its dry, char (ash), atomize, clean-out, and cool-off stages. As the AAS cycles through its program the sample solution is desolvated, the volatile organic and inorganic matrix material is vaporized and swept out of the tube, the analyte is atomized and its absorbance measured, any remaining analyte or matrix residue is eliminated, and the water-cooled GF assembly drops the tube to ambient temperature prior to the introduction of the next aliquot of sample. The graphite tube is bathed by a continuous stream of inert gas (usually argon) to prevent its oxidation at high temperature. The GF has several disadvantages -- a laborious program optimization procedure must be done for every analyte/matrix combination, marked background problems must be compensated for (discussed below), severe

interferences are common, carbide formation can occur, memory effects and contamination are common, and longer instrumental times are required (eg, 2-4 min/sample vs 5-10 s/sample for flame AAS).

Background Interference

The analyte sample normally contains a variety of non-analyte constituents (eg, ions, molecules) that are released to the gaseous phase at high temperature. Molecular species, in particular, may absorb at the analyte's resonance line and/or scatter the source beam. If not compensated for, this so-called non-atomic (background) absorption would result in an elevated absorbance reading and an inaccurate analyte determination. Three types of background correction systems (BCS) are available -- the deuterium lamp (continuum) BCS, the Zeeman BCS, and the Smith-Hieftje BCS; newer instruments have one or more BCS as a standard feature. Each BCS works on different principles, but their effect is the same; they measure non-atomic absorption which is electronically subtracted from the total signal so an accurate analyte absorbance is recorded (Fig 9).

Sample Preparation

The amount of sample preparation required for biological fluids depends on the analyte and its concentration, sample type and composition, and on the precision and accuracy

needed. No one procedure is applicable in all cases. Some metals can be determined directly in blood or urine; others must be preconcentrated or have at least a portion of the interfering matrix constituents removed. Many times the presence of organic material precludes analyte determination unless it is first destroyed. This is always the case in the trace metal analysis of tissues and fecal matter. Once the organic matter is destroyed and the analyte is brought into solution, the digest may be directly analyzed if the element of interest is present in sufficiently high concentration. If not, a preconcentration step may be necessary to eliminate remaining interferants and to increase analyte concentration so that a determination can be made.

The risk for sample contamination and analyte loss is particularly high during the preparatory steps. Potential sources of contamination are contaminated reagents and dirty glass/plasticware and laboratory equipment (homogenizers, grinders, desiccators). Analyte losses may arise through analyte volatilization at elevated temperature and by analyte adsorption to the walls of beakers, flasks, test tubes or other labware.

Destruction of Organic Matter

Decomposition procedures generally fall into two classes, dry ashing or wet ashing. Sample decomposition procedures release the analyte from the biological matrix by oxidizing

organic material to volatile molecules (eg, CO_2 , H_2O , N_2) leaving the analyte in simple inorganic form suitable for analysis. The destruction method used depends on a number of factors: Analyte volatility; sample matrix composition; and the compatibility of the final digest with the AAS or its suitability for the follow-on sample preparatory step.

Dry ashing is relatively straight forward and simple. An accurately weighed sample (5-10 g) is placed in a platinum, silica or porcelain vessel and heated on a hot plate at moderate temperature until it chars. The vessel and sample are transferred to a cold muffle furnace and the temperature is gradually increased to 450-500° C and held there overnight. If any organic material remains, a small amount of water or dilute nitric acid is added to the sample and the drying process repeated. The ash is then dissolved in a dilute acid solution or other appropriate solvent for introduction to the AAS. The method can not be used for volatile elements like arsenic, mercury, zinc or cadmium; partial losses occur with lead, nickel and thallium. (Note: Many variants of this procedure can be found in the literature.)

Wet ashing destroys organic matter by exposing it to strong oxidizing reagents at moderate temperature. The most commonly used oxidants are concentrated mineral acids (HCl , H_2SO_4 and perchloric acid [HClO_4]), which may be used individually or as acid mixtures. The digestion is done in a covered beaker or covered Erlenmeyer flask, or preferably in

a Kjeldahl flask. The wet ash procedure described below is but one of many procedures that can be found in the literature.

An accurately weighed sample of ~5 g is placed in a vessel and HNO_3 (5 ml) is added. The mixture is allowed to stand at room temperature until the initial vigorous reaction subsides. H_2SO_4 (8 ml) is added and the mixture is heated on hot plate until it darkens. With a pasteur pipette, 1-2 ml portions of HNO_3 are added until the mixture remains pale yellow in color (avoid charring). After the mixture cools, HClO_4 (2 ml) is added and it is gently boiled until the almost colorless solution gives off white fumes. The mixture is cooled, H_2O (2 ml) is added, and the process is repeated again. The solution is cooled, H_2O (5 ml) is added, and the solution is quantitatively transferred to a suitable volumetric flask and made to volume.

One should always exercise caution when using hot concentrated HClO_4 . If HClO_4 is heated in the presence of carbohydrates or alcohols unstable perchlorate esters will form that can violently and spontaneously explode. Always perform a preliminary digest with HCl or HNO_3 which will completely oxidize carbohydrates and alcohols (23).

Wet ashing is generally preferred to dry ashing because analyte loss due to volatilization and retention on the vessel wall is less likely. Other destruction methods are available and are mentioned but not discussed -- the Parr bomb (a

pressure system), microwave digestion, fusion techniques, and plasma ashing (free radical generation). Several good sources for detailed information on destruction techniques are available (23,24).

Separation and Preconcentration

In trace metal analysis of biological samples it is often necessary to separate the analyte metal from the sample matrix in order to reduce interfering substances and/or to sufficiently concentrate the metal so it can be determined by AAS (Fig 10).

Solvent extraction is a convenient separation technique because often separation and preconcentration can be accomplished in one quick and easy step. A simple batch separation technique (Fig 11) frequently used in AAS procedures consists of the following: A volume (say ~30 ml) of pH-adjusted aqueous solution (eg, urine) containing the metal ion (M^+) of interest is transferred into a separatory funnel; a complexing agent (L^-) is added, the solution is shaken and a ML complex forms; a measured volume (say ~3 ml) of organic solvent is added, the two phases are shaken, and the ML complex is quantitatively extracted into the organic phase; the two phases are allowed to separate and the aqueous phase is discarded. The organic phase is directly aspirated into the flame or injected into the GF. Note that the analyte has been moved to a less complex solution (ie, many interferants are

left in the aqueous phase) and the analyte has been concentrated 10 fold. An additional 2-5 fold sensitivity enhancement is normally obtained by using an organic solvent in flame AAS, which is attributable to its improved operating characteristics in the pre-mix burner and flame.

Sometimes batch separations can not concentrate the metal enough for an AAS determination to be made. More powerful preconcentration methods must be resorted to, such as multiple batch separations or continuous separation techniques. Comprehensive analytical chemistry texts (25, 26) and specialized works (27) cover analytical separations in more detail.

Standardization

AAS is a comparative method which, by definition, requires calibration against known standards in order for accurate quantitative results to be obtained. In all comparative methods there is a mathematical relationship that expresses the measured physical parameter as a function of analyte concentration. In AAS, absorbance is the physical parameter measured.

Spectrophotometric methods obey Beer's Law which states, in AAS terms, that the intensity of a source lamp resonance line passing through a mass of absorbing gas decreases exponentially as the number of ground state analyte atoms

increases arithmetically. Mathematically:

$$A = \log I_0/I = abc$$

where A is absorbance, I_0 is incident beam intensity, I is transmitted beam intensity, a is absorptivity, b is the path length, and c is analyte concentration. Since a and b are constants, analyte concentration is linearly related to absorbance which means that a plot of A vs. c results in a straight line calibration curve, at least within a limited concentration range. At higher analyte concentrations the straight line curves downward towards the concentration axis due to loss of efficiency in the absorption process (Fig 12). It should be noted that a perfect linear relationship does not exist for the data points in the linear region because indeterminate errors always occur in AAS. The method of least squares is often used to fit a straight line to the plotted data points (Fig 13).

In practice, the analyst prepares a blank and a series of analyte standards and measures their absorbance. Samples of unknown analyte concentration are similarly measured. Regression analysis of analyte concentration vs. blank-corrected absorbances is calculated, from which the analyte concentration in the samples can be determined. If necessary, samples are diluted to fall within the concentration range of the standards.

AAS standards can be prepared in various ways. The simplest and fastest method is to prepare aqueous standards over the concentration range desired. However, aqueous standards are often unreliable because they do not compensate for matrix and interelement effects, incomplete recoveries and sample contamination. It is better to use standards that have been subjected to the same procedure as the samples.

It is important to match the standard matrix and sample matrix as closely as possible, since often absorbance readings are altered by the presence of non-analyte components (eg, salts, acids, molecules) in the matrix. Matrix matching is difficult to do with complex samples like biological materials. One method of attempting to overcome this problem is to calibrate and analyze within the sample matrix itself by using the standard additions method (SAM). In this procedure an aliquot of sample is analyzed. Known amounts of standard are added to separate aliquots of sample and their absorbances are measured. The increase in absorbance observed is linearly related to the amount of standard added, and a direct comparison is made between the sample absorption and the increased absorption due to the added standard (Fig 14). This relationship takes the form:

$$C = A_0 C_{sn} / (A_n - A_0)$$

where C is unknown analyte concentration in the sample; A_0 is

the measured sample absorbance with no standard added; C_{sn} is the total increase in analyte concentration after n additions of standard has been made; and A_n is the absorbance measured after n additions of standard. If C_{sn} vs. A is plotted, a linear relationship is seen; A_0 is the y-intercept, and C is found by extrapolating the best fit line back through the x axis.

The SAM must be used with some precaution. Two or more standard additions should be used to insure that absorbance and concentration are linear over the concentration range used. If chemical interferences are observed, they must be constant over the concentration range used. The SAM assumes that the observed absorbance is due only to the analyte being determined. Effective background correction must be verified to insure that erroneously high analyte concentrations are not accepted. A good discussion of SAM calculations and related statistics has been written by Bader (28).

DETERMINATION OF THALLIUM IN BIOLOGIC MATERIALS BY ASS

AAS procedures for the determination of thallium in biological materials have gained widespread acceptance in the clinical laboratory because they are highly specific, sensitive and accurate. Since the flame AAS instrument preceded the GF AAS in development, the early methods for thallium determination were naturally designed for the former. Flame

methods are still applicable in cases of severe acute poisoning and in animal toxicological studies, but they do not have the DLs required to detect chronic thallium exposure (ie, occupational monitoring) or to monitor the treatment of thallotoxicosis. The literature has been reviewed by Subramanian (29,30) and Leloux (31).

Flame AAS Methods

Thallium has a DL of 3 ppm in flame AAS (32), so some type of preconcentration step is necessary in these methods. Early flame AAS procedures were summarized by Zitko (33) and Van Ormer (34).

The Wilson and Hausman method (35) detects microgram quantities of thallium in $\text{HNO}_3/\text{H}_2\text{O}_2$ digested tissue samples (1-3 g) after neutralizing the digest with NH_3 , adding liquid bromine + HBr and heating to expel the excess bromine, and extracting TlBr into 2-octanone. The organic phase is aspirated directly into the flame and absorbance is measured at 377.6 nm. Thallium recoveries of $98.2 \pm 1.76\%$ are obtained.

Berman (36) determined thallium in urine, blood and acid-digested tissues by chelation with diethyldithiocarbamate (NDDC) and extraction into methylisobutylketone (MIBK). Prior to chelation/extraction blood samples are treated with 5% trichloroacetic acid (TCA) to remove proteins, urine samples are brought to a pH of 6.0-7.5 with NaOH , and tissue samples

are digested with $\text{HNO}_3/\text{HClO}_4$ and then similarly pH-adjusted. This method has DL of ~ 0.5 ppm at a resonance line of 276.8 nm; 95-110% of added thallium was detected in recovery studies. The procedure has been adapted for GF AAS (37).

Savoy et al (38) wet-ashed blood, tissues and feces with a mixture of $\text{H}_2\text{SO}_4/\text{HNO}_3/\text{HClO}_4$. Thallium is converted to TlBr_3 by addition of bromine water and the metal halide extracted into diethyl ether which is evaporated to dryness. The residue is dissolved in a mixture of dilute acid and aspirated into the flame. DLs of 0.07 ppm (urine) and 0.7 ppm (blood) are claimed at $\lambda=276.8$ nm. Nineteen metals/anions were tested for interference at various concentrations, and $\leq 1\%$ change in absorption by thallium standards was noted. This method is fairly precise; coefficients of variation (CVs) at different concentrations ranged from 3.5 to 6.9%. Thallium levels determined by this method were compared to levels measured by the Christian-Purdy (39) coulometric method, and a 0.98 correlation coefficient was obtained.

Arguably the most frequently used procedure for thallium determination in biological samples by flame AAS is that of Curry et al (40). Tissue and feces are acid digested in a mixture of $\text{H}_2\text{SO}_4/\text{HNO}_3$. The digest's pH is adjusted between 5.0-6.0 with 2.5N NaOH and the thallium is then chelated with 1% NDDC (1 ml) and extracted into water-saturated MIBK (5 ml) which is then nebulized into the flame. Whole blood (1 ml) is mixed with 5% TCA (1 ml), shaken for 1 h, then centrifuged.

The supernatant is transferred to a suitable container and the precipitate is washed with deionized-distilled water (DI H₂O) (5 ml), stirred and centrifuged again. After the supernatants are combined and the pH is adjusted to 6.0 with 1N NaOH, chelation and extraction are performed as previously stated. Urine (2 ml) is adjusted to pH 6.0 by adding either 5% TCA or 2N NaOH. If a precipitate forms, the mixture is centrifuged and the supernatant transferred to a separate container. The precipitate is washed with DI H₂O (5 ml), stirred and centrifuged. The supernatants are combined and the pH readjusted to 6.0. Chelation and extraction with NDDC and MIBK (2 ml) are performed as above and the organic phase is aspirated into the flame. A DL of 0.04 ppm for MIBK-extracted thallium is obtained vs a DL of 0.2 ppm in aqueous solution. The improved sensitivity is attributed to an increased sample aspiration rate, the formation of smaller sized droplets, and lower flame temperature (decreased analyte ionization). Good thallium recoveries (95-105%) were achieved and the reasonably low CVs obtained (3.5-8.5) indicate the procedure is fairly precise. A modification of this procedure using a tantalum boat decreases DLs to the ppb range, but severe interferences occur which necessitates standardization by SAM.

Wall (41) developed a rapid procedure with sufficient sensitivity for screening urine in cases of suspected thal-
lotoxicosis. Urine samples and aqueous standards are aspi-
rated directly into a 3-slot Belling burner using an air/

acetylene flame. A DL is not reported but ~ 0.1 ppm at the 276.8 nm resonance line can be inferred. CVs of $\leq 3\%$ were reported for urine samples spiked with 0.5, 1.0 and 5.0 ppm thallium. The possibility of matrix interference in urine was investigated but none was found when samples were aspirated directly into the air/acetylene flame.

Graphite Furnace AAS Methods

GF AAS is approximately 100 times more sensitive than standard flame methods for the determination of thallium in biological materials. Until recently, enhanced performance came with a penalty in the form of severe matrix interferences and relatively poor precision compared to flame AAS. This was particularly true for matrices high in chloride (Cl^-) content, like urine. However, the development of commercial GF AAS instruments incorporating Stabilized Temperature Platform Furnace (STPF) (L'vov platform, Zeeman background correction, signal integration, stop-gas during atomization, maximum power heating and matrix modification) (42) technology and powerful data processing stations has gone a long way towards making GF AAS an interference-free technique (30).

Early GF AAS methods for thallium determination used chelation and extraction steps to overcome matrix interferences. Kubasik and Volsin (43) found direct injection of acidified (HNO_3) urine unsatisfactory because background interference could not be reduced to correctable levels using

the deuterium BCS without seriously compromising sensitivity. NDDC and MIBK were used to transfer thallium into a relatively matrix-free environment, but SAM was required for accurate calibration. A sensitivity of 1.5 ppb was achieved using 1.6 μ l samples. By using essentially the same method and 20 μ l samples, Schaller et al (44) improved the sensitivity to 0.3 ppb.

Chandler and Scott (45) reduced urine matrix interference by using NDDC/toluene to separate thallium after adjusting the aqueous phase to pH 7. The mixed phases form an emulsion that require centrifugation to separate. Calibration is accomplished by using thallium-spiked pooled urine. By using an autosampler to deliver 40 μ l samples to a the graphite tube, they achieved good sensitivity (0.1 ppb DL) and excellent precision (3.5% within-batch RSD and 4.4% between-batch RSD). The investigators compared the performance of a standard (uncoated) graphite tube, a pyrolytically coated graphite tube, a L'vov platform in an uncoated graphite tube, and an uncoated graphite tube having an interlay of tantalum foil. The foil-lined tube performed best, enhancing absorbance by a factor of 2, but the tantalum survived only a few firings. Atomization off the wall (uncoated tube) and off the platform (L'vov platform uncoated tube) performed equally well. Interestingly, the uncoated graphite tube performed much better than the pyrolytically coated graphite tube.

Grobenski et al (46) used STPF technology to develop a

direct thallium determination method for the GF AAS. Urine is diluted with 2% HNO_3 , and a 10 μl aliquot is injected into the GF. The autosampler then delivers a 10 μl portion of matrix modifier solution composed of 2% ammonium dihydrogen phosphate ($\text{HN}_4\text{H}_2\text{PO}_4$) and 0.02% Triton X-100. The modifier stabilizes thallium and allows a char temperature of 700° C, which removes many interfering matrix constituents thus reducing background absorption to acceptable levels. The authors claim a DL of 0.13 ppb using a 10 μl sample. Pachel and Bailey (47) used a similar approach, but with a matrix modifier solution composed of 4% HNO_3 , 10% magnesium nitrate [$\text{Mg}(\text{NO}_3)_2$] and 0.1% Triton X-100. Urine is diluted 1+1 with the modifier by sequential autosampler injections into the L'vov platform graphite tube. Zeeman background correction is required and matrix matched standards are used for standardization.

Leloux et al (48) developed a direct thallium determination method for urine, blood and feces which was applied in a study of thallotoxicosis in rats. Urine and blood are injected directly into the L'vov platform graphite tube; tissue and fecal samples are dissolved in concentrated HNO_3 at 60-70° C and their supernatants used for the analysis. A matrix modifier solution composed of 1% H_2SO_4 , 2% ascorbic acid and 2% Triton X-100 is used to reduce chloride interference and to increase the absorbance signal. The temperature program parameters used were dry-1 120° C (10 s), dry-2 250° C (20 s), char 800° C (62 s), atomize 1800° C (4.6 s), and

clean-out 2600° C (2 s). DLs of 5 ppb for urine, tissues and feces and 10 ppb for blood are achieved using 4 µl samples + 2 µl modifier. SAM is required for calibration. The authors note that ash buildup in the graphite tube becomes problematic when blood samples are analyzed which causes memory effects, diminished sensitivity and reduced precision. The authors recommend cleaning the graphite tube periodically by scraping off deposits with a disposable pipet tip. Delves and Shuttler (49) expressed concern over the use of only one standard addition for calibration and suggested that ascorbic acid may contribute to the build-up or residue.

Welz et al (50,51) demonstrated that Cl^- interferes with the GF determination of thallium in two ways -- the metal can prematurely volatilize as TlCl (mp 430° C; bp 720° C (52)) during the char stage of the temperature program and thallium can combine with Cl^- to form TlCl instead of elemental thallium (Tl^0) during atomization stage. These researchers used the metal palladium [as $\text{Pd}(\text{NO}_3)_2$] pre-treated in the GF at 1000° C and 5% hydrogen as chemical modifiers. Palladium works by thermally stabilizing thallium, thereby allowing higher char temperatures which increase the volatilization of Cl^- species. The presence of H_2 in the purge gas enhances the elimination of Cl^- by promoting the formation of volatile HCl . In this method the modifier (10 µl) and undiluted urine (10 µl) are sequentially injected into the GF; more easily prepared acid-matched aqueous standards are used for calibra-

tion since the modifier eliminates all Cl^- interference. With its 2 ppb DL and its apparent freedom from interference, this method appears quite promising for the routine analysis of thallium in the clinical laboratory.

CONCLUSIONS

Thallium is one of the most toxic heavy metals to which animals and humans are exposed. Acute exposure to high levels of thallium produces a complex array of symptoms involving the peripheral and central nervous systems, GI system, cardiovascular system, kidney and skin. The health risk of low-level chronic exposure to humans and animals is not well understood and warrants further investigation. The need for research in this area is underscored by the continued development of new technologies and production processes that use thallium and by periodic reports in the literature of human and animal exposures to the metal (53).

The molecular basis for thallium's toxicity has been largely ascribed to its ability to interfere with K^+ -based processes (12). However, there is a growing body of experimental evidence suggesting that other factors may be involved, such as thallium-mediated neurochemical changes (in amino acid and neurotransmitter levels) in the central nervous system (54) and thallium-mediated induction of lipid peroxidation in certain tissues (55). Work directed towards identifying and

characterizing the molecular targets of thallium toxicity should continue.

The dire effects of thallium toxicity were first documented shortly after the element's discovery. Yet, to this date, there remains to be discovered a safe and effective parenteral antidote for thallototoxicosis. More effort should be focused on chelator development and on the clinical evaluation of possible chelator combinations.

Over the past two decades AAS has become the dominant analytical tool for the quantification of thallium levels in biological materials. Acute toxic exposure to thallium can be quickly and easily assessed by flame AAS. Reliable methods are available for the detection of thallium at ppb levels using the GF AAS. The development of direct methods for the determination of thallium (and other metals) that exploit the advantages of Stabilized Temperature Platform Furnace (STPF) technology will undoubtedly improve the clinical laboratory's efficiency and responsiveness to the clinician. The continued development of chemical modifiers is key in this regard.

REFERENCES

1. Downs WL, Scott JK, Steadman LT et al: Acute and subacute toxicity studies of thallium compounds. Am Ind Hyg Assoc J 21:399-406, 1960.
2. Beliles RP: The lesser metals. In Oehme FW ed: Toxicity of Heavy Metals. Part 2. Hazardous and Toxic Substances. Marcel Dekker, New York: 596-597, 1979.
3. Fergusson JE: The Heavy Elements: Chemistry, Environmental Impact and Health Effects. Pergamon, New York: 18, 275, 1980.
4. Weinig E, Zink P: Quantitative mass spectrometric determination of the normal thallium content in the human body. Arch Toxicol 22:275, 1967.
5. Geilmann W, Beyermann K, Neeb KH et al: Thallium as a trace element for animals and plants. Biochem Z 333:62, 1960.
6. Adriano DC: Trace Elements in the Terrestrial Environment. Springer Verlag, Berlin: 115, 1986.
7. Ben-Assa B: Indirect thallium poisoning in a Bedouin family. Harefuah 62: 378-380, 1982.
8. Zhou D, Lin D: Chronic thallium poisoning in a rural area of Guizhou Province, China. J Environ Health 48:14-18, 1985.
9. Hakala JE: Thallium poisoning in a dog. Mod Vet Pract 65:783-784, 1984.

10. Bradley-Moore PR, Lebowitz E, Greene MW et al: Thallium-201 for medical use. Part 2. Biologic behavior. J Nucl Med 16:156-160, 1975.
11. Atkins HL, Budinger TF, Lebowitz E: Thallium-201 for medical use. Part 3. Human distribution and physical imaging properties. J Nucl Med 18:133-140, 1977.
12. Sabbioni E, Marafante E, Rade J et al: Metabolic patterns of low and toxic doses of thallium in the rat. In Holmstedt B, Lauwerys R, Mercier M et al: Mechanisms of Toxicity and Hazard Evaluation. Proceedings of the Second International Congress on Toxicology held in Brussels, Belgium, July 6-11, 1980, Elsevier, Amsterdam: 559-564, 1980.
13. Gehring PJ, Hammond PB: The interrelationship between thallium and potassium in animals. Pharmacol Exp Ther 155:187-201, 1967.
14. Rauws AG: Thallium pharmacokinetics and its modification by prussian blue. Naunyn-Schmiedeberg's Arch Pharmacol 284:295-306, 1974.
15. Manzo L, Sabbioni E: Thallium toxicity and the nervous system. In Bondy SC, Prasad KN ed: Metal Neurotoxicity, CRC Press, Boca Raton: 36-54, 1988.
16. Moeschlin S: Thallium poisoning. Clin Toxicol 17:133-146, 1980.
17. Saddique A, Peterson CD: Thallium poisoning: A review. Vet Hum Toxicol 25:16-22, 1983.

18. Sabbioni E, Manzo L: Metabolism and toxicity of thallium. In Manzo L ed: Advances in Neurotoxicology. Pergamon, New York: 249-270, 1980.
19. Truhant R: The toxicology of thallium. J Occup Med 2:334-336, 1960.
20. Willis JB: Flame emission and atomic absorption spectrometry. In McKenzie HA, Smythe LE eds: Quantitative Trace Analysis of Biological Materials. Elsevier, New York: 135-154, 1988.
21. Robinson JW: Atomic absorption spectroscopy. In Elving PJ, Meehan EJ, Kolthoff IM eds: Treatise on Analytical Chemistry. Part 1. Theory and Practice, 2nd ed. J Wiley & Sons, New York: 730-799, 1981.
22. Slavin M: Atomic Absorption Spectroscopy, 2nd ed. J Wiley & Sons, New York: 15-26, 1978.
23. Gorsuch TT: The Destruction of Organic Matter. Pergamon, New York: 1-39, 1970.
24. Bock R: Handbook of the Decomposition Methods in Analytical Chemistry. J Wiley & Sons, New York: 1-56, 1979.
25. Willard HH, Merit LL, Dean JA et al: Instrumental Methods of Analysis. Van Nostrand Reinhold, New York: 335-383, 1981.
26. Harris DC: Quantitative Chemical Analysis, 2nd ed. WH Freeman, New York: 592-669, 1987.

27. Mizuike A: Enrichment Techniques for Inorganic Trace Analysis. Springer Verlag, Berlin: 30-51, 1983.
28. Bader M: A systematic approach to standard addition methods in instrumental analysis. J Chem Ed 57:703-706, 1980.
29. Subramanian KS: Determination of trace metals in human blood by graphite furnace atomic absorption spectrometry. Prog analyt Spectrosc 9:237-334, 1986.
30. Subramanian KS: Determination of trace elements in biological fluids other than blood by graphite furnace atomic absorption spectrometry. Prog analyt Spectrosc 11:511-608, 1988.
31. Leloux MS, Lich NP, Claude J-C: Flame and graphite furnace atomic absorption spectroscopy methods for thallium - a review. At Spectrosc 8:71-75, 1987.
32. Smith IC, Carson BL: Trace Metals in the Environment. Volume 1 - Thallium. Ann Arbor Science, Ann Arbor: 45, 1977.
33. Zitko V: Toxicity and pollution potential of thallium. Sci Total Environ 4:185-192, 1975.
34. Van Ormer DG: Atomic absorption analysis of some trace metals of toxicological interest. J Forensic Sci 20:595-623, 1975.
35. Wilson JW Jr, Hausman R: The determination of thallium in organs and body fluids by a flame spectrophotometric method. J Lab Clin Med 64:154-159, 1964.

36. Berman E: Determination of cadmium, thallium and mercury in biological materials by atomic absorption. At Absorpt News1 6:57-60, 1967.
37. Berman E: Thallium. In Grove EL ed: Applied Atomic Spectroscopy. Vol 2. Plenum Press, New York: 127-131, 1978.
38. Savory J, Roszel NO, Mushak P et al: Measurements of thallium in biologic materials by atomic absorption spectrometry. Am J Clin Path 50:505-509, 1968.
39. Christian GD, Purdy WC: Coulometric determination of thallium in blood and urine. Am J Clin Path 46:185-188, 1966.
40. Curry AS, Read JF, Knott AR: Determination of thallium in biological material by flame spectrophotometry and atomic absorption. Analyst 94:744-753, 1969.
41. Wall CD: The determination of thallium in urine by atomic absorption spectroscopy and emission spectrography. Clin Chim Acta 76:259-265, 1977.
42. Slavin W, Carnick GR: The possibility of standardless furnace atomic absorption spectroscopy. Spectrochim Acta 39B:271-282, 1984.
43. Kubasik NP, Volosin MT: A simplified determination of urinary cadmium, lead and thallium with use of carbon rod atomization and atomic absorption spectrophotometry. Clin Chem 19:954-958, 1973.

44. Schaller KH, Manke G, Raithel HJ et al: Investigations of thallium-exposed workers in cement factories. *Int Arch Occup Environ Health* 47:223-232, 1980.
45. Chandler HA, Scott M: Determination of low levels of thallium in urine using chelation with sodium diethyldithiocarbamate, extraction in toluene, and atomic absorption spectrophotometry with electrothermal atomization. *At Spectrosc* 5:230-233, 1984.
46. Grobowski Z, Lehmann R, Radziuk B et al: Graphite furnace AAS detection limits in real samples. *At Spectrosc* 7:61-63, 1986.
47. Paschel DC, Bailey GG: Determination of thallium in urine with Zeeman effect graphite furnace atomic absorption. *J Anal Toxicol* 10:252-256, 1986.
48. Leloux MS, Nguyen PL, Claude J-R: Determination of thallium in various biological matrices by graphite furnace atomic absorption spectrophotometry using platform technology. *At Spectrosc* 8:75-77, 1987.
49. Delves HT, Shuttler IL: Elemental analysis of body fluids and tissues by electrothermal atomization and atomic absorption spectrometry. In Haswell SJ ed: *Atomic Absorption Spectrometry - Theory, Design and Applications*. Elsevier, New York: 381-438, 1991.

50. Welz B, Schlemmer G, Mudakavi JR: Palladium nitrate-magnesium nitrate modifier for graphite furnace atomic absorption spectrometry. Part 2. Determination of arsenic, cadmium, copper, manganese, lead, antimony, selenium and thallium in water. J Anal At Spectrom 3:695-701, 1988.
51. Welz B, Sclemmer G, Mudakavi JR: Investigation and elimination of chloride interference of thallium in graphite furnace atomic absorption spectrometry. Anal Chem 60:2567-2572, 1988.
52. Korenman IM: Analytical Chemistry of Thallium. Lerman Z translator. Ann Arbor-Humphrey Science Publishers, Ann Arbor: 119, 1969.
53. Dolgner R, Brockhaus A, Ewers U et al: Repeated surveillance of exposure to thallium in a population living in the vicinity of a cement plant emitting dust containing thallium. Int Arch Occup Environ Health 52:79-94, 1983.
54. Ali SF, Jairaj K, Newport GD et al: Thallium intoxication produces neurochemical alterations in rat brain. Neurotoxicology 11:381-390, 1990.
55. Aoyama H, Yoshida M, Yamamura Y: Induction of lipid peroxidation in tissues of thallous malonate-treated hamsters. Toxicology 53:11-18, 1988.

56. Beaty RD: Concepts, Intrumentation and Techniques in Atomic Absorption Spectrophotometry. Perkin-Elmer, Norwalk: 1.1-7.5, 1988.
57. Tsalev DL, Zaprianov ZK: Atomic Absorption Spectrometry in Occupational and Environmental Health Practice. CRC Press, Boca Raton: 1-36, 1983.

TABLE 1. THALLIUM CONTENT (ppm) OF CRUSTAL MATERIAL.
Adapted from Fergusson JE (3).

IGNEOUS (mean)		GRANITE (mean)		OTHER	
Basalt	0.08	Shale	1.2	Mn nodules	100
Granite	1.1	Limestone	0.14	Phosphate	<0.03-1
		Sandstone	0.36	Coal	0.01-2



TABLE 2. SYMPTOMS SEEN IN ACUTE THALLOTOXICOSIS


SYSTEM	EARLY EFFECTS	LATE EFFECTS
Gastro-intestinal	constipation loss of appetite nausea & vomiting "brick red" mucous membranes (dog/cat) & tip of tongue (man)	abdominal pain
Nervous	hyperesthesia of soles of feet hyperreflexia excessive thirst sleeplessness psychoses, hallucina- tions, dementia convulsions, coma	hypoesthesia areflexia (10-15 d) inability to walk
Cardio-vascular	tachycardia moderate increase in blood pressure arrhythmias	
Renal	albuminuria occasionally RBCs, WBCs and casts in urine	
Skin	anhidrosis; dry scaly skin; acne black pigmentation of hair roots	alopecia (10-20 d) semilunar white stripes on nails (Mee's lines)



TABLE 3. SYMPTOMS OF SUBACUTE AND CHRONIC THALLOTOXICOSIS


SYSTEM	SYMPTOMS
Gastro-intestinal	Nausea/vomiting; anorexia; weight loss; stomatitis
Nervous	Paresthesia to definite peripheral polyneuritis (particular of the lower extremities); ataxia; muscle/joint pain; aptosis; strabismus; facial palsy; mydriasis; psychotic signs (permanent neurological and psychiatric disturbances may occur)
Cardio-vascular	tachycardia, transient EKG changes; arrhythmias
Renal	albuminuria
Skin	delayed alopecia (weeks or months) black pigmentation of hair roots


ATOMIC VAPOR







































CAPTIONS

Figure 1. Atomic absorption spectroscopy (AAS) is an analytical technique for quantifying metal (analyte) concentrations in biologic samples, based on the absorption of radiation by free atoms of the analyte of interest. The atomizer heats the sample to create population of free atoms (atomic vapor). The light source emits the spectrum of the analyte of interest. The light beam contains a resonance line (λ_a) of intensity (I_0), that is partially absorbed by free analyte atoms in sample cell (atomizer) to produce a transmitted light beam of intensity (I). A monochromator and a narrow slit-width (bandpass \approx 2 nm) isolate λ_a from other emitted spectral lines (λ_e). The detector measures radiation intensity, which is converted to an absorbance signal that is proportionate to the analyte concentration in the sample, $A = \log (I_0/I) = k C$.

Figure 2. All absorption spectrometers have components that fulfill 3 basic requirements. There must be a light source, a sample cell and a means of specific light measurement. A graphite furnace replaces the flame burner assembly in electrothermal AAS. (From 56, with permission.)

Figure 3. Optical paths for the single beam (top) and double-beam (bottom) systems. (From 56, with permission.)

Figure 4. The Perkin-Elmer AS-3 autosampler. (From 56, with permission.)

Figure 5. Schematic of a pre-mix burner. (From 57, with permission.)

Figure 6. Pulse-nebulization technique. Small sample volumes are injected into a teflon funnel. (From 57, with permission.)

Figure 7. Graphite furnace tube with L'vov platform.

Figure 8. Cross section of the Perkin-Elmer graphite furnace. Inert gas is introduced at both ends of the graphite tube to prevent thermal oxidation of the tube and oxide formation of the free analyte atoms. (From 56, with permission.)

Figure 9. The background correction system uses a continuum source (deuterium lamp) to measure non-atomic absorption (BG), which is subtracted from the combined atomic and non-atomic absorption signal (AA+BG) of the primary source to produce a readout that indicates true atomic absorption ($AA = [AA+BG] - BG$). (From 56, with permission.)

Figure 10. Extraction of a chelated metal ion into the organic phase. It is assumed that M^{n+} is the predominant form of the metal in aqueous solution and that ML_n is the predominant form in the organic phase.

Figure 11. Apparatus used in batch extraction. A = Separatory funnel, B = Centrifuge tube. (From 27, with permission.)

Figure 12. AAS calibration curve. At higher concentrations, the calibration curve departs from linearity. The most accurate measurements are those falling in the center of the linear portion of the calibration curve, whereas the least accurate measurements are those obtained from the upper part of the curve.

Figure 13. AAS calibration curve. Analyte standards falling in the linear region of the calibration curve are fitted with a calibration line by linear regression. The analyte concentration in the sample is found by rearranging the linear regression equation and solving for $x = [y-b]/m = [y-0.0009]/0.9997$.

Figure 14. Calibration by the standard addition method is used for analyte determinations in complex matrices displaying unpredictable degrees of interference.

CHAPTER 3

A STUDY OF THE ANTIDOTAL EFFICACY OF 2,3-DIMERCAPTO-1-PROPANESULFONIC ACID AND PRUSSIAN BLUE IN THE TREATMENT OF ACUTE THALLOTOXICOSIS IN RATS

James P. Mulkey and Frederick W. Oehme

Comparative Toxicology Laboratories

Kansas State University

Manhattan, KS 66506

(913) 532-4334

(Fundam Appl Toxicol, submitted for publication)

ABSTRACT

A Study of the Antidotal Efficacy of 2,3-Dimercapto-1-propanesulfonic Acid and Prussian Blue in the Treatment of Acute Thallotoxicosis in Rats. Mulkey, J.P. and Oehme, F.W. (1993). *Fundam. Appl. Toxicol.* __, __-__.

Thallium (Tl) is a highly toxic cumulative poison in animals and man. Unithiol (2,3-dimercapto-1-propanesulfonic acid, DMPS) and prussian blue (potassium ferric hexacyanoferrate(II), PB), given alone and in combination, were evaluated as antidotes in the treatment of acute thallotoxicosis in male Sprague-Dawley rats. Animals were poisoned with equivalent doses of 20 mg Tl/kg BW po on day 0, using thallous sulfate. On day 1 (24 h later), antidotal treatments began and were continued through day 4 as follows: 50 mg PB/kg BW po, 2/d; 5 mg DMPS/kg BW ip, 6/d (day 1), 4/d (day 2), 2/d (days 3-4); or their combination. Animals were sacrificed by ip injection of sodium phenobarbital 24 h after the last antidotal treatment (day 5) and tissue samples collected. Thallium concentrations in kidney, liver, heart, brain, whole blood and feces were determined by electrothermal atomic absorption spectroscopy. The relative accumulation of Tl in organs was kidney>>heart>liver=brain. PB induced significant decorporation of Tl from all tissues. DMPS failed to significantly decrease the Tl content in any organ, but significantly

decreased the Tl content in whole blood. PB+DMPS treatment significantly decreased the Tl content in all organs, but to no greater extent than PB alone. PB and PB+DMPS treatments significantly increased the Tl content of feces, whereas DMPS treatment alone produced little effect. This study indicates that PB is a beneficial antidote in the treatment of acute thallotoxicosis in rats. The failure of DMPS to significantly decrease the Tl content in 4 target organs suggests it would not be useful in the treatment of Tl poisoning.

KEYWORDS: Thallium; poison; antidote; chelator; rat; prussian blue; potassium ferric hexacyanoferrate(II); Unithiol; 2,3-dimercapto-1-propanesulfonic acid.

INTRODUCTION

Thallium (Tl) is one of the most toxic heavy metals to animals (LD_{50} ~30 mg/kg, rat) and humans (LD_{50} 8-12 mg/kg) (Downs et al., 1960; Smith and Carson, 1977; Goyer, 1991). Its continued use as a rodenticide in many developing countries accounts for the number of accidental and intentional poisonings reported (Ben-Assa, 1982; Hakala, 1984; Zhou and Lin, 1985; Pai, 1987; Rangel-Guerra et al., 1990). Thallium's unique physico-chemical properties have spurred its increasing use in an expanding number of new technologies such as high-temperature ceramic superconductor materials (Wahlbeck et al., 1991; Betz et al., 1992), thus underscoring concern about exposure risk to animals and humans (Sabbioni et al., 1984; Hapke, 1990).

Water-soluble Tl salts are rapidly and completely absorbed from the respiratory and gastrointestinal (GI) systems or skin, and are widely distributed to organs and tissues, including the brain, heart, kidney, skeletal muscle and testis, Tl's principal target organs (Sabbioni et al., 1980). Because Tl and potassium cations (K^+) share the same charge and similar ionic radii, Tl^+ follows K^+ distribution pathways and alters a number of K-dependent processes (Gehring and Hammond, 1967). Free plasma Tl^+ rapidly moves to the intracellular compartment, as indicated by its short half-life in blood ($t_{1/2}$ =196 min) and large apparent volumes of distribu-

tion (V_D), i.e., 20 L/kg for plasma and 5-6 L/kg for whole blood (Rauws, 1974; Lameijer and van Zwieten, 1977). The metal is only slowly excreted in feces, urine, hair and secretory products of humans and animals; therefore it is considered a cumulative poison. Possible toxic mechanisms of Tl include ligand formation with protein sulfhydryl (-SH) groups, inhibition of cellular respiration, interaction with riboflavin and riboflavin-based cofactors, and disruption of calcium homeostasis (Mulkey and Oehme, 1993a). The principal clinical features of thallotoxicosis are gastroenteritis, peripheral neuropathy and alopecia. The toxicity of Tl has been the subject of several reviews (Oehme, 1972; Saddique and Peterson, 1983; Manzo and Sabbioni, 1988; Mulkey and Oehme, 1993a).

The treatment objective in Tl poisoning is to enhance the metal's elimination without promoting redistribution to target organs, particularly the brain. To this end, the therapeutic efficacy of different heavy metal chelators has been investigated in attempts to find an effective antidote for thallotoxicosis. Tl is categorized as a soft acid under Pearson's (1968) Hard-Soft-Acid-Base (HSAB) system, and as such tends to form stable metal-ligand (ML) complexes with soft bases such as -SH containing compounds. Thus the ineffectiveness of polyaminocarboxylic acids (e.g., ethylenediaminetetraacetic acid and diethylenetriaminepentaacetic acid) in the treatment of Tl poisoning is not surprising, since these compounds are

considered hard bases (Catsch and Harmuth-Hoene, 1979). Dithiocarb (sodium diethyldithiocarbamate) forms a stable lipophilic complex with Tl^+ in vitro, but was found to increase brain Tl concentration (Kamerbeek et al., 1971). Lund (1956) found dithizone (diphenyldithiocarbazone) formed a stable ML complex with Tl^+ , thereby increasing the metal's urinary elimination in laboratory animals. But in human trials dithizone produced equivocal results (Chamberlain et al., 1958), and other studies showed it to be diabetogenic and goitrogenic (Kadota and Midorikawa, 1951; Jensen and Kjersulf-Jensen, 1945). Other sulfur-containing compounds, dimercaprol (British anti-Lewisite, BAL), D-penicillamine (PA), and cysteine yielded negative or equivocal results (Catsch and Harmuth-Hoene, 1979).

Potassium (as KCl) enhances urinary excretion of Tl (Gehring and Hammond, 1967; Chamerlain et al., 1958), possibly by displacing Tl from intracellular storage sites; but by raising serum Tl levels, K^+ also increases the risk of Tl redistribution to target organs (Nogué et al., 1982-1983).

The most effective Tl chelator yet discovered is the inorganic dye, prussian blue (potassium ferric hexacyanoferrate(II), PB) (Stevens et al., 1974). Given orally, this non-absorbable compound adsorbs Tl^+ within its crystal lattice, thereby interrupting the toxic metal's enterohepatic circulation (Rauws, 1974). Found to be essentially non-toxic (Heydlauf, 1969), PB greatly enhances the fecal elimination of

Tl (Thompson, 1981; Lehman and Favari, 1984).

The use of 2 or more antidotes, each using different modes of action to remove toxic metals, has been recognized as a useful therapeutic approach for several years. This so-called synergistic chelate therapy has produced positive results in a number of heavy metal toxicities (Jones, 1983). Recently, Rios and Monroy-Noyola (1992) demonstrated that the combined use of PA and PB in rats provided significantly greater protection against Tl poisoning than PA or PB alone, and suggested that a synergistic interaction between the 2 antidotes may be operative. This finding is surprising because PA is known to promote Tl redistribution to the brain. Additionally, it raises the possibility of finding therapeutic roles for compounds presently considered ineffective when used singly by employing them in synergistic chelate therapy regimens to combat metal toxicity.

The therapeutic effectiveness of the heavy-metal chelator Unithiol (2,3-dimercapto-1-propanesulfonic acid, DMPS), a water-soluble analog of BAL, has been appreciated for more than 30 years in Russia, China and Japan. Compared to BAL, DMPS is chemically stable, much less toxic (LD_{50} 5.02 mmol/kg vs. 0.72 mmol/kg BAL [ip,mice]), and can be given orally (Aaseth, 1983). In Russia DMPS is the antidote of choice for inorganic mercury poisoning. Thallium and inorganic mercury compounds (i.e., mercuric chloride, $HgCl_2$) share similar distribution patterns and target organs in mammals (Aaseth,

1983; Aposhian, 1983) and possess similar physico-chemical properties, as is expected of neighboring elements in the periodic table. Although the therapeutic effectiveness of DMPS has been reported for a number of heavy metals (Aposhian, 1983), including the HSAB soft-acid cations Hg^{2+} and silver (Ag^+), we are unaware of any reports concerning the use of DMPS for Tl poisoning.

This study was designed to compare the antidotal efficacy of DMPS to the well-characterized efficacy of PB in acute Tl exposure, and to compare the efficacy of the combined use of DMPS and PB to the single use of these heavy metal antidotes.

MATERIALS AND METHODS

Protocol

A total of 51 male Sprague-Dawley rats weighing 200-250 g were acclimated for 5 d in the Animal Resource Facility (ARF), Kansas State University, Manhattan, KS. They were housed in a room maintained at a temperature between 22 and 24 °C with a light:dark cycle of 12 h and were fed ARF 3 Lab Chow (Kansas State University Feed Processing Center, Manhattan, KS) and tap water *ad libitum* before and during the study. The animals were randomly assigned to 6 different treatment (T) or non-treatment (NT) groups, fasted for 12 h prior to intoxication, and then dosed by gavage with 24.70 mg $\text{Tl}_2\text{SO}_4/\text{kg BW}$ (20 mg Tl/kg BW) (Fisher Scientific, St. Louis, MO; Lot T-89

784912; FW 504.8) dissolved in deionized-distilled water (DDW).

The rats were allocated to the 6 different groups as follows: 30 animals were placed into 3 T groups (received antidote) of 10 animals each; 21 animals were assigned into 3 NT (received no antidote) groups of 7 animals each. A separate group of 18 rats served as negative controls, receiving no T1 nor antidotal treatment. The PB treatment group (T_{PB}) animals received 50 mg PB/kg BW suspended in 1% Tween-80 (~0.7 ml), twice daily. The DMPS treatment group (T_{DMPS}) rats received 5 mg DMPS/kg BW dissolved in DDW ip (~0.5 ml) 6 times daily on day 1, 4 times daily on day 2, and twice daily on days 3-4. The PB+DMPS treatment group ($T_{PB+DMPS}$) animals received both antidotes in the same doses and by the same routes described above. The 3 NT groups (NT_{PB} , NT_{DMPS} , $NT_{PB+DMPS}$) were given the same volume of suspending vehicle as their T-group counterparts (1% Tween-80, DDW and Tween-80+DDW, respectively). Antidotal treatment began 24 h after dosing with T1 and was maintained for 4 d (Table 1). Body weights were taken daily. The rats were closely monitored for adverse affects after T1 administration and during antidotal treatment.

Sample Collection

The rats were sacrificed by a lethal ip injection of 0.5 ml sodium phenobarbital (Anthony Products, Arcadia, CA; lot

9104) 24 h after the last antidotal treatment (day 5). Blood samples were collected by intracardial puncture using 10 ml plastic syringes and 12-gauge stainless-steel needles, and transferred into heparinized (Elkin-Sinn, Cherry Hill, NJ; lot 101013) 20 ml pyrex test tubes. Brain, liver and kidneys were removed, weighed and stored individually in plastic specimen bags. Fecal samples (pellets) were removed from the large intestine, weighed and then stored in specimen bags. Sample collection required ~10 min/animal and samples were stored at -20 °C until analyzed.

Thallium Analysis

Thallium concentrations in samples were determined by electrothermal atomic absorption spectrometry (ET-AAS) (Perkin-Elmer Model 306 AAS equipped with a GF 2200 graphite furnace) using the Curry et al. (1969) procedure as modified by us. Tissue and fecal samples were wet ashed with 1 ml concentrated H_2SO_4 (Fisher trace metal grade, St. Louis, MO) and 3 ml concentrated HNO_3 (Fisher trace metal grade, St. Louis, MO) on a Corning hotplate at 70 °C. The sample digests were taken to a residual volume of ~1 ml and quantitatively transferred to acid-washed 50 ml polypropylene centrifuge tubes, then adjusted to pH 6.0 ± 0.1 with 6N NaOH (Fisher trace metal grade, St. Louis, MO). Freshly prepared 2% (w/v) sodium diethyldithiocarbamic acid (NDDC) (1 ml) was added and the mixture shaken by hand for 2 min to allow chelate complex

formation. Water-saturated methylisobutylketone (MIBK) (Fisher, St. Louis, MO) (1-5 ml) was added and the mixture shaken by hand for 3 min to extract the Tl-NDDC chelate complex into the organic phase. The samples were then centrifuged at 2500 rpm for 10 min to facilitate separation of the 2 immiscible phases. Aliquots of the upper organic phase (15 μ l) were manually pipetted into the graphite furnace and peak heights recorded by a Perkin-Elmer Model 56 recorder. Blood samples were pretreated with an equal volume of 5% (w/v) trichloroacetic acid (TCA) (Fisher, St. Louis, MO) and shaken for 1 h to precipitate proteins. The mixture was centrifuged at 2500 rpm for 10 min and the supernatant transferred to a clean polypropylene centrifuge tube. The supernatant was then pH-adjusted, chelated with NDDC, extracted with MIBK, and analyzed as above. Standards were prepared in an identical manner using Tl-free rat tissues, feces and blood spiked with known amounts of the metal. All glass and plasticware were soaked for 24 h in a 20% (v/v) HCl bath, then soaked for 24 h in a 20% (v/v) HNO₃ bath, and thoroughly rinsed with DDW and air-dried prior to use. The safety precautions required for acid-digestion of biologic materials has been presented elsewhere (Mulkey and Oehme, 1993b).

The accuracy of the method was assessed by recovery studies. A series of 5 liver and 5 blood samples were spiked with 0.5, 1.0 or 10.0 μ g Tl using a Tl nitrate standard (SPEX Industries, Edison, NJ) and then analyzed using the procedure

described above. Recoveries ranged from 96 to 101% for the liver samples and from 95 to 103% for the blood samples. The precision of the method, expressed as the coefficient of variation for liver and blood samples spiked with 1.0 µg Tl, was 12 and 14%, respectively.

Statistical Analysis

The experimental unit in this study was the individual rat. A statistical software package, SAS version 6.03, was used for data analysis (SAS Institute, Inc., 1988). Body weight, weight gain, organ weight/body weight (OW/BW) ratio, and Tl content data for each experimental group were examined for homogeneity of variance using Barlett's test and then compared by analysis of variance techniques (Gad and Weill, 1986) using SAS PROC GLM. Groups showing significant differences were further evaluated by multiple comparison testing using the Tukey-Kramer procedure (all data) or Duncan's multiple range test (weight gain and OW/BW ratio data only) (Ott, 1988). Survival rates for different groups were tested by the rxc chi-square test using SAS PROC FREQ and no significant differences were found. The 0.05 level of probability was used as the criterion of significance. Data are expressed as the mean \pm standard error ($\bar{x} \pm SE$) unless otherwise indicated.

RESULTS

The 3 NT groups displayed overt signs of toxicity after being dosed with the equivalent of 20 mg Tl/kg BW po, as evidenced by a marked decrease in weight gain after exposure to the metal (Fig. 1). The T_{DMPS} group had only slightly greater weight gain than the NT_{DMPS} group. Both the T_{PB} and $T_{PB+DMPS}$ groups had much better weight gain after Tl intoxication than their respective untreated control groups. The post-exposure weight-gain rates of the T_{PB} and $T_{PB+DMPS}$ groups were only moderately reduced (97 and 83%, respectively) compared to their pre-exposure weight-gain rates. Clinical manifestations of acute Tl toxicity in NT group animals included diarrhea, slight tremor and gross hair loss upon handling (days 4-5), whereas no such effects were observed in T group animals, except for diarrhea and tremor in 2 NT_{DMPS} animals. NT_{PB} and NT_{DMPS} had 1 mortality each and $NT_{PB+DMPS}$ had 2 mortalities (n=7/gp) in contrast to the 3 T groups (n=10/gp) which had no deaths (Fig. 2).

Organ Weight/Body Weight Ratios

Organ weight/body weight (OW/BW) ratio data showed slight differences between T and NT groups with the exception of the T_{DMPS} group, which had significantly lower liver and kidney OW/BW ratios than its corresponding NT group ($p \leq 0.05$) (Fig. 3).

Thallium Content - Body Organs

The Tl content of selected body organs 5 d after Tl exposure is depicted in Fig. 4. We observed significant differences in the organ distribution pattern of Tl. The relative accumulation of Tl in body organs was kidney>>heart>liver=brain, with kidney accumulation of Tl significantly greater ($p \leq 0.01$) than in other organs. The pattern of Tl deposition observed in this work and the Tl concentrations in blood and feces (discussed below) are in agreement with findings in previous studies (Thyresson, 1951; Sabbioni et al., 1980; Manzo et al., 1983; Rios et al., 1989; Mulkey and Oehme, 1993c).

The T_{PB} group had significantly lower (30-50% of NT_{PB} group) Tl content in all organs compared to the NT_{PB} group ($p \leq 0.05$, brain, liver, heart; $p \leq 0.01$, kidney). The $T_{PB+DMPS}$ group had significantly reduced (30-47% of $NT_{PB+DMPS}$ group) Tl content than the $NT_{PB+DMPS}$ group ($p \leq 0.05$, brain, liver, heart; $p \leq 0.01$, kidney). In the T_{PB} and $T_{PB+DMPS}$ groups, more than a 3-fold reduction in brain (critical target organ) Tl levels occurred compared to the NT_{PB} and $NT_{PB+DMPS}$ groups; in contrast to the T_{DMPS} group, where only a minor decrease in Tl levels were noted.

Thallium Content - Blood and Feces

Fig. 5 shows the Tl content of whole blood and feces obtained at necropsy. The T_{PB} group had a significantly lower

(15% of NT_{PB} group) Tl concentration in blood compared to the NT_{PB} group ($p \leq 0.05$). The T_{DMPS} and T_{PB+DMPS} groups had highly significant decreases (5 and 3% of NT_{DMPS} and NT_{PB+DMPS} groups, respectively) in blood Tl concentrations compared to the NT_{DMPS} and NT_{PB+DMPS} groups ($p \leq 0.01$). The T_{PB} and T_{PB+DMPS} groups had 2.2-fold and 2.0-fold greater fecal Tl content compared to their respective control groups ($p \leq 0.05$ and $p \leq 0.01$, respectively). The difference between T_{DMPS} and NT_{DMPS} group fecal Tl content was negligible.

DISCUSSION

As evidenced by demonstrable clinical effects and as seen in Fig. 2, the Tl dosage used in this study was high enough to cause acute toxicity in NT group animals. At least 1 rat died in each NT group. As expected, the PB-treated animals were protected from the effects of Tl. None of the DMPS-treated animals died or showed signs of acute toxicity, despite accumulating substantial concentrations of Tl in several critical organs (Fig. 4). A possible explanation for this observation is that DMPS provided a protective effect against Tl poisoning by some undetermined mechanism (e.g., *in situ* inhibition of Tl's biologic activity) not measurable in terms of organ Tl content. Drawing such a conclusion, however, must be viewed with considerable skepticism. A more reasonable explanation for the lack of deaths in the T_{DMPS} group is that

the sample size of this group (n=10) was not large enough to detect the low incidence of lethal effect.

This study clearly shows that PB is an effective antidote in the treatment of thallotoxicosis. Prussian blue interrupts the enterohepatic circulation of Tl by adsorbing the metal ion within its crystal lattice (Rauws, 1974; Lehmann and Favari, 1984), but the extent to which this occurs *in vivo* is not well known. Treatment with PB probably resulted in the enteral dialysis of Tl⁺; its reabsorption from the GI tract was blocked by adsorption to the complex cyanoferrate clathrate (Dvorák, 1969). Thus, fecal Tl⁺ levels were significantly raised and tissue Tl levels were markedly reduced. The ion-exchange action of PB probably played the principal role in protecting the T_{PB+DMPS} group animals from acute Tl toxicity.

Deductively, DMPS would be expected to decrease the body burden of Tl *in vivo*. The stability constant for the Tl-DMPS chelate complex is 1.43×10^{17} (Martell and Smith, 1982). Moreover, DMPS has been shown effective in enhancing the decorporation of other HSAB soft-acid metal ions, Ag⁺ and Hg²⁺ (Gabard, 1976; Aaseth, 1983). The observation that DMPS enhances the biliary excretion of ²⁰³Hg²⁺ (Cikrt and Tichy, 1980) provides a mechanistic basis for presuming that DMPS and PB would interact cooperatively to reduce Tl levels in acutely intoxicated rats. However, this was not the case. DMPS alone only marginally reduced organ Tl levels in the T group compared to its NT-group counterpart. Joint administration of

PB and DMPS likewise produced unremarkable results. The distribution of DMPS, a hydrophilic compound, is largely confined to the extracellular space (Catsch and Harmuth-Hoene, 1976; Gabard, 1978). DMPS's ineffectiveness in the treatment thallium toxicity may be due to its inability to access intracellular Tl deposits.

PB enhanced fecal elimination of Tl, but DMPS only marginally increased fecal Tl elimination. The reduced fecal Tl level observed in the $T_{PB+DMPS}$ group was likely due to enhanced urinary elimination of the metal, but this hypothesis was not proven in our study.

PB and DMPS significantly reduced the Tl concentration in whole blood. In blood, the PB+DMPS combination appeared to have had some cooperative effect in that Tl levels were reduced 5- and 1.6-fold compared to administration of the single antidotes.

Examination of OW/BW ratio data (Fig. 3) suggests that the T_{DMPS} group experienced hepatic and renal toxicity. This effect was not observed in the $T_{PB+DMPS}$ group. DMPS has been reported non-toxic at the dose (5 mg DMPS/kg BW ip) used in this study (Planas-Bohne et al., 1980; Aposhian, 1983). The change in OW/BW ratios in these organs are likely due to increased Tl levels caused by mobilization of plasma Tl to kidney and liver as a Tl-DMPS complex, rather than to intrinsic toxicity of the chelator itself.

This study has shown that PB is an effective antidote for

acute Tl toxicity in rats, as evidenced by its ability to reduce Tl levels in 4 target organs -- kidney, liver, heart and brain. In contrast, the sole administration of DMPS failed to mobilize Tl in any organ. The combined use of PB+DMPS produced no significant changes in Tl levels in target organs compared to the use of PB alone. The chelator combination significantly reduced Tl concentrations in whole blood. Based on our findings and the reports of others (Lund, 1956; Heydlauf, 1969; Thompson, 1981; Rios and Monroy-Noyola, 1992), PB should continue to be considered the antidote of choice for treating acute thallium poisoning. The inability of DMPS to reduce Tl levels in target organs, when given singly or in combination with PB, suggests it is of little benefit in the treatment of thallotoxicosis.

REFERENCES

- Aaseth, J.(1983). Recent advances in the therapy of metal poisonings with chelating agents. *Human Toxicol.* **2**,257-272.
- Aposhian, H.V.(1983). DMSA and DMPS - water soluble antidotes for heavy metal poisoning. *Ann. Rev. Pharmacol. Toxicol.* **23**,193-215.
- Ben-Assa, B.(1982). Indirect thallium poisoning in a Bedouin family. *Harefuah* **62**,378-380.
- Betz, J., Piehler, A., Pechen, E.V.(1992). *In situ* preparation of high- T_c thallium barium calcium copper oxide thin films by a combination of laser ablation and thermal evaporation. *J. Appl. Phys.* **71**,2478-2479.
- Catsch, A. and Harmuth-Hoene, A.E.(1979). Pharmacology and therapeutic applications of agents used in heavy metal poisoning. In *The Chelation of Heavy Metals* (W.G. Levine, Ed.), pp. 106-224. Pergamon, New York.
- Chamberlain, P.H., Stavinoha, B., Davis, H., Kniker, W.T., Panos, T.C.(1958). Thallium poisoning. *Pediatrics* **22**,1170-1178.
- Cikrt, M. and Tichy M.(1980). Effect of some chelating agents on the biliary excretion of mercury. I. Excretion kinetics and distribution of mercury in the organism. *J. Hyg. Epidemiol. Microbiol. Immunol.* **24**,346-355.

- Curry, A.S., Read, J.F., Knott, A.R. (1969). Determination of thallium in biological material by flame spectrophotometry and atomic absorption. *Analyst* **94**, 744-753.
- Downs, W.L., Scott, J.K., Steadman, L.T., Maynard, E.A. (1960). Acute and subacute toxicity studies of thallium compounds. *Am. Ind. Hyg. Assoc. J.* **21**, 399-406.
- Dvorák, P. (1969). Kolloidale hexacyanoferrate(II) als antidote bei der thallium-intoxikation. *Z. ges. exp. Med.* **89**: 151-157.
- Gabard, B. (1978). Distribution and excretion of the mercury chelating agent sodium 2,3-dimercaptopropane-1-sulfonate in the rat. *Arch. Toxicol.* **39**, 289-298.
- Gabard, B. (1976). Treatment of methyl mercury poisoning in the rat with sodium 2,3-dimercaptopropane-1-sulfonate: Influence of dose and mode of administration. *Toxicol. Appl. Pharmacol.* **38**, 415-424.
- Gad, S.C. and Weil, C.S. (1986). *Statistics and Experimental Design for Toxicologists*. pp. 1-372. Telford Press, Caldwell.
- Gehring, P.J. and Hammond, P.B. (1967). The interrelationship between thallium and potassium in animals. *Pharmacol. Exp. Ther.* **155**, 187-201.
- Goyer, R.A. (1991). Toxic effects of metals. In Casarett and Doull's *Toxicology: The Basic Science of Poisons*, 4th ed. (M.O. Amdur, J. Doull, D.C. Klaassen Eds.), 4th ed., pp. 623-680. Pergamon, New York.

- Hakala, J.E.(1984). Thallium poisoning in a dog. *Mod. Vet. Pract.* 65,783-784.
- Hapke, H.J.(1990). Chronic thallotoxicosis in ruminants and transfer of thallium from feed to edible tissues. In *Veterinary Pharmacology, Toxicology and Therapy in Food Producing Animals*. (F. Simon, P. Lees, G. Semjen, Eds.), pp. 359-366. Proceedings of the 4th Congress of the European Association for Veterinary Pharmacology and Toxicology held in Budapest, Aug 28-Sept 2, 1988. University of Veterinary Science, Budapest.
- Heydlauf, H.(1969). Ferric-cyanoferrate(II): An effective antidote in thallium poisoning. *Eur. J. Pharmacol.* 6,340-344.
- Jensen, K.R. and Kjersulf-Jensen, K.(1945). On the relation between goitrogenic effect and chemical constitution. *Acta Pharmacol.* 1,280-286.
- Jones, M.M.(1983). Therapeutic chelating agents. In *Metal Ions in Biological Systems* (H. Sigel, Ed.), Vol. 16, pp. 47-83. Marcel Dekker, New York.
- Kadota, I. and Midorikawa, O.(1951). Diabetogenic action of organic reagents: Destructive lesions of the islets of Langerhans caused by sodium diethyldithiocarbamate and potassium ethylxanthate. *J. Lab. Clin. Med.* 38,671-688.

- Kamerbeek, H.H., Rauws, A.G., Ham, M. ten, Heijst, A.N.P. van(1971). Dangerous redistribution of thallium by treatment with sodium diethyldithiocarbamate. *Acta Med. Scand.* **189**,149-154.
- Lehmann, P.A. and Favari, L.F.(1984). Parameters for the adsorption of thallium ions by activated charcoal and prussian blue. *Clin. Toxicol.* **22**,331-339.
- Lameijer, W., Zweiten, P.A. van(1977). Kinetic behavior of thallium in the rat. Accelerated elimination of thallium owing to treatment with potent diuretic agents. *Arch. Toxicol.* **37**,265-273, 1977.
- Lund, A.(1956). The effect of various substances on the excretion and toxicity of thallium in the rat. *Acta Pharmacol. et Toxicol.* **12**,260-268.
- Manzo, L. and Sabbioni, E.(1988). Thallium toxicity and the nervous system. In *Metal Neurotoxicity*. (S.C. Bondy and K.N. Prasad, Eds.), pp. 35-64. CRC Press, Boca Raton.
- Martell, A.E. and Smith, R.M.(1982). *Critical Stability Constants*, Vols. 1-5. Plenum Press, New York.
- Mulkey, J.P. and Oehme, F.W.(1993a). A review of thallium toxicity. *Vet. Hum. Toxicol.*, in press.
- Mulkey, J.P. and Oehme, F.W.(1993b). Quantitative analysis of trace levels of thallium in biological materials by atomic absorption spectroscopy. *Vet. Hum. Toxicol.*, submitted for publication.

- Mulkey, J.P. and Oehme, F.W.(1993c). A safety study of thallium-containing ceramic superconductor material in rats. *Fundam. Appl. Toxicol.*, submitted for publication.
- Oehme, F.W.(1972). Mechanisms of heavy metal toxicities. *Clin. Toxicol.* 5,151-167.
- Ott, L.(1988). *An Introduction of Statistical Methods and Data Analysis*, 3rd ed., pp. 1-835. PWS-Kent Publishing, Boston.
- Nogué, S., Mas, A., Pares, A., Nadal, P., Bertran, A., Milla, J., Carrera, M., To, J., Pazos, M.R., Corbessa, J.(1982-1983). Acute thallium poisoning: An evaluation of different forms of treatment. *J. Toxicol. Clin. Toxicol.* 19,1015-1021.
- Pai, V.(1987). Acute thallium poisoning: Prussian blue therapy in 9 cases. *W. I. Med. J.* 36,256-258.
- Pearson, R.G.(1968). Hard and soft acids and bases, HSAB, Part II. Underlying theories. *J. Chem. Educ.* 45,437-455.
- Planas-Bohne F., Gabard B., Schäffer, E.H.(1980). Toxicological studies on 2,3-dimercaptopropane-1-sulfonate in the rat. *Arzneim.-Forsch.* 30:1291-1294.
- Rangel-Guerra, R., Martinez, H.R., Villarreal, H.J.(1990). Intoxicación por talio. Experiencia con 50 pacientes. *Gac. Med. Mex.* 126,487-494.
- Rauws, A.G.(1974). Thallium pharmacokinetics and its modification by prussian blue. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 284,295-306.


- Rios, C., Galvan-Arzate, S., Tapia, R.(1989). Brain regional thallium distribution in rats acutely intoxicated with Tl_2SO_4 . *Arch. Toxicol.* **63**,34-37.
- Rios, C. and Monroy-Noyola, A.(1992). D-Penicillamine and prussian blue as antidotes against thallium intoxication in rats. *Toxicology* **74**,69-76, 1992.
- Sabbioni, E., Goetz, L., Bignoli, G.(1984). Health and environmental implications of trace metals released from coal-fired power plants: An assessment study of the situation in the European Community. *Sci. Total Environ.* **40**,141-154.
- Sabbioni, E., Marafante, E., Rade, J., DiNucci, A., Gregotti, C., Manzo, L.(1980). Metabolic patterns of low and toxic doses of thallium in the rat. In *Mechanisms of Toxicity and Hazard Evaluation*. (B. Holmstedt, R. Lauwerys, M. Mercier and M. Roberfroid, Eds.), pp. 559-564. Proceedings of the Second International Congress on Toxicology held in Brussels, Belgium, July 6-11, 1980. Elsevier, Amsterdam.
- Saddique, A. and Peterson, C.D.(1983). Thallium poisoning: A review. *Vet. Hum. Toxicol.* **25**,16-22, 1983.
- SAS Institute, Inc.(1988). *SAS® Procedures Guide*, Release 6.03 ed. SAS Institute, Cary, NC.
- Smith, I.C. and Carson, B.L.(1977). *Trace Metals in the Environment. Vol. 1 - Thallium*, pp. 309-316. Ann Arbor Science, Ann Arbor.


- Stevens, W., Peteghem, C. van, Heyndrickx, A., Barbier, F.(1974). Eleven cases of thallium intoxication treated with prussian blue. *Int. J. Clin. Pharmacol.* 10,1-22.
- Thompson, D.F.(1981). Management of thallium poisoning. *Clin. Toxicol.* 18,979-990.
- Thyresson, N.(1951). Experimental investigation on thallium poisoning in the rat. *Acta Derm. Venereol.* 31,3-27.
- Wahlbeck, P.G., Richards, R.R., Myers, D.L.(1991). Vaporization reactions of thallium(III) oxide and thallium activities in thallium superconductors. *J. Chem. Phys.* 95,9122-9127.
- Zhou, D. and Lin, D.(1985). Chronic thallium poisoning in a rural area of Guizhou Province, China. *J. Environ. Health* 48,14-18.


TABLE 1


Antidote treatment schedule for the thallium antidote study. Treatment began 24 h after poisoning animals with the equivalent of 20 mg Tl/kg BW and was maintained for 4 d. Animals were sacrificed by ip phenobarbital 24 h after last antidotal treatment. (PB = prussian blue, potassium ferric hexacyanoferrate (II); DMPS = 2,3-dimercapto-1-propanesulfonic acid; T = treatment group; NT = non-treatment group)


GROUPS	ANIMALS PER GROUP	DOSE	ROUTE	DOSES PER DAY	DAY
T _{PB}	10	50 mg PB/kg BW suspended in 1% Tween 80 (1 ml)	po	2	1-4
T _{DMPS}	10	5 mg DMPS/kg BW dissolved in DI H ₂ O (1 ml)	ip	6 4 2	1 2 3,4
T _{PB+DMPS}	10	50 mg PB/kg BW suspended in 1% Tween 80 (1 ml) 5 mg DMPS/kg BW dissolved in DI H ₂ O (1 ml)	po ip	2 6 4 2	1-4 1 2 3,4
NT _{PB}	7	1% Tween 80 (1 ml)	po	2	1-4
NT _{DMPS}	7	DI H ₂ O (1 ml)	ip	6 4 2	1 2 3,4
NT _{PB+DMPS}	7	1% Tween 80 (1 ml) DI H ₂ O (1 ml)	po ip	2 6 4 2	1-2 1 2 3,4











CAPTIONS

FIG. 1. The effect of acute thallium (Tl) toxicity (20 mg Tl/kg BW) and antidotal treatments on body weight (Main) and on daily weight gain (Insert). * Significantly different from corresponding control (NT) group ($p \leq 0.05$, Duncan's test after significant ANOVA). For clarity the SE's for only 1 treatment (T) and 1 NT group are shown; they are representative of the variation seen in the other T and NT groups. The large NT group SE's are due to the terminal weight loss of at least 1 rat/NT group. Data are expressed as the $\bar{x} \pm \text{SE}$ ($n=10/\text{T gp}$; $n=7/\text{NT gp}$).

FIG. 2. The effect of antidotal treatment (T) or no treatment (NT) on the survival rates for different groups. PB = prussian blue; DMPS = Unithiol (2,3-dimercapto-1-propane-sulfonic acid). Numbers above bar are the number of survivors/total number of animals in each group.

FIG. 3. Organ weight/body weight ratios for different treatment (T) and non-treatment (NT) groups. For clarity, all NT groups are combined since there was little difference between the 3 NT groups. * Significantly different from corresponding NT group ($p \leq 0.05$, Duncan's test after significant ANOVA). Results are expressed as $\bar{x} \pm \text{SE}$ ($n=10/\text{T gp}$; $n=7/\text{NT gp}$). T = treatment gp; NT = non-treatment gp; A =

prussian blue (PB); B = Unithiol (DMPS); C = A+C (PB+DMPS).

FIG. 4. Thallium (Tl) content of body organs after dosing with 20 mg Tl/kg BW po and treatment with chelators (T gps) or respective suspending vehicle only (NT gps). Results are expressed as $\bar{x} \pm SE$ ($n=10/T$ gp; $n=7/NT$ gp). T = treatment gp; NT = non-treatment gp; A = prussian blue (PB); B = Unithiol (DMPS); C = A+C (PB+DMPS); B = brain; L = liver; H = heart; K = kidney. Significant differences from untreated controls (Tukey-Kramer test after significant ANOVA): * ($p \leq 0.05$); ** ($p \leq 0.01$).

FIG. 5. Thallium (Tl) content in blood and feces after dosing with 20 mg Tl/kg BW po and treatment with chelators (T gps) or suspending vehicle only (NT gps). Results are expressed as $\bar{x} \pm SE$ ($n=10/T$ gp; $n=7/NT$ gp). 5x = values shown are 5 times actual values. T = treatment gp; NT = non-treatment gp; A = prussian blue (PB); B = Unithiol (DMPS); C = A+C (PB+DMPS). Significant differences from untreated controls (Tukey-Kramer test after significant ANOVA): * ($p \leq 0.05$); ** ($p \leq 0.01$).

APPENDIX A

INDIVIDUAL ANIMAL DATA

WEIGHT TABLE

WHOLE BODY WEIGHTS (g)

THALLIUM
GIVENANTIDOTE GIVEN
DAY 1 - DAY 4ANIMALS
SACRIFICED

TREATMENT GROUP	DAY -4	DAY -3	DAY -2	DAY -1	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	COMMENTS
PB											
CA 1		200	207	219	202	225	232	228	248	253	
CA 2		227	240	244	214	288	288	246	257	256	
CA 3	216	226	233	240	210	238	243	255	280	288	
CA 4	224	231	239	246	214	248	248	239	244	252	
CA 5	213	224	229	238	209	235	237	237	240	240	
CA 6	221	229	241	242	221	229	212	193	178	178	DIED DAY 4
CA 7	217	228	231	239	209	231	222	231	248	248	
MEAN	216.2	223.3	231.4	238.6	211.3	234.4	232.9	233.9	239.4	243.7	
STD DEV	4.3	10.5	11.7	8.3	5.9	7.8	12.3	16.6	28.0	29.8	
SEM	1.9	4.0	4.4	3.5	2.2	2.9	4.7	7.4	10.6	11.3	

RECEIVED VEHICLE ONLY: 1% TWEEN-80 po

TREATMENT GROUP	DAY -4	DAY -3	DAY -2	DAY -1	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	COMMENTS
DMP5											
CB 1		228	240	245	216	238	244	255	281	306	
CB 2		208	219	221	200	220	227	232	240	245	
CB 3	215	223	230	240	215	233	218	197	170	163	DIED DAY 5
CB 4	221	231	239	242	213	230	218	207	208	214	
CB 5	223	235	245	248	217	245	248	280	250	262	
CB 6	220	236	245	250	221	250	247	254	288	272	
CB 7	202	214	223	235	208	231	231	233	248	253	
MEAN	216.2	224.9	233.6	240.4	212.9	235.4	236.0	234.6	236.1	239.3	
STD DEV	8.5	10.7	10.3	9.9	8.9	10.1	13.5	25.1	35.8	38.7	
SEM	3.8	4.1	3.9	3.7	2.8	3.8	5.1	8.5	13.5	14.6	

RECEIVED VEHICLE ONLY: DI H2O ip

TREATMENT GROUP	DAY -4	DAY -3	DAY -2	DAY -1	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	COMMENTS
PB+DMP5											
CC 1		224	231	241	212	237	241	248	256	280	
CC 2		221	232	246	219	241	250	248	280	273	
CC 3		190	201	208	190	209	217	226	229	242	
CC 4	217	226	232	238	218	225	210	196	174	166	DIED DAY 5
CC 5	220	229	236	244	218	232	211	190	180	180	DIED DAY 4
CC 6	219	228	244	252	216	241	234	248	280	299	
CC 7	223	229	235	242	218	242	228	234	242	251	
MEAN	218.6	221.0	230.1	236.4	212.7	232.4	227.3	227.3	228.7	234.4	
STD DEV	2.5	14.0	13.6	15.0	10.3	12.0	15.4	25.0	37.1	43.4	
SEM	1.3	5.3	5.1	5.7	3.9	4.5	5.8	9.4	14.0	16.4	

RECEIVED VEHICLE ONLY: 1% TWEEN-80 po + DI H2O ip

WHOLE BODY WEIGHTS (g)

THALLIUM
GIVENANTIDOTE GIVEN
DAY 1 - DAY 4ANIMALS
SACRIFICED

TREATMENT GROUP	DAY -4	DAY -3	DAY -2	DAY -1	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	COMMENTS
PB											
CA 1		300	307	218	202	225	232	236	248	253	
CA 2		227	240	244	214	236	236	248	257	256	
CA 3	218	226	238	240	210	236	243	255	260	269	
CA 4	224	231	239	248	214	240	246	239	244	252	
CA 5	213	224	229	236	208	235	237	237	240	249	
CA 6	221	229	241	242	221	239	212	183	178	178	DIED DAY 4
CA 7	217	226	231	239	208	231	222	231	249	249	
MEAN	216.2	223.3	231.4	236.6	211.3	234.4	232.9	233.9	239.4	243.7	
STD DEV	4.3	10.5	11.7	8.3	5.9	7.8	12.3	16.9	26.0	29.8	
SEM	1.9	4.0	4.4	3.5	2.2	2.9	4.7	7.4	10.6	11.3	

RECEIVED VEHICLE ONLY: 1% TWEEN-80 po

TREATMENT GROUP	DAY -4	DAY -3	DAY -2	DAY -1	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	COMMENTS
DMPs											
CB 1		226	240	245	216	239	244	255	261	266	
CB 2		208	219	221	200	220	227	232	240	245	
CB 3	215	223	230	240	215	236	216	187	170	163	DIED DAY 5
CB 4	221	231	239	242	213	230	218	207	208	214	
CB 5	223	236	245	248	217	245	248	260	259	262	
CB 6	220	236	245	250	221	250	247	258	266	272	
CB 7	202	214	223	236	206	231	231	236	249	253	
MEAN	216.2	224.9	233.6	240.4	212.9	235.4	233.0	234.9	238.1	239.3	
STD DEV	8.5	10.7	10.3	9.9	6.9	10.1	13.5	25.1	25.9	26.7	
SEM	3.8	4.1	3.9	3.7	2.8	3.9	5.1	8.5	13.5	14.6	

RECEIVED VEHICLE ONLY: DI H2O ip

TREATMENT GROUP	DAY -4	DAY -3	DAY -2	DAY -1	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	COMMENTS
PB+DMPs											
CC 1		224	231	241	212	237	241	248	256	260	
CC 2		221	232	248	219	241	250	248	260	273	
CC 3		180	201	206	180	209	217	226	229	242	
CC 4	217	226	232	236	216	225	210	186	174	166	DIED DAY 5
CC 5	220	229	236	244	216	232	211	190	180	180	DIED DAY 4
CC 6	219	228	244	252	216	241	234	246	260	269	
CC 7	229	229	235	242	216	242	226	234	242	251	
MEAN	219.8	221.0	230.1	236.4	212.7	232.4	227.3	227.8	226.7	234.4	
STD DEV	2.5	14.0	13.6	15.0	10.3	12.0	15.4	25.0	37.1	43.4	
SEM	1.3	5.3	5.1	5.7	3.9	4.5	5.8	8.4	14.0	16.4	

RECEIVED VEHICLE ONLY: 1% TWEEN-80 po + DI H2O ip

WEIGHT GAIN TABLE

-
-

CHANGE IN BODY WEIGHT FROM BASELINE MEASUREMENT AT DAY 0 (g)

THALLIUM
GIVENANTIDOTE GIVEN
DAY 1 - DAY 4ANIMALS
SACRIFICED

T PB GROUP	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	COMMENTS
TA 1	0	16	16	30	41	43	
TA 2	0	20	20	29	38	43	
TA 3	0	22	26	30	35	50	
TA 4	0	22	32	38	40	47	
TA 5	0	20	34	40	47	58	
TA 6	0	24	39	38	41	58	
TA 7	0	22	38	38	42	59	
TA 8	0	21	25	37	40	39	
TA 9	0	21	33	44	55	35	
TA 10	0	20	31	30	42	43	
MEAN	0.0	20.6	29.5	35.4	41.4	48.6	
STD DEV	0.0	2.1	6.9	5.2	6.3	7.5	
SEM	0.0	0.7	2.2	1.7	2.0	2.4	

RECEIVED 50 mg PB / kg BW SUSPENDED IN 1% TWEEN-80 po

T DMPS GROUP	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	COMMENTS
TB 1	0	34	16	22	31	35	
TB 2	0	16	0	16	10	11	
TB 3	0	20	28	28	28	43	
TB 4	0	16	16	21	22	25	
TB 5	0	28	42	39	43	52	
TB 6	0	29	8	13	10	25	
TB 7	0	31	37	42	55	59	
TB 8	0	31	21	21	16	22	
TB 9	0	23	24	24	16	18	
TB 10	0	25	22	24	28	39	
MEAN	0.0	23.3	23.2	28.0	27.8	33.8	
STD DEV	0.0	4.7	13.6	10.1	14.8	13.0	
SEM	0.0	1.5	4.3	3.2	4.7	4.1	

RECEIVED 5 mg DMPS / kg BW DISSOLVED IN DI H2O ip

T PB+DMPS GROUP	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	COMMENTS
TC 1	0	30	18	25	28	25	
TC 2	0	10	4	27	20	28	
TC 3	0	25	28	25	48	47	
TC 4	0	24	25	41	43	55	
TC 5	0	28	40	50	54	77	
TC 6	0	22	30	47	55	52	
TC 7	0	25	35	40	38	44	
TC 8	0	27	29	24	21	31	
TC 9	0	23	28	28	27	25	
TC 10	0	28	24	22	44	28	
MEAN	0.0	22.9	27.6	34.9	38.1	46.3	
STD DEV	0.0	6.2	10.7	9.3	11.2	14.4	
SEM	0.0	1.9	3.4	2.9	3.6	4.6	

RECEIVED 50 mg PB / kg BW SUSPENDED IN 1% TWEEN-80 po + 5 mg DMPS / kg BW DISSOLVED

CHANGE IN BODY WEIGHT FROM BASELINE MEASUREMENT AT DAY 0 (g)

THALLIUM
GIVENANTIDOTE GIVEN
DAY 1 - DAY 4ANIMALS
SACRIFICED

NT PB GROUP	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	COMMENTS
CA 1	0	23	30	34	46	51	DIED DAY 4
CA 2	0	22	22	32	43	42	
CA 3	0	26	33	45	50	56	
CA 4	0	35	34	25	30	36	
CA 5	0	26	26	36	31	40	
CA 6	0	8	-9	-26	-43	-43	
CA 7	0	22	13	22	40	40	
MEAN	0.0	23.1	21.6	22.6	26.1	32.4	
STD DEV	0.0	6.1	15.3	23.5	32.2	34.1	
SEM	0.0	3.0	5.5	8.9	12.2	12.9	

RECEIVED VEHICLE ONLY: 1% TWEEN-80 po

NT DMPS GROUP	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	COMMENTS
CB 1	0	23	26	36	45	50	DIED DAY 5
CB 2	0	20	27	32	40	45	
CB 3	0	16	1	-16	-45	-52	
CB 4	0	17	5	-6	-7	1	
CB 5	0	26	31	43	42	45	
CB 6	0	29	29	37	47	51	
CB 7	0	23	23	25	41	45	
MEAN	0.0	22.6	20.1	21.7	23.3	26.4	
STD DEV	0.0	4.6	12.0	24.0	35.5	36.7	
SEM	0.0	1.6	4.5	8.1	13.4	14.6	

RECEIVED VEHICLE ONLY: DI H2O lp

NT PB+DMPS GROUP	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	COMMENTS
CC 1	0	25	29	36	44	48	DIED DAY 5 DIED DAY 4
CC 2	0	22	31	39	41	54	
CC 3	0	19	27	36	39	52	
CC 4	0	9	-8	-20	-42	-50	
CC 5	0	14	-7	-26	-36	-36	
CC 6	0	25	16	33	44	53	
CC 7	0	34	10	16	24	28	
MEAN	0.0	19.7	14.6	14.6	16.0	21.7	
STD DEV	0.0	6.2	16.1	27.3	36.9	45.6	
SEM	0.0	2.3	6.1	10.3	14.7	17.2	

RECEIVED VEHICLE ONLY: 1% TWEEN-80 po + DI H2O lp

ORGAN WEIGHT TABLE

ANIMAL ORGAN WEIGHTS (g)

T PB GROUP	LIVER	KIDNEY	HEART	BRAIN	COMMENTS
TA 1	10.28	1.37	0.92	1.71	
TA 2	8.47	1.18	1.13	1.80	
TA 3	10.85	1.38	1.21	1.82	
TA 4	11.02	1.70	0.89	1.72	
TA 5	10.85	1.14	1.28	1.78	
TA 6	12.59	1.61	1.36	1.82	
TA 7	11.85	1.14	1.04	1.74	
TA 8	9.89	1.14	1.02	1.82	
TA 9	10.51	1.55	0.92	1.64	
TA 10	12.08	1.19	0.80	1.58	
MEAN	10.80	1.34	1.07	1.88	
STD DEV	1.16	0.22	0.17	0.07	
SEM	0.37	0.07	0.05	0.02	

T DMP'S GROUP	LIVER	KIDNEY	HEART	BRAIN	COMMENTS
TB 1	8.83	1.27	1.17	1.84	
TB 2	8.98	1.18	1.12	1.53	
TB 3	8.98	0.80	1.19	1.42	
TB 4	8.78	0.83	0.94	1.85	
TB 5	8.52	1.22	0.88	1.57	
TB 6	8.88	1.00	0.90	1.57	
TB 7	8.41	1.31	1.12	1.80	
TB 8	8.47	1.00	0.92	1.71	
TB 9	8.38	0.98	1.38	1.81	
TB 10	8.95	0.98	1.08	1.80	
MEAN	8.71	1.04	1.07	1.62	
STD DEV	0.24	0.21	0.18	0.10	
SEM	0.08	0.07	0.05	0.03	

T PB+DMP'S GROUP	LIVER	KIDNEY	HEART	BRAIN	COMMENTS
TC 1	10.25	1.27	1.12	1.55	ONLY 1 KIDNEY
TC 2	9.67	1.40	0.92	1.84	
TC 3	10.25	1.20	1.13	1.88	
TC 4	10.28	1.18	1.22	1.87	
TC 5	11.61	1.32	1.37	1.52	
TC 6	10.29	1.40	1.04	1.75	
TC 7	10.12	1.41	1.26	1.80	
TC 8	10.38	1.25	0.93	1.59	
TC 9	10.83	1.29	0.99	1.39	
TC10	10.84	1.42	0.91	1.86	
MEAN	10.43	1.31	1.09	1.63	
STD DEV	0.51	0.09	0.18	0.13	
SEM	0.16	0.03	0.05	0.04	

ANIMAL ORGAN WEIGHTS (g)

NT PB GROUP	LIVER	KIDNEY	HEART	BRAIN	COMMENTS
CA 1	10.94	1.16	1.25	1.55	DIED DAY 4
CA 2	9.61	1.30	0.99	1.51	
CA 3	9.61	1.11	0.97	1.66	
CA 4	10.39	1.11	0.94	1.52	
CA 5	10.31	1.01	1.15	1.52	
CA 6	9.80	1.18	0.84	1.39	
CA 7	8.29	1.16	1.36	1.57	
MEAN	9.82	1.15	1.07	1.53	
STD DEV	0.85	0.09	0.19	0.09	
SEM	0.32	0.03	0.07	0.03	

NT DMPS GROUP	LIVER	KIDNEY	HEART	BRAIN	COMMENTS
CB 1	9.71	1.20	1.31	1.51	DIED DAY 5
CB 2	9.61	1.01	1.34	1.50	
CB 3	6.99	0.95	0.94	1.42	
CB 4	11.41	1.31	0.87	1.59	
CB 5	9.27	1.32	1.29	1.61	
CB 6	11.88	1.30	1.35	1.52	
CB 7	10.75	1.29	1.09	1.55	
MEAN	9.95	1.20	1.17	1.53	
STD DEV	1.63	0.15	0.20	0.06	
SEM	0.62	0.06	0.06	0.02	

NT PB+DMPS GROUP	LIVER	KIDNEY	HEART	BRAIN	COMMENTS
CC 1	11.04	1.24	1.39	1.50	DIED DAY 5 DIED DAY 4
CC 2	12.56	1.24	1.22	1.63	
CC 3	10.01	1.00	1.20	1.52	
CC 4	6.19	1.03	0.89	1.44	
CC 5	8.98	1.21	0.84	1.46	
CC 6	9.83	1.19	1.07	1.61	
CC 7	9.13	1.13	1.35	1.54	
MEAN	9.66	1.19	1.14	1.53	
STD DEV	1.97	0.10	0.21	0.07	
SEM	0.74	0.04	0.06	0.03	

ANIMAL ORGAN WEIGHTS (g)

GROUP	LIVER	KIDNEY	HEART	BRAIN	COMMENTS
CA 1	10.94	1.16	1.25	1.55	
CA 2	9.61	1.30	0.99	1.51	
CA 3	9.61	1.11	0.97	1.68	
CA 4	10.39	1.11	0.94	1.52	
CA 5	10.31	1.01	1.15	1.52	
CA 6	9.60	1.18	0.84	1.39	DIED DAY 4
CA 7	8.29	1.16	1.36	1.57	
CB 1	9.71	1.20	1.31	1.51	
CB 2	9.61	1.01	1.34	1.50	
CB 3	8.99	0.95	0.94	1.42	DIED DAY 5
CB 4	11.41	1.31	0.87	1.59	
CB 5	9.27	1.32	1.29	1.61	
CB 6	11.88	1.30	1.35	1.52	
CB 7	10.75	1.29	1.09	1.55	
CC 1	11.04	1.24	1.39	1.50	
CC 2	12.96	1.24	1.22	1.63	
CC 3	10.01	1.00	1.20	1.32	
CC 4	6.19	1.03	0.89	1.44	DIED DAY 5
CC 5	8.96	1.21	0.84	1.46	DIED DAY 4
CC 6	9.83	1.19	1.07	1.61	
CC 7	9.13	1.13	1.36	1.54	
MEAN	9.81	1.16	1.13	1.53	
STD DEV	1.46	0.11	0.20	0.07	
SEM	0.32	0.02	0.04	0.02	

ORGAN WEIGHT/BODY WEIGHT RATIO TABLE

ORGAN WEIGHT / BODY WEIGHT RATIO TABLE (%)

GROUP	ORGAN WEIGHT / BODY WEIGHT RATIO (%)				COMMENTS
	LIVER	KIDNEY	HEART	BRAIN	
TA 1	4.13	0.55	0.37	0.69	
TA 2	3.47	0.48	0.46	0.66	
TA 3	3.99	0.51	0.44	0.60	
TA 4	4.27	0.66	0.34	0.67	
TA 5	3.96	0.42	0.47	0.65	
TA 6	4.56	0.58	0.48	0.59	
TA 7	4.41	0.43	0.36	0.66	
TA 8	3.85	0.44	0.40	0.63	
TA 9	4.17	0.62	0.37	0.65	
TA 10	4.86	0.48	0.36	0.63	
MEAN	4.17	0.52	0.41	0.64	
STD DEV	0.39	0.08	0.05	0.03	
SEM	0.12	0.03	0.02	0.01	

GROUP	ORGAN WEIGHT / BODY WEIGHT RATIO (%)				COMMENTS
	LIVER	KIDNEY	HEART	BRAIN	
TB 1	3.77	0.54	0.50	0.70	
TB 2	4.05	0.52	0.50	0.69	
TB 3	3.39	0.23	0.35	0.54	
TB 4	3.67	0.39	0.39	0.69	
TB 5	3.12	0.45	0.32	0.61	
TB 6	3.67	0.41	0.37	0.65	
TB 7	3.19	0.49	0.42	0.61	
TB 8	3.51	0.41	0.38	0.71	
TB 9	3.80	0.42	0.56	0.69	
TB 10	3.59	0.36	0.43	0.72	
MEAN	3.56	0.42	0.44	0.66	
STD DEV	0.27	0.09	0.06	0.06	
SEM	0.09	0.03	0.02	0.02	

GROUP	ORGAN WEIGHT / BODY WEIGHT RATIO (%)				COMMENTS
	LIVER	KIDNEY	HEART	BRAIN	
TC 1	3.97	0.49	0.43	0.60	
TC 2	3.78	0.55	0.36	0.64	
TC 3	3.73	0.22	0.41	0.68	
TC 4	3.94	0.45	0.47	0.64	
TC 5	3.81	0.43	0.45	0.50	
TC 6	3.78	0.51	0.38	0.64	
TC 7	4.27	0.59	0.53	0.68	
TC 8	4.40	0.53	0.39	0.67	
TC 9	4.36	0.53	0.41	0.57	
TC 10	4.46	0.58	0.37	0.68	
MEAN	4.05	0.49	0.42	0.63	
STD DEV	0.29	0.11	0.05	0.06	
SEM	0.09	0.03	0.02	0.02	

ORGAN WEIGHT / BODY WEIGHT RATIO TABLE (%)

GROUP	ORGAN WEIGHT / BODY WEIGHT RATIO (%)				COMMENTS
	LIVER	KIDNEY	HEART	BRAIN	
CA 1	4.32	0.46	0.49	0.81	DIED DAY 4
CA 2	3.75	0.51	0.39	0.59	
CA 3	3.57	0.41	0.36	0.82	
CA 4	4.12	0.44	0.37	0.80	
CA 5	4.14	0.41	0.46	0.81	
CA 6	5.39	0.88	0.47	0.78	
CA 7	3.33	0.47	0.56	0.83	
MEAN	4.09	0.48	0.44	0.84	
STD DEV	0.67	0.09	0.07	0.07	
SEM	0.25	0.03	0.03	0.02	

GROUP	ORGAN WEIGHT / BODY WEIGHT RATIO (%)				COMMENTS
	LIVER	KIDNEY	HEART	BRAIN	
CB 1	3.65	0.45	0.49	0.57	DIED DAY 5
CB 2	3.92	0.41	0.55	0.81	
CB 3	4.29	0.58	0.58	0.87	
CB 4	5.33	0.81	0.41	0.74	
CB 5	3.54	0.50	0.49	0.81	
CB 6	4.37	0.46	0.50	0.56	
CB 7	4.25	0.51	0.43	0.81	
MEAN	4.19	0.51	0.49	0.85	
STD DEV	0.80	0.07	0.06	0.11	
SEM	0.23	0.03	0.02	0.04	

GROUP	ORGAN WEIGHT / BODY WEIGHT RATIO (%)				COMMENTS
	LIVER	KIDNEY	HEART	BRAIN	
CC 1	4.25	0.48	0.53	0.58	DIED DAY 5 DIED DAY 4
CC 2	4.80	0.45	0.45	0.80	
CC 3	4.14	0.41	0.50	0.83	
CC 4	3.73	0.82	0.54	0.87	
CC 5	4.89	0.87	0.47	0.81	
CC 6	3.65	0.44	0.40	0.80	
CC 7	3.84	0.45	0.54	0.81	
MEAN	4.14	0.50	0.49	0.87	
STD DEV	0.92	0.10	0.06	0.12	
SEM	0.20	0.04	0.02	0.04	

ORGAN WEIGHT / BODY WEIGHT RATIO TABLE (%)

GROUP	ORGAN WEIGHT / BODY WEIGHT RATIO (%)				COMMENTS
	LIVER	KIDNEY	HEART	BRAIN	
CA 1	4.32	0.46	0.49	0.61	
CA 2	3.75	0.51	0.39	0.59	
CA 3	3.57	0.41	0.36	0.62	
CA 4	4.12	0.44	0.37	0.60	
CA 5	4.14	0.41	0.46	0.61	
CA 6	5.39	0.66	0.47	0.78	DIED DAY 4
CA 7	3.33	0.47	0.55	0.63	
CB 1	3.65	0.45	0.49	0.57	
CB 2	3.62	0.41	0.55	0.61	
CB 3	4.29	0.56	0.58	0.67	DIED DAY 5
CB 4	5.33	0.61	0.41	0.74	
CB 5	3.54	0.50	0.49	0.61	
CB 6	4.37	0.48	0.50	0.56	
CB 7	4.25	0.51	0.43	0.61	
CC 1	4.25	0.48	0.53	0.56	
CC 2	4.60	0.45	0.45	0.60	
CC 3	4.14	0.41	0.50	0.63	
CC 4	3.73	0.62	0.54	0.67	DIED DAY 5
CC 5	4.99	0.67	0.47	0.61	DIED DAY 4
CC 6	3.65	0.44	0.40	0.60	
CC 7	3.64	0.45	0.54	0.61	
MEAN	4.14	0.50	0.47	0.65	
STD DEV	0.57	0.06	0.06	0.10	
SEM	0.12	0.02	0.01	0.02	

**THALLIUM CONTENT OF
ORGANS, BLOOD AND FECES**

THALLIUM CONTENT (ppm) OF
RAT ORGANS, BLOOD & FECES

PB TREATMENT GROUP	THALLIUM CONTENT (ppm)						COMMENTS
	KIDNEY	LIVER	HEART	BRAIN	BLOOD	FECES	
TA 1	37.4	5.7	14.8	3.1	0.27	8.7	
TA 2	44.1	5.3	13.7	2.7	0.34	8.8	
TA 3	38.7	5.5	9.8	4.5	0.18	8.5	
TA 4	40.8	4.8	9.4	2.8	0.17	5.7	
TA 5	34.4	4.3	8.2	3.4	0.33	7.0	
TA 6	40.8	5.0	12.3	3.3	0.27	7.3	
TA 7	41.8	4.9	12.3	2.7	0.25	10.9	
TA 8	39.9	5.2	13.0	2.2	0.26	7.0	
TA 9	34.7	4.6	11.8	2.9	0.21	7.8	
TA 10	38.7	5.1	11.3	2.8	0.17	6.6	
MEAN	39.2	5.0	11.7	3.0	0.23	7.9	
STD DEV	3.0	0.4	1.8	0.8	0.06	1.5	
SEM	1.0	0.1	0.6	0.2	0.02	0.5	

RECEIVED 50 mg PB / kg BW SUSPENDED IN 1% TWEEN-80 po

DMPS TREATMENT GROUP	THALLIUM CONTENT (ppm)						COMMENTS
	KIDNEY	LIVER	HEART	BRAIN	BLOOD	FECES	
TB 1	56.1	10.2	21.4	9.5	0.071	3.6	
TB 2	52.2	9.5	22.2	12.1	0.073	3.6	
TB 3	50.8	8.4	16.1	8.8	0.078	3.1	
TB 4	84.1	7.8	18.8	9.8	0.112	3.9	
TB 5	88.0	9.0	18.8	10.7	0.102	2.8	
TB 6	80.5	8.2	24.7	7.4	0.080	4.2	
TB 7	74.0	8.2	25.4	9.8	0.068	3.8	
TB 8	78.8	11.4	19.7	8.8	0.088	2.6	
TB 9	70.3	7.8	22.1	8.4	0.088	2.2	
TB 10	77.1	8.4	20.7	8.4	0.070	2.2	
MEAN	72.8	9.0	21.0	9.2	0.075	3.2	
STD DEV	15.7	1.2	2.8	1.8	0.018	0.7	
SEM	5.0	0.4	0.9	0.6	0.006	0.2	

RECEIVED 5 mg DMPS / kg BW DISSOLVED IN DI H2O ip

DMPS + PB TREATMENT GROUP	THALLIUM CONTENT (ppm)						COMMENTS
	KIDNEY	LIVER	HEART	BRAIN	BLOOD	FECES	
TC 1	38.8	5.7	10.1	2.8	0.088	7.3	
TC 2	37.3	5.3	11.3	2.8	0.064	7.2	
TC 3	37.8	5.4	13.5	2.4	0.085	6.8	
TC 4	29.3	5.5	10.7	3.9	0.057	7.3	
TC 5	29.3	5.2	8.5	4.2	0.059	8.1	
TC 6	38.3	7.5	10.2	3.9	0.040	6.7	
TC 7	38.4	5.8	7.8	3.5	0.041	7.7	
TC 8	34.5	6.0	8.6	2.4	0.037	6.4	
TC 9	27.2	6.8	8.8	3.1	0.032	6.7	
TC 10	35.8	6.2	8.3	2.4	0.058	6.9	
MEAN	34.6	5.9	10.0	3.1	0.047	7.3	
STD DEV	4.4	0.7	1.8	0.7	0.012	1.0	
SEM	1.4	0.2	0.5	0.2	0.004	0.3	

RECEIVED 50 mg PB / kg BW SUSPENDED IN 1% TWEEN-80 po + 5 mg DMPS / kg BW
DISSOLVED IN DI H2O ip

THALLIUM CONTENT (ppm) OF
RAT ORGANS, BLOOD & FECES

PB CONTROL GROUP	THALLIUM CONTENT (ppm)						COMMENTS
	KIDNEY	LIVER	HEART	BRAIN	BLOOD	FECES	
CA 1	79.5	8.4	18.5	10.8	1.3	3.7	DIED DAY 4
CA 2	78.8	8.1	24.8	10.2	1.8	2.7	
CA 3	80.8	8.0	24.8	11.8	1.3	3.8	
CA 4	75.3	8.2	18.9	7.2	1.2	4.0	
CA 5	78.8	10.2	18.8	7.2	1.1	3.8	
CA 6	83.8	12.6	30.0	12.8	2.1	2.8	
CA 7	79.5	10.2	25.8	8.8	1.4	4.4	
MEAN	78.5	8.7	23.5	10.0	1.5	3.6	
STD DEV	2.5	1.6	3.8	2.2	0.4	0.6	
SEM	0.8	0.6	1.5	0.8	0.1	0.2	

RECEIVED VEHICLE ONLY: 1% TWEEN-80 po

DMPS CONTROL GROUP	THALLIUM CONTENT (ppm)						COMMENTS
	KIDNEY	LIVER	HEART	BRAIN	BLOOD	FECES	
CB 1	87.0	10.4	22.4	8.5	1.0	3.4	DIED DAY 6
CB 2	72.0	8.7	18.4	8.4	1.7	4.3	
CB 3	80.5	12.3	28.8	13.4	1.8	3.2	
CB 4	74.5	8.1	18.3	10.1	0.8	4.5	
CB 5	83.1	8.6	18.5	7.8	1.4	2.8	
CB 6	81.8	9.7	22.3	10.4	1.8	4.3	
CB 7	78.8	8.8	20.2	9.8	1.8	4.7	
MEAN	81.2	9.8	21.7	10.0	1.5	3.8	
STD DEV	6.5	1.3	3.8	1.7	0.4	0.7	
SEM	2.5	0.5	1.3	0.8	0.1	0.3	

RECEIVED VEHICLE ONLY: DI H2O ip

PB + DMPS CONTROL GROUP	THALLIUM CONTENT (ppm)						COMMENTS
	KIDNEY	LIVER	HEART	BRAIN	BLOOD	FECES	
CC 1	55.3	10.8	22.5	10.3	1.7	3.4	DIED DAY 6 DIED DAY 4
CC 2	81.7	11.4	21.8	8.8	1.0	2.8	
CC 3	84.0	10.5	18.3	8.2	1.1	3.2	
CC 4	80.5	12.4	28.0	13.8	1.7	5.1	
CC 5	82.3	12.3	23.3	14.2	1.8	4.5	
CC 6	88.8	10.1	22.7	7.8	1.5	3.1	
CC 7	88.8	11.8	21.8	8.1	1.4	3.4	
MEAN	74.2	11.4	22.8	10.3	1.4	3.7	
STD DEV	14.1	0.8	3.2	2.6	0.3	0.8	
SEM	5.3	0.3	1.2	1.0	0.1	0.3	

RECEIVED VEHICLE ONLY: 1% TWEEN-80 po + DI H2O ip

CLINICAL OBSERVATIONS

CLINICAL OBSERVATIONS TABLE

The clinical effects of thallium poisoning in rats are diarrhea, tremor, and alopecia, whereas scruffy coat is non-specific sign of illness. Animals having these signs are indicated below.

GROUP	DIARRHEA	TREMOR	SCRUFFY COAT	ALOPECIA
TA	N/A	N/A	N/A	N/A
TB	TB2 TB4	TB2 TB4	N/A	N/A
TC	N/A	N/A	N/A	N/A
CA	CA5 CA6	CA1 CA6	CA1 CA6	CA6
CB	CB5 CB3	CB6 CB3	CB6 CB3	CB3
CC	CC4 CC5	CC4 CC5	CC4 CC5	CC4 CC5

TA = Prussian blue (PB) treatment (T) group; TB = Unithiol (DMPS) T group; TC = PB+DMPS T group; CA = PB non-treatment (NT) group; CB = DMPS NT group; CC = PB+DMPS NT group; N/A = not applicable

Observations from gross examination of animals that died before the end of the study:

- CA6 none; had minimal amount of fecal matter in bowel.
- CB3 colon distended with bloody serous liquid; no ulceration observed.
- CC4 enlarged, distended colon containing 2.7 g feces; dimensions of enlarged colon 3.5 x 3.1 x 1.9 cm; lower left and right lobes had patchy dark-red areas.
- CC5 small amount of liquid feces (no pellets).

APPENDIX B

THALLIUM DETERMINATION WORKSHEETS

KIDNEY

SAMPLE: KIDNEY

GROUPS: PB (TX & NO TX)

RUN 1 T1 STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.1					5.1
0.10	17.1					17.1
0.30	60.2					60.2
0.50	90.2					90.2
0.70	110.4					110.4
1.00	157.0					157.0

RUN 2 T1 STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	4.6					4.6
0.1	15.9					15.9
0.3	58.3					58.3
0.5	83.6					83.6
0.7	116.2					116.2
1.00	162.0					162.0

RUN 3 T1 STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	3.5					3.5
0.1	14.8					14.8
0.3	58.4					58.4
0.5	77.2					77.2
0.7	115.2					115.2
1.00	162.4					162.4

SAMPLE: KIDNEY

GROUPS: PB (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	2.9	0.9	-0.4
0.05	5.1	4.6	3.5	10.9	9.1	7.8
0.10	17.1	15.9	14.8	18.8	17.3	16.0
0.30	60.2	58.3	58.4	50.4	50.1	48.8
0.50	90.2	83.6	77.2	82.1	82.9	81.5
0.70	110.4	116.2	115.2	113.7	115.7	114.3
1.00	157.0	162.0	162.4	161.2	164.9	163.4

Regression Output: RUN 1

Constant	2.9407234
Std Err of Y Est	6.8553053
R Squared	0.9889467
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	158.26878
Std Err of Coef.	7.4829335

Regression Output: RUN 3

Constant	-0.361021
Std Err of Y Est	5.1696727
R Squared	0.9940992
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	163.78382
Std Err of Coef.	5.6431934

Regression Output: RUN 2

Constant	0.8532765
Std Err of Y Est	4.4586333
R Squared	0.9056165
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	164.01021
Std Err of Coef.	4.8668374


Regression Output: 3 STD RUNS
COMBINED

Constant	1.1443282
Std Err of Y Est	5.0946372
R Squared	0.9925941
No. of Observations	21
Degrees of Freedom	19

X Coefficient(s)	162.02127
Std Err of Coef.	3.2106851

SAMPLE: KIDNEY

GROUPS: PB (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TA 1	76.5	78.4			77.5	0.47
TA 2	85.0	84.6			84.8	0.52
TA 3	89.6	88.8			89.2	0.54
TA 4	85.0	80.0			82.5	0.50
TA 5	77.2	72.0			74.6	0.45
TA 6	80.4	85.4			82.9	0.50
TA 7	77.0	74.2			75.6	0.46
TA 8	83.6	83.4			83.5	0.51
TA 9	70.4	76.0			73.2	0.44
TA 10	83.0	80.9			81.7	0.50
CA 1	82.0	79.6			80.8	0.49
CA 2	81.0	73.2			77.1	0.47
CA 3	81.8	79.8			80.8	0.49
CA 4	67.0	82.4			64.7	0.39
CA 5	73.0	76.8			74.9	0.46
CA 6	70.8	73.8			72.3	0.44
CA 7	81.8	79.4			80.6	0.49

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE WET ASHED: 2/10/93

FILE: A_A_K2

THALLIUM ANTIDOTE STUDY
WET ASH DATA WORKSHEET

DATE ANALYZED: 2/10/93

PATH: c:\data\Volue2.3
a:\Volue2TISSUE TYPE: KIDNEY
PB

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TAPE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TI CONC ug TI/g tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H) $F \times G / C$	
TA 1	81.8820	81.4102	0.2518	5.0	4	20	0.47	37.41	
TA 2	80.1808	59.9488	0.2340	5.0	4	20	0.52	44.13	
TA 3	58.5971	58.3232	0.2739	5.0	4	20	0.54	39.88	
TA 4	80.7675	80.5203	0.2472	5.0	4	20	0.50	40.83	
TA 5	81.9423	81.8787	0.2638	5.0	4	20	0.45	34.40	
TA 6	48.8325	48.3839	0.2488	5.0	4	20	0.50	40.60	
TA 7	48.8225	48.8018	0.2209	5.0	4	20	0.48	41.81	
TA 8	48.1424	48.8875	0.2548	5.0	4	20	0.51	39.88	
TA 9	80.4747	80.2188	0.2581	5.0	4	20	0.44	34.73	
TA 10	82.2589	82.0032	0.2557	5.0	4	20	0.50	38.71	
CA 1	48.3483	48.1010	0.2473	5.0	8	40	0.48	79.52	
CA 2	58.8708	58.6329	0.2380	5.0	8	40	0.47	78.79	
CA 3	50.3318	50.0883	0.2435	5.0	8	40	0.48	80.78	
CA 4	82.2850	82.0685	0.2085	5.0	8	40	0.38	75.28	
CA 5	82.3711	82.1404	0.2307	5.0	8	40	0.48	78.93	
CA 6	82.8985	82.8882	0.2101	5.0	8	40	0.44	83.81	
CA 7	81.7857	81.5490	0.2467	5.0	8	40	0.48	79.51	DIED DAY 4
MEAN			0.2431						

FILE A_8_K1

THALLIUM ANTIDOTE STUDY
PEAK HEIGHT WORKSHEET

DATE 2/12/83

SAMPLE: KIDNEY

GROUPS: DMPS (TX & NO TX)

RUN 1 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	4.1					4.1
0.10	9.9					9.9
0.30	42.2					42.2
0.50	75.6					75.6
0.70	88.4					88.4
1.00	134.2					134.2

RUN 2 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	4.0					4.0
0.1	9.7					9.7
0.3	41.3					41.3
0.5	76.0					76.0
0.7	92.2					92.2
1.00	136.6					136.6

RUN 3 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	3.8					3.8
0.1	9.5					9.5
0.3	40.8					40.8
0.5	71.4					71.4
0.7	89.2					89.2
1.00	136.2					136.2

SAMPLE: KIDNEY

GROUPS: DMPS (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	-0.8	-1.1	-1.7
0.05	4.1	4.0	3.8	6.2	5.8	5.2
0.10	9.9	9.7	9.5	12.9	12.7	12.0
0.30	42.2	41.3	40.8	40.0	40.5	39.4
0.50	75.8	76.0	71.4	67.1	68.3	66.7
0.70	88.4	92.2	89.2	94.1	96.0	94.1
1.00	134.2	136.6	136.2	134.7	137.7	135.2

Regression Output: RUN 1

Constant -0.598425
Std Err of Y Est 4.9029981
R Squared 0.9019644
No. of Observations 7
Degrees of Freedom 5

X Coefficient(s) 135.31659
Std Err of Coef. 5.4500162

Regression Output: RUN 3

Constant -1.689319
Std Err of Y Est 3.4803747
R Squared 0.9962089
No. of Observations 7
Degrees of Freedom 5

X Coefficient(s) 136.87744
Std Err of Coef. 3.7771848

Regression Output: RUN 2

Constant -1.144425
Std Err of Y Est 4.2438908
R Squared 0.9944618
No. of Observations 7
Degrees of Freedom 5

X Coefficient(s) 138.79659
Std Err of Coef. 4.6322162


Regression Output: 3 STD RUNS
COMBINED

Constant -1.144056
Std Err of Y Est 3.8757308
R Squared 0.9939986
No. of Observations 21
Degrees of Freedom 19

X Coefficient(s) 136.90687
Std Err of Coef. 2.4425198

SAMPLE: KIDNEY

GROUPS: DMP8 (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TB 1	40.5	41.5			41.0	0.31
TB 2	42.1	41.3			41.7	0.31
TB 3	36.0	38.1			37.1	0.28
TB 4	73.0	72.8			72.9	0.54
TB 5	72.6	75.2			73.9	0.56
TB 6	70.0	70.8			70.4	0.52
TB 7	61.8	64.8			63.3	0.47
TB 8	66.6	67.8			67.1	0.50
TB 9	60.4	57.8			59.0	0.44
TB 10	60.2	56.8			58.5	0.44
CB 1	69.4	70.8			70.0	0.52
CB 2	62.0	64.6			63.3	0.47
CB 3	71.8	69.8			70.8	0.53
CB 4	64.4	61.8			63.1	0.47
CB 5	71.4	62.6	66.6		67.5	0.50
CB 6	62.5	66.2			64.4	0.48
CB 7	66.8	59.2	61.5		62.5	0.46

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE WET ASHED: 2/11/83
 FILE: A_B_K2
 THALLIUM ANTIDOTE STUDY
 WET ASH DATA WORKSHEET
 TISSUE TYPE: KIDNEY
 DMPS

DATE ANALYZED: 2/12/83

PATH: c:\data\Volume2.3
 a:\volume

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TARE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TIC CONC ug TIG tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	
FB 1	72.0817	71.8725	0.2102	5.0		40	0.31	56.14	
FB 2	71.8856	71.4463	0.2396	5.0		40	0.31	52.23	
FB 3	78.8258	78.4061	0.2197	5.0		40	0.28	50.78	
FB 4	81.1039	80.8467	0.2572	5.0		40	0.54	84.08	
FB 5	76.1013	77.8731	0.2282	5.0		40	0.56	86.02	
FB 6	79.2751	79.0442	0.2309	5.0		40	0.52	90.47	
FB 7	78.8299	78.6756	0.2543	5.0		40	0.47	73.99	
FB 8	79.8885	79.6386	0.2508	5.0		40	0.50	78.78	
FB 9	72.4496	72.1968	0.2528	5.0		40	0.44	70.30	
FB 10	72.4942	72.2983	0.2259	5.0		40	0.44	77.09	
CB 1	78.9090	78.6991	0.2099	5.0		40	0.52	88.95	
CB 2	78.0448	77.7831	0.2615	5.0		40	0.47	71.95	
CB 3	81.7529	81.5207	0.2322	5.0		40	0.53	90.47	
CB 4	78.1559	77.9040	0.2519	5.0		40	0.47	74.47	
CB 5	72.0197	71.7783	0.2414	5.0		40	0.50	83.07	
CB 6	72.1473	71.9136	0.2337	5.0		40	0.48	81.83	
CB 7	81.8231	81.3002	0.2329	5.0		40	0.46	79.78	
MEAN			0.2306						DIED DAY 5

SAMPLE: KIDNEY

GROUPS: PB + DMPS (TX & NO TX)

RUN 1 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	4.1					4.1
0.10	10.3					10.3
0.30	43.7					43.7
0.50	75.0					75.0
0.70	90.8					90.8
1.00	138.8					138.8

RUN 2 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	4.0					4.0
0.1	10.1					10.1
0.3	44.8					44.8
0.5	81.2					81.2
0.7	92.2					92.2
1.00	138.8					138.8

RUN 3 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	3.7					3.7
0.1	11.8					11.8
0.3	46.4					46.4
0.5	78.4					78.4
0.7	97.4					97.4
1.00	145.4					145.4

SAMPLE: KIDNEY

GROUPS: PB + DMPs (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	-0.9	-0.3	-0.8
0.05	4.1	4.0	3.7	6.1	6.8	6.5
0.10	10.3	10.1	11.5	13.0	13.8	13.8
0.30	43.7	44.8	46.4	40.8	42.0	43.2
0.50	75.0	81.2	78.4	68.6	70.1	72.5
0.70	90.8	92.2	97.4	96.5	98.2	101.8
1.00	138.8	138.8	145.4	136.2	140.5	145.8

Regression Output: RUN 1

Constant -0.885872
Std Err of Y Est 4.3623581
R Squared 0.9941712
No. of Observations 7
Degrees of Freedom 5

X Coefficient(s) 139.05702
Std Err of Coef. 4.7617479

Regression Output: RUN 3

Constant -0.821446
Std Err of Y Est 3.9855572
R Squared 0.9956633
No. of Observations 7
Degrees of Freedom 5

X Coefficient(s) 140.90042
Std Err of Coef. 4.3286184

Regression Output: RUN 2

Constant -0.257318
Std Err of Y Est 6.1989767
R Squared 0.9885708
No. of Observations 7
Degrees of Freedom 5

X Coefficient(s) 140.71744
Std Err of Coef. 6.7865157


Regression Output: 3 STD RUNS
COMBINED

Constant -0.854879
Std Err of Y Est 4.7198744
R Squared 0.9917487
No. of Observations 21
Degrees of Freedom 19

X Coefficient(s) 142.14466
Std Err of Coef. 2.9745063

SAMPLE: KIDNEY

GROUPS: PB + DMPS (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TC 1	70.0	71.2			70.6	0.50
TC 2	72.2	70.6			71.4	0.51
TC 3	73.0	72.6			72.8	0.52
TC 4	48.6	53.4			51.0	0.36
TC 5	51.2	53.6			52.4	0.37
TC 6	67.8	66.8			66.8	0.49
TC 7	63.2	66.4			64.8	0.46
TC 8	66.0	63.4			64.7	0.46
TC 9	48.2	56.6			52.5	0.37
TC 10	66.0	66.2			66.1	0.47
CC 1	46.2	52.2			50.2	0.36
CC 2	66.4	66.0			66.2	0.49
CC 3	56.0	60.6			58.3	0.41
CC 4	67.2	66.8			66.0	0.48
CC 5	71.0	77.4			74.2	0.53
CC 6	62.0	64.0			63.0	0.45
CC 7	65.8	65.6			65.7	0.47

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE ANALYZED: 2/13/83
 PATH: c:\data\volus2.3
 a:\volus

THALLIUM ANTIDOTE STUDY
 WET ASH DATA WORKSHEET
 TISSUE TYPE: KIDNEY
 PB + DMPS

DATE WET ASHED: 2/12/83
 FILE: A_C_12

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TAKE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TIC CONC ug TVG tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C) = A - B	(D)	(E)	(F) = D x E	(G)	(H) = F x G / C	
TC 1	60.2169	59.9462	0.2727	5	4	20	0.50	36.78	
TC 2	60.2214	59.9494	0.2720	5	4	20	0.51	37.27	
TC 3	58.5960	58.3228	0.2731	5	4	20	0.52	37.57	
TC 4	49.6324	49.3642	0.2682	5	4	20	0.36	29.28	
TC 5	61.8322	61.5776	0.2546	5	4	20	0.37	29.32	
TC 6	49.6325	49.3639	0.2686	5	4	20	0.49	39.31	
TC 7	61.8019	61.5894	0.2125	5	4	20	0.48	39.44	
TC 8	60.2606	59.9943	0.2663	5	4	20	0.48	34.53	
TC 9	60.4831	60.2184	0.2747	5	4	20	0.37	27.23	
TC 10	61.4574	61.1937	0.2637	5	4	20	0.47	36.82	
CC 1	62.3578	62.1388	0.2190	5	8	40	0.38	56.25	
CC 2	62.9283	62.6966	0.2317	5	8	40	0.49	81.87	
CC 3	61.8053	61.5482	0.2571	5	8	40	0.41	84.03	
CC 4	49.3142	49.1007	0.2135	5	8	40	0.48	90.49	
CC 5	59.8907	59.6325	0.2582	5	8	40	0.53	92.31	
CC 6	50.2984	50.0361	0.2623	5	8	40	0.45	88.56	
CC 7	62.3352	62.0551	0.2801	5	8	40	0.47	90.90	
MEAN			0.2559						DIED DAY 5 DIED DAY 4

LIVER

FILE A_A_L1

THALLIUM ANTIDOTE STUDY
PEAK HEIGHT WORKSHEET

DATE 2/14/93

SAMPLE: LIVER

GROUPS: PB (TX & NO TX)

RUN 1 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.4					5.4
0.10	15.1					15.1
0.30	46.9					46.9
0.50	79.4					79.4
0.70	104.4					104.4
1.00	152.1	148.2				150.7

RUN 2 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.4					5.4
0.1	15.2					15.2
0.3	44.3					44.3
0.5	81.6					81.6
0.7	105.0					105.0
1.00	150.2	151.8				150.9

RUN 3 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.1					5.1
0.1	12.7					12.7
0.3	45.5					45.5
0.5	76.6	76.0				76.3
0.7	102.0					102.0
1.00	146.5	147.7				148.1

SAMPLE: LIVER

GROUPS: PB (TX & NO TX)

TI STDs	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	0.1	-0.2	-0.8
0.05	5.4	5.4	5.1	7.6	7.4	6.6
0.10	15.1	15.2	12.7	15.2	15.0	14.1
0.30	46.9	44.3	45.5	45.5	45.5	43.9
0.50	79.4	81.6	76.3	76.8	76.0	73.8
0.70	104.4	106.0	102.0	106.1	106.5	103.7
1.00	150.7	150.9	148.1	151.6	152.2	148.4

Regression Output: RUN 1

Constant	0.0538836
Std Err of Y Est	2.1717750
R Squared	0.9987772
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	151.48914
Std Err of Coef.	2.3706090

Regression Output: RUN 3

Constant	-0.844836
Std Err of Y Est	1.8156932
R Squared	0.9991195
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	149.28851
Std Err of Coef.	1.9619296

Regression Output: RUN 2

Constant	-0.224680
Std Err of Y Est	2.8591175
R Squared	0.9979067
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	152.44255
Std Err of Coef.	3.1208801


Regression Output: 3 STD RUNS
COMBINED

Constant	-0.338574
Std Err of Y Est	2.2948829
R Squared	0.9982618
No. of Observations	21
Degrees of Freedom	19

X Coefficient(s)	151.07673
Std Err of Coef.	1.4462564

SAMPLE: LIVER

GROUPS: PB (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TA 1	88.4	86.8			87.6	0.58
TA 2	84.8	83.8			84.2	0.56
TA 3	75.4	75.2			75.3	0.50
TA 4	73.2	68.8			71.0	0.47
TA 5	66.8	67.0			66.4	0.44
TA 6	78.8	77.8			78.2	0.52
TA 7	78.0	78.8			78.4	0.52
TA 8	77.2	79.2			78.2	0.52
TA 9	66.4	63.8			64.5	0.43
TA 10	77.0	79.0			78.0	0.52
CA 1	76.4	75.4			75.9	0.50
CA 2	62.2	65.8			63.9	0.43
CA 3	79.0	77.8			78.4	0.52
CA 4	59.8	65.8			62.8	0.42
CA 5	74.4	77.8			76.1	0.51
CA 6	66.8	68.0			67.4	0.65
CA 7	81.4	83.0			82.2	0.55

$$TI \text{ CONC} = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE WET ASHED: 2/13/83

FILE: A_A_L2

THALLIUM ANTIDOTE STUDY
WET ASH DATA WORKSHEET

DATE ANALYZED: 2/14/83

PATH: c:\data\lotus2.3
a:\lotusTISSUE TYPE: LIVER
PB

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TAPE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TI CONC ug TI/g tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C) A - B	(D)	(E)	(F) D x E	(G)	(H) F x G / C	
TA 1	62.0700	61.5618	0.5081	5	1	5	0.58	5.72	
TA 2	49.2671	48.7378	0.5293	5	1	5	0.58	5.29	
TA 3	59.0566	58.8023	0.4543	5	1	5	0.50	5.51	
TA 4	58.8080	58.3128	0.4952	5	1	5	0.47	4.79	
TA 5	62.2119	61.8954	0.3165	5	1	5	0.44	4.28	
TA 6	63.0479	62.5243	0.5236	5	1	5	0.52	4.98	
TA 7	62.6862	62.1511	0.5371	5	1	5	0.52	4.85	
TA 8	61.7739	61.2282	0.4957	5	1	5	0.52	5.24	
TA 9	61.7609	61.3148	0.4661	5	1	5	0.43	4.60	
TA 10	59.5348	59.0297	0.5049	5	1	5	0.52	5.14	
CA 1	62.5622	62.0249	0.5373	5	2	10	0.50	9.39	
CA 2	59.5578	59.0315	0.5263	5	2	10	0.43	8.08	
CA 3	60.3988	59.8217	0.5771	5	2	10	0.52	9.03	
CA 4	62.4908	61.9734	0.5074	5	2	10	0.42	8.21	
CA 5	56.3914	55.8974	0.4940	5	2	10	0.51	10.24	
CA 6	62.8578	62.3449	0.5127	5	2	10	0.65	12.82	
CA 7	62.2272	61.8924	0.5348	5	2	10	0.55	10.22	DIED DAY 4
MEAN			0.5129						

SAMPLE: LIVER

GROUPS: DMPS (TX & NO TX)

RUN 1 T1STD5 (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.7					5.7
0.10	13.5					13.5
0.30	57.8					57.8
0.50	76.0					76.0
0.70	103.4					103.4
1.00	120.2	124.8				127.5

RUN 2 T1STD5 (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.4					5.4
0.1	12.5					12.5
0.3	53.3					53.3
0.5	72.6					72.6
0.7	105.6					105.6
1.00	137.2	136.8				137.0

RUN 3 T1STD5 (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.0					5.0
0.1	6.6	8.7				7.7
0.3	56.7					56.7
0.5	67.0	68.0				67.5
0.7	96.4					96.4
1.00	125.4	132.7				129.1

SAMPLE: LIVER

GROUPS: DMPS (TX & NO TX)

TI STDs	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	4.5	1.5	1.5
0.05	5.7	5.4	5.0	11.2	8.5	8.2
0.10	13.5	12.5	7.7	17.5	15.9	14.9
0.30	57.5	53.3	55.7	44.4	44.1	41.4
0.50	75.0	72.5	57.5	71.0	72.3	57.5
0.70	103.4	105.5	95.4	97.5	100.5	84.3
1.00	127.5	137.0	129.1	137.4	142.9	134.1

Regression Output: RUN 1

Constant	4.5305744
Std Err of Y Est	9.0180558
R Squared	0.9732923
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	132.57559
Std Err of Coef.	9.5437244

Regression Output: RUN 3

Constant	1.6220425
Std Err of Y Est	8.1270744
R Squared	0.9780555
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	132.43234
Std Err of Coef.	8.5711377

Regression Output: RUN 2

Constant	1.7714893
Std Err of Y Est	5.5491825
R Squared	0.9995707
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	141.13191
Std Err of Coef.	5.3545955


Regression Output: 3 STD RUNS
COMBINED

Constant	2.5443557
Std Err of Y Est	7.2459528
R Squared	0.9785533
No. of Observations	21
Degrees of Freedom	15

X Coefficient(s)	135.45025
Std Err of Coef.	4.5583727

SAMPLE: LIVER

GROUPS: DMPS (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TB 1	72.6	70.0			71.3	0.51
TB 2	72.0	70.2			71.1	0.51
TB 3	61.4	63.0			62.2	0.44
TB 4	60.8	61.8			60.8	0.43
TB 5	60.0	60.4	57.8		62.1	0.44
TB 6	63.4	66.4			60.9	0.43
TB 7	68.6	63.6			66.1	0.47
TB 8	60.8	63.2			62.0	0.50
TB 9	63.8	57.0	66.2		60.7	0.42
TB 10	67.0	65.4			66.2	0.47
CB 1	76.4	74.0			74.7	0.53
CB 2	62.0	60.0			61.0	0.43
CB 3	63.2	61.6			62.4	0.46
CB 4	68.0	66.4			67.2	0.48
CB 5	60.0	61.0			60.5	0.43
CB 6	64.2	64.8			64.5	0.46
CB 7	66.6	64.6			65.6	0.46

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE ANALYZED: 2/15/83
 PATH: c:\data\lotus2.3
 a:\lotus

THALLIUM ANTIDOTE STUDY
 WET ASH DATA WORKSHEET
 TISSUE TYPE: LIVER
 DMP8

DATE WET ASHED: 2/14/83
 FILE: A.B.L2

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TAPE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TI CONC ug TH ₂₁₂ tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C) A - B	(D)	(E)	(F) D x E	(G)	F x G / C	
TB 1	82.0178	81.5219	0.4959	5.0	2	10	0.51	10.22	
TB 2	79.5735	79.0440	0.5295	5.0	2	10	0.51	9.54	
TB 3	61.9104	61.3808	0.5296	5.0	2	10	0.44	8.44	
TB 4	78.4223	77.8730	0.5493	5.0	2	10	0.43	7.81	
TB 5	72.3691	71.9136	0.4555	5.0	2	10	0.44	9.04	
TB 6	72.7214	72.1804	0.5410	5.0	2	10	0.43	8.34	
TB 7	61.4201	60.8463	0.5738	5.0	2	10	0.47	8.16	
TB 8	72.2933	71.7781	0.5152	5.0	2	10	0.59	11.44	
TB 9	72.4248	71.8723	0.5525	5.0	2	10	0.42	7.82	
TB 10	60.1368	59.6369	0.5000	5.0	2	10	0.47	9.37	
CB 1	78.9164	78.4058	0.5106	5.0	2	10	0.53	10.42	
CB 2	79.0596	78.5754	0.4844	5.0	2	10	0.43	8.71	
CB 3	78.3197	77.7832	0.5365	5.0	2	10	0.68	12.35	
CB 4	78.4263	77.9037	0.5226	5.0	2	10	0.48	9.12	
CB 5	78.1204	77.6210	0.4994	5.0	2	10	0.43	8.55	
CB 6	71.8211	71.4507	0.4704	5.0	2	10	0.46	9.71	
CB 7	72.7083	72.2379	0.4714	5.0	2	10	0.48	9.88	
MEAN			0.5145						DIED DAY 5

SAMPLE: LIVER

GROUPS: PB + DMPS (TX & NO TX)

RUN 1 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.0	4.0				4.5
0.10	13.8					13.8
0.30	61.8					61.8
0.50	93.6					93.6
0.70	136.6					136.6
1.00	149.8	149.0				149.4

RUN 2 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.0					5.0
0.1	14.6					14.6
0.3	59.3					59.3
0.5	94.2					94.2
0.7	127.8					127.8
1.00	157.0	160.8				158.9

RUN 3 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	4.8					4.8
0.1	13.4					13.4
0.3	59.8					59.8
0.5	88.2					88.2
0.7	120.4					120.4
1.00	159.0					159.0

SAMPLE: LIVER

GROUPS: PB + DMPS (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	3.5	2.1	1.3
0.05	4.5	5.0	4.8	11.7	10.5	9.5
0.10	13.8	14.6	13.4	19.9	18.9	17.7
0.30	61.8	59.3	59.8	52.8	52.5	50.7
0.50	93.8	94.2	88.2	85.6	86.1	83.6
0.70	136.6	127.8	120.4	118.5	119.6	116.6
1.00	149.4	158.9	159.0	167.8	170.0	166.0

Regression Output: RUN 1

Constant	3.4536170
Std Err of Y Est	13.508045
R Squared	0.9913230
No. of Observations	7
Degrees of Freedom	5
X Coefficient(s)	164.34893
Std Err of Coef.	14.742573

Regression Output: RUN 3

Constant	1.2805857
Std Err of Y Est	6.4257872
R Squared	0.9910123
No. of Observations	7
Degrees of Freedom	5
X Coefficient(s)	164.69276
Std Err of Coef.	7.0141023

Regression Output: RUN 2


Constant	2.1340425
Std Err of Y Est	8.4394227
R Squared	0.9851701
No. of Observations	7
Degrees of Freedom	5
X Coefficient(s)	167.67234
Std Err of Coef.	9.2109911

Regression Output: 3 STD RUNS
COMBINED

Constant	2.2894184
Std Err of Y Est	8.8867211
R Squared	0.9787404
No. of Observations	21
Degrees of Freedom	19
X Coefficient(s)	165.63801
Std Err of Coef.	5.8004898

SAMPLE: LIVER

GROUPS: PB + DMPS (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TC 1	95.6	95.2			95.4	0.56
TC 2	90.6	93.6			92.1	0.54
TC 3	97.0	99.0			98.0	0.58
TC 4	89.6	89.0			89.3	0.53
TC 5	96.0	96.8			97.4	0.57
TC 6	126.0	121.2			123.6	0.73
TC 7	106.0	107.2			107.6	0.64
TC 8	91.0	102.8			96.9	0.57
TC 9	110.8	111.0			110.9	0.66
TC 10	109.0	103.0			106.0	0.63
CC 1	90.0	92.8			91.3	0.54
CC 2	91.2	88.4			89.8	0.53
CC 3	106.0	105.6			106.8	0.63
CC 4	124.4	126.8			125.6	0.74
CC 5	120.0	119.8			119.9	0.71
CC 6	104.8	98.4			101.5	0.60
CC 7	99.4	100.0			99.7	0.59

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y -INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE ANALYZED: 2/10/93
 PATH: c:\data\lobur2.3
 a:\lobur

THALLIUM ANTIDOTE STUDY
 WET ASH DATA WORKSHEET
 TISSUE TYPE: LIVER
 PB + DMPs

DATE WET ASHED: 2/15/93
 FILE: A_C_L2

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TAPE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TI CONC ug TVg tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	
TC 1	81.5268	81.0348	0.4920	5.0	1	5	0.56	5.71	
TC 2	72.3008	71.7951	0.5147	5.0	1	5	0.54	5.27	
TC 3	78.9341	78.3964	0.5347	5.0	1	5	0.58	5.40	
TC 4	78.6052	78.1262	0.4780	5.0	1	5	0.53	5.52	
TC 5	78.8098	78.0903	0.5483	5.0	1	5	0.57	5.24	
TC 6	78.9908	78.5007	0.4901	5.0	1	5	0.73	7.47	
TC 7	78.5785	78.0308	0.5478	5.0	1	5	0.64	5.80	
TC 8	78.8097	78.3346	0.4751	5.0	1	5	0.57	5.01	
TC 9	78.2641	77.7819	0.4822	5.0	1	5	0.66	6.80	
TC 10	72.4319	71.9302	0.5017	5.0	1	5	0.63	6.24	
CC 1	78.3580	77.8643	0.4917	5.0	2	10	0.54	10.93	
CC 2	78.7411	78.2775	0.4636	5.0	2	10	0.53	11.40	
CC 3	72.7781	72.2753	0.5028	5.0	2	10	0.63	10.47	
CC 4	72.5363	72.2390	0.5663	5.0	2	10	0.74	12.41	
CC 5	78.9808	78.7149	0.5777	5.0	2	10	0.71	12.29	
CC 6	78.3542	78.0623	0.5919	5.0	2	10	0.60	10.12	
CC 7	71.9995	71.3758	0.6237	5.0	2	10	0.59	11.91	
MEAN			0.5226						DIED DAY 5 DIED DAY 4

HEART

FILE A_A_H1

THALLIUM ANTIDOTE STUDY
PEAK HEIGHT WORKSHEET

DATE 2/17/83

SAMPLE: HEART

GROUPS: PB (TX & NO TX)

RUN 1 T1 STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.0					5.0
0.10	13.2					13.2
0.30	59.8					59.8
0.50	89.0					89.0
0.70	121.8					121.8
1.00	170.4	165.4				167.9

RUN 2 T1 STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	4.6					4.6
0.1	13.3					13.3
0.3	57.7					57.7
0.5	79.8					79.8
0.7	118.0					118.0
1.00	154.0	162.0				156.0

RUN 3 T1 STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	4.7					4.7
0.1	14.7					14.7
0.3	58.6					58.6
0.5	84.8					84.8
0.7	114.8					114.8
1.00	158.2	160.0				158.1

SAMPLE: HEART

GROUPS: PB (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	0.1	0.2	1.2
0.05	5.0	4.6	4.7	8.7	8.3	9.3
0.10	13.2	13.3	14.7	17.3	18.4	17.3
0.30	59.6	57.7	56.6	51.7	48.6	49.6
0.50	86.0	79.6	84.6	86.1	81.3	81.8
0.70	121.6	118.0	114.8	120.4	113.7	114.0
1.00	167.9	158.0	156.1	172.0	162.3	162.3

Regression Output: RUN 1

Constant	0.1297446
Std Err of Y Est	4.9021295
R Squared	0.9951755
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	171.84595
Std Err of Coef.	5.3506373

Regression Output: RUN 3

Constant	1.2407659
Std Err of Y Est	5.2480535
R Squared	0.9937146
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	161.06212
Std Err of Coef.	5.7285320

Regression Output: RUN 2

Constant	0.2417872
Std Err of Y Est	5.3304622
R Squared	0.9935674
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	162.07829
Std Err of Coef.	5.8184855


Regression Output: 3 RUNS
COMBINED

Constant	0.5374328
Std Err of Y Est	5.1858617
R Squared	0.9928011
No. of Observations	21
Degrees of Freedom	19

X Coefficient(s)	164.99546
Std Err of Coef.	3.2680466

SAMPLE: HEART

GROUPS: PB (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TA 1	114.0	114.2			114.1	0.89
TA 2	107.4	112.0			109.7	0.88
TA 3	87.4	79.0			83.2	0.50
TA 4	78.0	84.4			81.2	0.49
TA 5	89.2	79.8			84.5	0.51
TA 6	112.2	105.4			108.8	0.88
TA 7	101.4	87.4			99.4	0.80
TA 8	100.8	98.8			99.7	0.89
TA 9	103.2	100.8			101.9	0.81
TA 10	103.8	100.2	104		102.6	0.82
CA 1	86.0	84.0			85.0	0.51
CA 2	114.4	110.8			112.6	0.88
CA 3	100.8	80.4			95.6	0.58
CA 4	87.8	72.0	80.4		80.0	0.48
CA 5	84.8	80.0			82.3	0.50
CA 6	127.4	125.2			126.3	0.78
CA 7	110.8	100.8			105.7	0.84

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y-INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE WET ASHED: 2/16/93
 FILE: A_A_H2
 THALLIUM ANTIDOTE STUDY
 WET ASH DATA WORKSHEET
 TISSUE TYPE: HEART
 PB
 DATE ANALYZED: 2/17/93
 PATH: c:\data\Volun2.3
 e:\Volun

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TAPE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TI CONC ug TIG tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C) A - B	(D)	(E)	(F) D x E	(G)	(H) F x G / C	
TA 1	62.4487	61.9824	0.4663	5.0	2	10	0.88	14.76	
TA 2	48.9843	48.4822	0.4821	5.0	2	10	0.88	13.72	
TA 3	65.8116	65.2908	0.5208	5.0	2	10	0.50	9.62	
TA 4	61.8129	61.2947	0.5182	5.0	2	10	0.49	9.43	
TA 5	80.5026	79.9613	0.5413	5.0	2	10	0.51	9.23	
TA 6	77.8517	77.3171	0.5346	5.0	2	10	0.88	12.27	
TA 7	79.2121	78.7236	0.4885	5.0	2	10	0.80	12.37	
TA 8	72.5254	72.0882	0.4372	5.0	2	10	0.59	12.96	
TA 9	72.1018	71.5815	0.5203	5.0	2	10	0.81	11.81	
TA 10	80.4398	79.8923	0.5475	5.0	2	10	0.82	11.92	
CA 1	79.2217	78.8684	0.3533	5.0	4	20	0.51	19.49	
CA 2	77.4592	76.9130	0.5462	5.0	4	20	0.88	24.87	
CA 3	79.4323	78.9879	0.4444	5.0	4	20	0.58	24.81	
CA 4	72.4809	71.9957	0.4852	5.0	4	20	0.48	19.85	
CA 5	78.2175	77.7187	0.4988	5.0	4	20	0.50	19.87	
CA 6	78.8401	78.3325	0.5076	5.0	4	20	0.78	30.03	
CA 7	78.9483	78.4483	0.4990	5.0	4	20	0.84	25.90	DIED DAY 4
MEAN			0.5087						

FILE A_B_H1

THALLIUM ANTIDOTE STUDY
PEAK HEIGHT WORKSHEET

DATE 2/18/93

SAMPLE: HEART

GROUPS: DMPS (TX & NO TX)

RUN 1 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.9					5.9
0.10	16.3					16.3
0.30	63.6					63.6
0.50	89.2					89.2
0.70	112.8					112.8
1.00	142.4					142.4

RUN 2 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	6.4					6.4
0.1	18.5					18.5
0.3	62.1					62.1
0.5	86.8					86.8
0.7	113.0					113.0
1.00	140.4	151.0	145.0			145.5

RUN 3 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	9.0					9.0
0.1	14.4					14.4
0.3	65.0					65.0
0.5	84.0					84.0
0.7	114.0					114.0
1.00	147.4	142.8				145.1

SAMPLE: HEART

GROUPS: DMPS (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	5.5	4.5	4.4
0.05	5.9	6.4	6.0	12.9	12.0	11.9
0.10	16.3	15.5	14.4	20.3	19.5	19.4
0.30	63.6	62.1	65.0	49.8	49.5	49.4
0.50	89.2	86.8	84.0	79.4	79.5	79.4
0.70	112.8	113.0	114.0	109.6	109.6	109.4
1.00	142.4	145.5	145.1	153.3	154.6	154.5

Regression Output: RUN 1
 Constant 5.4785106
 Std Err of Y Est 10.137846
 R Squared 0.9727599
 No. of Observations 7
 Degrees of Freedom 5

X Coefficient(s) 147.86806
 Std Err of Coef. 11.068003

Regression Output: RUN 3
 Constant 4.4153617
 Std Err of Y Est 9.5008784
 R Squared 0.9766661
 No. of Observations 7
 Degrees of Freedom 5

X Coefficient(s) 150.03489
 Std Err of Coef. 10.370716

Regression Output: RUN 2
 Constant 4.5084539
 Std Err of Y Est 8.8428676
 R Squared 0.9806249
 No. of Observations 7
 Degrees of Freedom 5


X Coefficient(s) 150.07829
 Std Err of Coef. 9.4341537

Regression Output: 3 STD RUNS
 COMBINED
 Constant 4.8007754
 Std Err of Y Est 8.4029900
 R Squared 0.9766623
 No. of Observations 21
 Degrees of Freedom 19

X Coefficient(s) 149.32709
 Std Err of Coef. 5.2966419

SAMPLE: HEART

GROUPS: DMPS (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TB 1	87.2	88.2			87.7	0.56
TB 2	84.8	81.2			82.9	0.52
TB 3	81.8	83.4			82.5	0.39
TB 4	71.2	78.8			74.0	0.46
TB 5	79.8	79.4			79.5	0.50
TB 6	81.8	82.0			81.9	0.58
TB 7	98.0	95.2			95.8	0.81
TB 8	79.2	79.0			79.1	0.50
TB 9	83.0	84.0			83.5	0.53
TB 10	82.2	82.4			82.3	0.52
CB 1	86.8	87.8			87.1	0.56
CB 2	80.4	80.0			80.2	0.50
CB 3	115.8	111.8			113.8	0.73
CB 4	78.8	78.4			78.5	0.48
CB 5	73.4	73.0			73.2	0.48
CB 6	86.8	85.4			86.1	0.54
CB 7	85.2	75.0	81.8		80.7	0.51

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y-INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE ANALYZED: 2/18/83
 PATH: c:\data\Volume2.3
 a:\Volume

THALLIUM ANTIDOTE STUDY
 WET ASH DATA WORKSHEET
 TISSUE TYPE: HEART
 CMPS

DATE WET ASHED: 2/17/83
 FILE: A_B_H2

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TARE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of calibration curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TI CONC ug TI/g tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C)	(D)	(E)	(F)	(G)	$F \times G / C$	
TB 1	79.3229	78.8051	0.5168	5.0	4	20	0.58	21.40	
TB 2	72.5101	71.8598	0.4703	5.0	4	20	0.52	22.24	
TB 3	72.1856	71.7147	0.4811	5.0	4	20	0.39	16.08	
TB 4	72.6174	72.1182	0.4992	5.0	4	20	0.46	18.57	
TB 5	78.2428	77.7101	0.5328	5.0	4	20	0.50	18.79	
TB 6	81.4878	81.0156	0.4721	5.0	4	20	0.58	24.71	
TB 7	81.8856	81.5052	0.4794	5.0	4	20	0.51	25.37	
TB 8	78.3357	77.8291	0.5046	5.0	4	20	0.50	19.72	
TB 9	78.2850	77.8089	0.4761	5.0	4	20	0.53	22.14	
TB 10	79.1022	78.5998	0.5024	5.0	4	20	0.52	20.88	
CB 1	81.2851	80.7728	0.4923	5.0	4	20	0.55	22.39	
CB 2	78.8490	78.3293	0.5197	5.0	4	20	0.50	19.41	
CB 3	53.4394	52.9453	0.4931	5.0	4	20	0.73	29.55	
CB 4	81.8912	81.1793	0.5119	5.0	4	20	0.49	19.28	
CB 5	50.5073	50.0130	0.4943	5.0	4	20	0.49	18.53	
CB 6	56.8795	56.3918	0.4877	5.0	4	20	0.54	22.53	
CB 7	61.7978	61.2955	0.5023	5.0	4	20	0.51	20.23	
MEAN			0.4904						DIED DAY 6

SAMPLE: HEART

GROUPS: PB + DMPS (TX & NO TX)

RUN 1 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	7.3					7.3
0.10	15.5					15.5
0.30	51.8	52.0				51.8
0.50	81.8					81.8
0.70	111.4					111.4
1.00	143.0					143.0

RUN 2 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	7.4					7.4
0.1	17.6					17.6
0.3	53.5					53.5
0.5	80.0					80.0
0.7	107.4					107.4
1.00	132.2					132.2

RUN 3 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	6.8					6.8
0.1	18.1					18.1
0.3	49.9					49.9
0.5	81.8					81.8
0.7	106.6					106.6
1.00	128.2					128.2

SAMPLE: HEART

GROUPS: PB + DMPs (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	2.8	5.1	5.1
0.05	7.3	7.4	6.8	10.2	11.9	11.8
0.10	15.5	17.8	18.1	17.8	18.8	18.5
0.30	51.8	53.5	49.9	47.1	48.1	45.4
0.50	81.8	80.0	81.8	76.8	73.5	72.2
0.70	111.4	107.4	106.6	108.1	100.9	99.1
1.00	143.0	132.2	128.2	150.4	141.9	139.3

Regression Output: RUN 1
 Constant 2.8388574
 Std Err of Y Est 5.5198895
 R Squared 0.9817298
 No. of Observations 7
 Degrees of Freedom 5

X Coefficient(s) 147.52785
 Std Err of Coef. 6.0248389

Regression Output: RUN 3
 Constant 5.0942127
 Std Err of Y Est 8.2998330
 R Squared 0.9777349
 No. of Observations 7
 Degrees of Freedom 5

X Coefficient(s) 134.24170
 Std Err of Coef. 9.0594946

Regression Output: RUN 2
 Constant 5.0894285
 Std Err of Y Est 7.8005841
 R Squared 0.9824189
 No. of Observations 7
 Degrees of Freedom 5


X Coefficient(s) 136.84340
 Std Err of Coef. 8.1872572

Regression Output: 3 STD RUNS
 COMBINED
 Constant 4.3321885
 Std Err of Y Est 6.8402584
 R Squared 0.9821893
 No. of Observations 21
 Degrees of Freedom 18

X Coefficient(s) 139.53758
 Std Err of Coef. 4.3107897

SAMPLE: HEART

GROUPS: PB + DMP3 (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TC 1	68.4	78.0	75.0		73.8	0.50
TC 2	80.0	84.8			82.4	0.56
TC 3	88.8	111.4	95.8		102.0	0.70
TC 4	74.8	80.2	86.2		77.1	0.52
TC 5	68.8	78.8			71.8	0.48
TC 6	78.4	78.8			78.5	0.52
TC 7	88.2	82.8			80.4	0.40
TC 8	78.0	84.2	82.8		86.3	0.46
TC 9	63.4	62.2			62.8	0.42
TC 10	75.0	81.0	82.8		86.2	0.44
CC 1	80.2	80.4			80.3	0.54
CC 2	84.0	83.8			83.9	0.57
CC 3	71.0	68.0			69.5	0.47
CC 4	106.8	101.8			104.2	0.72
CC 5	84.4	80.4			88.9	0.50
CC 6	83.2	85.8			84.5	0.57
CC 7	78.4	80.2			79.3	0.54

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE WET ASHED: 2/19/83

FILE: A_C_M2

THALLIUM ANTIDOTE STUDY
WET ASH DATA WORKSHEETTISSUE TYPE: HEART
PB + DMPS

DATE ANALYZED: 2/22/83

PATH: c:\data\lotus2.3
e:\lotus

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TAPE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBQ)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TI CONC ug TI/g tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C) A - B	(D)	(E)	(F) D x E	(G)	(H) F x G / C	
TC 1	83.2378	82.7453	0.4925	5.0	2	10	0.50	10.11	
TC 2	57.0579	56.5948	0.4631	5.0	2	10	0.59	11.35	
TC 3	60.8288	60.4108	0.5180	5.0	2	10	0.70	13.51	
TC 4	46.5108	46.0236	0.4872	5.0	2	10	0.52	10.70	
TC 5	81.8456	81.3347	0.5111	5.0	2	10	0.48	9.46	
TC 6	80.6417	80.1371	0.5046	5.0	2	10	0.52	10.25	
TC 7	83.0422	82.5253	0.5169	5.0	2	10	0.40	7.77	
TC 8	56.9941	56.4833	0.5108	5.0	2	10	0.46	8.64	
TC 9	60.5694	60.0878	0.4786	5.0	2	10	0.42	8.75	
TC 10	60.6006	60.1264	0.4744	5.0	2	10	0.44	8.35	
CC 1	48.0113	48.5264	0.4648	5.0	4	20	0.54	22.49	
CC 2	60.3088	59.7828	0.5273	5.0	4	20	0.57	21.63	
CC 3	62.4948	61.9943	0.5103	5.0	4	20	0.47	18.30	
CC 4	51.0541	50.5611	0.4930	5.0	4	20	0.72	28.03	
CC 5	30.6548	30.1474	0.5074	5.0	4	20	0.58	23.32	
CC 6	30.8219	30.4167	0.5052	5.0	4	20	0.57	22.74	
CC 7	30.9436	30.4502	0.4934	5.0	4	20	0.54	21.78	
MEAN			0.5017						DIED DAY 5 DIED DAY 4

BRAIN

SAMPLE: BRAIN

GROUPS: PB (TX & NO TX)

RUN 1 T1STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	6.8					6.8
0.10	17.2					17.2
0.30	50.8					50.8
0.50	80.0					80.0
0.70	104.4					104.4
1.00	131.8					131.8

RUN 2 T1STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	7.2					7.2
0.1	18.0					18.0
0.3	48.7					48.7
0.5	79.4					79.4
0.7	105.2					105.2
1.00	136.2					136.2

RUN 3 T1STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	6.4					6.4
0.1	17.0					17.0
0.3	48.8					48.8
0.5	77.6					77.6
0.7	108.2					108.2
1.00	137.0					137.0

SAMPLE: BRAIN

GROUPS: PB (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	4.4	3.7	2.9
0.05	6.8	7.2	8.4	11.2	10.6	10.0
0.10	17.2	18.0	17.0	18.0	17.6	17.0
0.30	50.8	48.7	48.8	45.2	45.4	45.3
0.50	80.0	79.4	77.6	72.3	73.3	73.6
0.70	104.4	105.2	108.2	99.8	101.2	101.9
1.00	131.6	136.2	137.0	140.3	142.9	144.3

Regression Output: RUN 1

Constant	4.3918297
Std Err of Y Est	6.7664332
R Squared	0.9854400
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	135.87063
Std Err of Coef.	7.3859249

Regression Output: RUN 3

Constant	2.9034042
Std Err of Y Est	5.3385231
R Squared	0.9915781
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	141.38723
Std Err of Coef.	5.8272844

Regression Output: RUN 2

Constant	3.6918297
Std Err of Y Est	5.1938828
R Squared	0.9917824
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	139.27063
Std Err of Coef.	5.6994018
Std Err of Coef.	5.6994018


Regression Output: 3 STD RUNS
COMBINED

Constant	3.6523546
Std Err of Y Est	5.2385794
R Squared	0.9993825
No. of Observations	21
Degrees of Freedom	19

X Coefficient(s)	138.84283
Std Err of Coef.	3.2996672
Std Err of Coef.	3.2996672

SAMPLE: BRAIN

GROUPS: PB (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TA 1	48.2	46.4			46.3	0.31
TA 2	40.0	44.2			42.1	0.28
TA 3	68.0	69.4			68.7	0.47
TA 4	40.0	40.4			40.2	0.28
TA 5	49.8	50.0			49.8	0.33
TA 6	50.2	51.4			50.8	0.34
TA 7	41.4	41.8			41.6	0.27
TA 8	31.2	37.4			34.3	0.22
TA 9	45.0	43.8			44.4	0.29
TA 10	42.8	47.0			44.8	0.30
CA 1	78.8	77.2			77.9	0.53
CA 2	71.0	71.8			71.3	0.48
CA 3	85.8	79.8			82.8	0.57
CA 4	51.8	51.8			51.8	0.36
CA 5	54.2	54.4			54.3	0.38
CA 6	83.2	82.8			82.9	0.64
CA 7	71.4	71.8			71.6	0.48

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE WET ASHED: 2/22/83
 FILE: A.A_BFR
 THALLIUM ANTIDOTE STUDY
 WET ASH DATA WORKSHEET
 TISSUE TYPE: BRAIN
 PG
 DATE ANALYZED: 2/23/83
 PATH: c:\data\Volume2.3
 a:\data

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TAPE WT (g)	NET WT SAMPLE (g)	DILUTION F23TOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TICONG ug TIVg tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C) A-B	(D)	(E)	(F) D x E	(G)	(H) F x G / C	
TA 1	30.4359	29.9425	0.4934	5.0	1	5	0.31	3.1	
TA 2	30.6307	30.3872	0.2435	5.0	1	5	0.28	2.7	
TA 3	31.0311	30.5108	0.5203	5.0	1	5	0.47	4.5	
TA 4	30.5222	30.0157	0.5065	5.0	1	5	0.26	2.6	
TA 5	30.8488	30.1562	0.6926	5.0	1	5	0.33	3.4	
TA 6	30.7783	30.2668	0.5115	5.0	1	5	0.34	3.3	
TA 7	30.6368	30.4275	0.2093	5.0	1	5	0.27	2.7	
TA 8	30.7869	30.3060	0.4809	5.0	1	5	0.22	2.2	
TA 9	30.7302	30.2187	0.5115	5.0	1	5	0.28	2.8	
TA 10	30.9457	30.4585	0.4872	5.0	1	5	0.30	2.9	
CA 1	31.4082	30.9122	0.4960	5.0	2	10	0.53	10.8	
CA 2	30.8514	30.4753	0.3761	5.0	2	10	0.48	10.2	
CA 3	25.7881	25.3078	0.4803	5.0	2	10	0.57	11.9	
CA 4	28.1204	28.0413	0.0791	5.0	2	10	0.36	7.2	
CA 5	28.4511	28.9478	0.5052	5.0	2	10	0.36	7.2	
CA 6	30.8212	30.4221	0.4991	5.0	2	10	0.64	12.9	
CA 7	30.8289	30.1270	0.7019	5.0	2	10	0.48	9.8	DIED DAY 4
MEAN			0.4889						

SAMPLE: BRAIN

GROUPS: DMPS (TX & NO TX)

RUN 1 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	8.0					8.0
0.10	22.2					22.2
0.30	70.2					70.2
0.50	105.2					105.2
0.70	129.2					129.2
1.00	169.8	169.0				167.4

RUN 2 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	8.2					8.2
0.1	23.2					23.2
0.3	67.8					67.8
0.5	92.8					92.8
0.7	127.0					127.0
1.00	167.8	168.8				168.1

RUN 3 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	9.2					9.2
0.1	22.4					22.4
0.3	59.2					59.2
0.5	94.8					94.8
0.7	130.2					130.2
1.00	169.8	172.0				170.8

SAMPLE: BRAIN

GROUPS: DMPS (TX & NO TX)

TI STDs	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	8.9	8.8	9.8
0.05	8.0	8.2	9.2	14.4	13.9	12.5
0.10	22.2	23.2	22.4	23.0	22.4	21.2
0.30	70.2	67.6	59.2	57.0	56.2	55.9
0.50	96.5	92.8	84.8	91.0	90.1	90.8
0.70	129.2	127.0	130.2	125.1	123.6	125.3
1.00	167.4	168.1	170.8	176.1	174.7	177.3

Regression Output: RUN 1

Constant	5.9346867
Std Err of Y Est	8.5434784
R Squared	0.9852053
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	170.17276
Std Err of Coef.	9.256628

Regression Output: RUN 3

Constant	3.8451814
Std Err of Y Est	4.9540449
R Squared	0.9851825
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	173.40553
Std Err of Coef.	5.4085881

Regression Output: RUN 2

Constant	5.4507859
Std Err of Y Est	7.0964404
R Squared	0.9896367
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	169.26212
Std Err of Coef.	7.7461453


Regression Output: 3 STD RUNS
COMBINED

Constant	5.3918595
Std Err of Y Est	7.0182780
R Squared	0.9879109
No. of Observations	21
Degrees of Freedom	19

X Coefficient(s)	171.43480
Std Err of Coef.	4.4229786

SAMPLE: BRAIN

GROUPS: DMPS (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TB 1	94.0	87.8			90.9	0.50
TB 2	105.6	106.0			105.3	0.58
TB 3	82.4	82.8			82.5	0.45
TB 4	86.6	87.0			86.3	0.48
TB 5	100.0	98.8			99.4	0.55
TB 6	84.8	85.2			85.0	0.35
TB 7	84.8	88.2			86.4	0.47
TB 8	86.0	85.0			80.5	0.32
TB 9	77.8	76.2			77.0	0.42
TB 10	79.4	78.0			78.7	0.43
CB 1	87.8	78.8			83.2	0.46
CB 2	87.8	74.8			81.2	0.44
CB 3	115.2	117.8			116.5	0.85
CB 4	99.4	89.4			82.9	0.51
CB 5	70.8	86.0			69.3	0.37
CB 6	85.8	87.4			86.8	0.53
CB 7	84.0	74.8			79.4	0.43

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE WET ASHED: 2/23/83

FILE: A_9_BR2

THALLIUM ANTIDOTE STUDY
WET ASH DATA WORKSHEETTISSUE TYPE: BRAIN
DMPS

DATE ANALYZED: 2/24/83

PATH: c:\data\volue2.3
a:\volue

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TARE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TI CONC ug Tl/g tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	
TS 1	30.8823	30.3562	0.5261	5.0	2	10	0.50	5.04	
TS 2	31.0075	30.5262	0.4813	5.0	2	10	0.58	12.11	
TS 3	30.1049	29.5919	0.5130	5.0	2	10	0.45	8.77	
TS 4	30.2180	29.7154	0.5026	5.0	2	10	0.48	9.53	
TS 5	30.3247	29.8139	0.5108	5.0	2	10	0.55	10.74	
TS 6	30.8671	30.4166	0.4705	5.0	2	10	0.35	7.39	
TS 7	30.2166	29.7364	0.4814	5.0	2	10	0.47	9.82	
TS 8	30.8106	30.3369	0.4717	5.0	2	10	0.32	8.89	
TS 9	30.8349	30.3345	0.5004	5.0	2	10	0.42	8.36	
TS 10	30.4620	29.9702	0.5118	5.0	2	10	0.43	8.36	
CS 1	31.4223	30.9462	0.4761	5.0	2	10	0.45	9.54	
CS 2	30.5968	30.1246	0.4722	5.0	2	10	0.44	9.37	
CS 3	29.7782	29.2981	0.4801	5.0	2	10	0.85	13.46	DIED DAY 5
CS 4	30.5466	30.0426	0.5063	5.0	2	10	0.51	10.08	
CS 5	30.3094	29.8592	0.4702	5.0	2	10	0.37	7.93	
CS 6	30.3547	29.8439	0.5111	5.0	2	10	0.53	10.41	
CS 7	30.8286	30.1473	0.6823	5.0	2	10	0.43	8.95	
MEAN			0.4922						

SAMPLE: BRAIN

GROUPS: PB + DMPS (TX & NO TX)

RUN 1 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	7.8					7.8
0.10	22.8					22.8
0.30	85.8					85.8
0.80	91.8					91.8
0.70	128.2					128.2
1.00	185.4					185.4

RUN 2 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	7.8					7.8
0.1	24.2					24.2
0.3	84.4					84.4
0.5	92.8					92.8
0.7	128.2					128.2
1.00	186.8	181.8				184.2

RUN 3 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	8.8					8.8
0.1	22.8					22.8
0.3	84.8					84.8
0.8	88.0					88.0
0.7	124.0					124.0
1.00	183.8	183.2				183.4

SAMPLE: BRAIN

GROUPS: PB + DMP8 (TX & NO TX)

TI STDs	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	6.9	6.9	6.9
0.05	7.8	7.8	8.8	14.5	14.8	14.4
0.10	22.6	24.2	22.8	22.5	22.8	22.2
0.30	65.8	64.4	64.8	54.5	54.5	53.6
0.50	91.8	82.8	88.0	86.5	86.3	85.0
0.70	126.2	126.2	124.0	118.5	118.1	116.3
1.00	155.4	154.2	153.4	166.4	165.8	163.4

Regression Output: RUN 1

Constant 8.5114893
Std Err of Y Est 9.2015724
R Squared 0.9806610
No. of Observations 7
Degrees of Freedom 5

X Coefficient(s) 158.93181
Std Err of Coef. 10.044009

Regression Output: RUN 3

Constant 6.5510538
Std Err of Y Est 8.5189590
R Squared 0.9827167
No. of Observations 7
Degrees of Freedom 5

X Coefficient(s) 158.80851
Std Err of Coef. 9.2989923

Regression Output: RUN 2

Constant 6.8862978
Std Err of Y Est 9.3537007
R Squared 0.9797658
No. of Observations 7
Degrees of Freedom 5

X Coefficient(s) 158.86638
Std Err of Coef. 10.210068


Regression Output: 3 STD RUNS
COMBINED

Constant 6.8496170
Std Err of Y Est 8.0667847
R Squared 0.9806742
No. of Observations 21
Degrees of Freedom 19

X Coefficient(s) 158.53880
Std Err of Coef. 5.0787043

SAMPLE: BRAIN

GROUPS: PB + DMPS (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TC 1	51.2	51.8			51.4	0.28
TC 2	53.4	48.2			50.8	0.28
TC 3	45.0	44.8			44.8	0.24
TC 4	68.2	66.4			67.3	0.38
TC 5	68.0	78.0			73.0	0.42
TC 6	66.2	66.4			66.3	0.38
TC 7	61.4	61.2			61.3	0.34
TC 8	43.4	45.4			44.4	0.24
TC 9	57.8	54.2			56.0	0.31
TC 10	43.6	44.4			44.0	0.24
CC 1	87.2	87.4			87.3	0.51
CC 2	75.2	79.2			77.2	0.45
CC 3	80.8	81.8			81.2	0.47
CC 4	114.8	113.0			113.9	0.68
CC 5	119.4	118.8			119.1	0.71
CC 6	66.8	66.0			66.4	0.38
CC 7	70.2	70.0			70.1	0.40

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y-INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE WET ASHED: 2/24/83
 FILE: A_C_8P2
 DATE ANALYZED: 2/25/83
 PATH: c:\data\vol2.3
 a:\lotus

THALLIUM ANTIDOTE STUDY
 WET ASH DATA WORKSHEET
 TISSUE TYPE: BRAIN
 PB + DMPS

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TAPE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TICONG ug TIVg tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C) A - B	(D)	(E)	(F) D x E	(G)	F x G / C	
TC 1	59.4534	59.9563	0.4971	5.0	1	5	0.28	2.84	
TC 2	60.3807	59.8784	0.5023	5.0	1	5	0.28	2.77	
TC 3	62.5953	62.0759	0.5104	5.0	1	5	0.24	2.36	
TC 4	60.2441	59.7559	0.4882	5.0	1	5	0.38	3.82	
TC 5	62.1248	61.6232	0.5016	5.0	1	5	0.42	4.17	
TC 6	60.9009	60.4459	0.4550	5.0	1	5	0.38	3.86	
TC 7	56.4926	57.9643	0.4693	5.0	1	5	0.34	3.46	
TC 8	58.7482	58.2459	0.5026	5.0	1	5	0.24	2.37	
TC 9	63.1529	62.6529	0.5003	5.0	1	5	0.31	3.11	
TC 10	62.4603	61.9618	0.4985	5.0	1	5	0.24	2.38	
CC 1	62.1171	61.6241	0.4930	5.0	2	10	0.51	10.32	
CC 2	62.9526	62.4492	0.5034	5.0	2	10	0.45	8.84	
CC 3	61.4210	60.9108	0.5102	5.0	2	10	0.47	9.22	
CC 4	62.4088	61.9112	0.4966	5.0	2	10	0.66	13.57	DIED DAY 5
CC 5	48.3065	48.8104	0.4981	5.0	2	10	0.71	14.24	DIED DAY 4
CC 6	48.7932	49.3022	0.4910	5.0	2	10	0.38	7.80	
CC 7	62.7688	62.2719	0.4967	5.0	2	10	0.40	8.08	
MEAN			0.4965						

BLOOD

FILE A_A_BL1

THALLIUM ANTIDOTE STUDY
PEAK HEIGHT WORKSHEET

DATE 2/28/93

SAMPLE: BLOOD

GROUPS: PB (TX & NO TX)

RUN 1 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	3.2					3.2
0.10	13.2					13.2
0.30	46.8					46.8
0.50	76.6					76.6
0.70	102.6					102.6
1.00	130.6	130.6				130.7

RUN 2 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.4					5.4
0.1	13.4					13.4
0.3	46.0					46.0
0.5	75.4					75.4
0.7	104.8					104.8
1.00	139.2	135.2				137.2

RUN 3 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	3.8					3.8
0.1	12.0					12.0
0.3	43.8					43.8
0.5	75.4					75.4
0.7	105.2					105.2
1.00	139.0	141.0				140.0

SAMPLE: BLOOD

GROUPS: PB (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	1.4	0.9	-0.7
0.05	3.2	5.4	3.8	8.2	8.0	6.8
0.10	13.2	13.4	12.0	15.1	15.1	13.8
0.30	48.8	48.0	43.8	42.5	43.5	42.9
0.50	76.8	75.4	75.4	70.0	71.8	72.0
0.70	102.8	104.8	105.2	97.4	100.2	101.0
1.00	130.7	137.2	140.0	138.5	142.7	144.6

Regression Output: RUN 1

Constant	1.3848065
Std Err of Y Est	0.0300848
R Squared	0.9886122
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	137.13448
Std Err of Coef.	6.5821390

Regression Output: RUN 3

Constant	-0.887148
Std Err of Y Est	3.5478622
R Squared	0.9884803
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	145.28880
Std Err of Coef.	3.8724854

Regression Output: RUN 2

Constant	0.9324255
Std Err of Y Est	4.0405485
R Squared	0.9951838
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	141.76340
Std Err of Coef.	4.4104784


Regression Output: 3 STD RUNS
COMBINED

Constant	0.5439617
Std Err of Y Est	4.3588803
R Squared	0.9828802
No. of Observations	21
Degrees of Freedom	19

X Coefficient(s)	141.38480
Std Err of Coef.	2.7468786

SAMPLE: BLOOD

GROUPS: PB (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TA 1	77.0	77.8			77.3	0.54
TA 2	72.4	65.8			69.0	0.48
TA 3	48.8	45.2			46.9	0.33
TA 4	48.2	51.0			49.6	0.35
TA 5	84.0	82.8			83.4	0.66
TA 6	76.0	76.0			76.0	0.53
TA 7	70.4	73.2			71.8	0.50
TA 8	75.4	73.4			74.4	0.52
TA 9	84.0	87.2			80.6	0.42
TA 10	49.2	49.0			49.1	0.34
CA 1	45.0	45.2			45.1	0.32
CA 2	67.6	68.8			68.2	0.48
CA 3	45.2	45.8			45.4	0.32
CA 4	43.0	44.8			43.9	0.31
CA 5	40.2	37.8			39.0	0.27
CA 6	76.0	74.2			75.1	0.53
CA 7	80.0	47.4			48.7	0.34

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

FILE: A_A_BL2

THALLIUM ANTIDOTE STUDY
TI ANALYSIS WORKSHEET

DATE ANALYZED: 2/28/93

SAMPLE: BLOOD
PB

SAMPLE	VOLUME BLOOD USED (ml)	VOLUME MIBK USED (ml)	INITIAL CONC FACTOR	DILUTION FACTOR	NET CONC FACTOR	TI CONC SAMPLE ANALYZED (ug/ml)	BLOOD TI CONC (ug/ml)	COMMENTS
FORMULA	(A)	(B)	(D) A / B	(E)	(F) D / E	(G)	(H) G / F	
TA 1	4.0	2.0	2	1	2	0.54	0.27	
TA 2	4.0	2.0	2	1	2	0.48	0.24	
TA 3	4.0	2.0	2	1	2	0.33	0.16	
TA 4	4.0	2.0	2	1	2	0.35	0.17	
TA 5	4.0	2.0	2	1	2	0.66	0.33	
TA 6	4.0	2.0	2	1	2	0.53	0.27	
TA 7	4.0	2.0	2	1	2	0.50	0.25	
TA 8	4.0	2.0	2	1	2	0.52	0.26	
TA 9	4.0	2.0	2	1	2	0.42	0.21	
TA 10	4.0	2.0	2	1	2	0.34	0.17	
CA 1	4.0	2.0	2	8	0.25	0.32	1.26	
CA 2	4.0	2.0	2	8	0.25	0.48	1.91	
CA 3	4.0	2.0	2	8	0.25	0.32	1.27	
CA 4	4.0	2.0	2	8	0.25	0.31	1.23	
CA 5	4.0	2.0	2	8	0.25	0.27	1.09	
CA 6	4.0	2.0	2	8	0.25	0.53	2.11	
CA 7	4.0	2.0	2	8	0.25	0.34	1.36	DIED DAY 4

Column (D): TI content in 4 ml whole blood extracted into 2 ml MIBK.
Column (E): Dilution required to put sample in linear range of calibration curve (if necessary).

SAMPLE: BLOOD

GROUPS: DMPS (TX & NO TX)

RUN 1 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	11.2	12.2				11.7
0.10	24.6					24.6
0.30	66.0					66.0
0.50	79.4					79.4
0.70	116.6	120.6				120.1
1.00	140.8	150.0				145.4

RUN 2 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	13.8					13.8
0.1	24.0					24.0
0.3	55.2					55.2
0.5	86.4					86.4
0.7	116.8					116.8
1.00	143.0	143.8				143.4

RUN 3 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	10.2					10.2
0.1	23.0					23.0
0.3	53.8					53.8
0.5	91.0					91.0
0.7	115.2					115.2
1.00	142.8	140.8				141.8

SAMPLE: BLOOD

GROUPS: DMPS (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	8.5	8.2	7.0
0.05	11.7	13.8	10.2	15.8	15.5	14.3
0.10	24.8	24.0	23.0	23.2	22.8	21.8
0.30	66.0	55.2	53.8	52.4	51.8	50.7
0.50	79.4	89.4	91.0	81.8	80.9	79.8
0.70	120.1	116.8	115.2	110.9	109.9	108.9
1.00	145.4	143.4	141.8	154.7	153.5	152.6

Regression Output: RUN 1
 Constant 8.5321276
 Std Err of Y Est 9.5336146
 R Squared 0.9752968
 No. of Observations 7
 Degrees of Freedom 5

X Coefficient(s) 146.21702
 Std Err of Coef. 10.408451

Regression Output: RUN 3
 Constant 7.0177021
 Std Err of Y Est 8.4731220
 R Squared 0.9802271
 No. of Observations 7
 Degrees of Freedom 5

X Coefficient(s) 145.81381
 Std Err of Coef. 9.2488672

Regression Output: RUN 2
 Constant 8.2194042
 Std Err of Y Est 7.6206251
 R Squared 0.9830343
 No. of Observations 7
 Degrees of Freedom 5


X Coefficient(s) 145.30723
 Std Err of Coef. 8.5388663

Regression Output: 3 STD RUNS
 COMBINED
 Constant 7.9230780
 Std Err of Y Est 7.7134802
 R Squared 0.9762918
 No. of Observations 21
 Degrees of Freedom 18

X Coefficient(s) 145.71282
 Std Err of Coef. 4.8611030

SAMPLE: BLOOD

GROUPS: DMPS (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TB 1	58.2	61.8			60.0	0.36
TB 2	60.6	61.4			61.0	0.36
TB 3	62.4	63.8			63.1	0.38
TB 4	60.0	60.2			60.6	0.56
TB 5	62.6	61.6			62.2	0.51
TB 6	54.0	48.8			51.4	0.30
TB 7	51.2	46.8			49.0	0.28
TB 8	54.0	58.6			56.3	0.33
TB 9	57.2	58.2			57.7	0.34
TB 10	58.4	56.2			58.8	0.36
CB 1	82.0	80.2			81.1	0.50
CB 2	137.4	130.0			133.7	0.86
CB 3	140.0	140.6			140.3	0.91
CB 4	96.8	71.8			89.3	0.42
CB 5	111.8	111.6			111.7	0.71
CB 6	141.4	145.2			143.3	0.93
CB 7	136.2	140.2			138.2	0.89

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

FILE: A_B_BL2

THALLIUM ANTIDOTE STUDY
TI ANALYSIS WORKSHEET

DATE ANALYZED: 2/27/93

SAMPLE: BLOOD
DMPS

SAMPLE	VOLUME BLOOD USED (ml)	VOLUME MIBK USED (ml)	INITIAL CONC FACTOR	DILUTION FACTOR	NET CONC FACTOR	TI CONC SAMPLE ANALYZED (ug/ml)	BLOOD TI CONC (ug/ml)	COMMENTS
FORMULA	(A)	(B)	(D)	(E)	(F)	(G)	(H) G / F	
TB 1	7.5	1.5	5	-	5	0.36	0.071	
TB 2	7.5	1.5	5	-	5	0.36	0.073	
TB 3	7.5	1.5	5	-	5	0.38	0.076	
TB 4	7.5	1.5	5	-	5	0.56	0.112	
TB 5	7.5	1.5	5	-	5	0.51	0.102	
TB 6	7.5	1.5	5	-	5	0.30	0.060	
TB 7	7.5	1.5	5	-	5	0.28	0.056	
TB 8	7.5	1.5	5	-	5	0.33	0.066	
TB 9	7.5	1.5	5	-	5	0.34	0.068	
TB 10	7.5	1.5	5	-	5	0.35	0.070	
CB 1	2.0	4.0	-	2	0.50	0.50	1.00	
CB 2	2.0	4.0	-	2	0.50	0.86	1.73	
CB 3	2.0	4.0	-	2	0.50	0.91	1.82	
CB 4	2.0	4.0	-	2	0.50	0.42	0.84	
CB 5	2.0	4.0	-	2	0.50	0.71	1.42	
CB 6	2.0	4.0	-	2	0.50	0.93	1.86	
CB 7	2.0	4.0	-	2	0.50	0.89	1.79	DIED DAY 4

Column (D): TI content in 7.5 ml whole blood extracted into 1.5 ml MIBK. Applicable to TB group only.

Column (E): Dilution required to put sample in linear range of calibration curve (if necessary). Applicable to CB group only.

SAMPLE: BLOOD

GROUPS: PS + DMPS (TX & NO TX)

RUN 1 T1STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	10.0					10.0
0.10	20.0					20.0
0.30	54.4					54.4
0.50	85.2					85.2
0.70	115.8					115.8
1.00	144.8	141.8				143.2

RUN 2 T1STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	9.0					9.0
0.1	22.6					22.6
0.3	49.8					49.8
0.5	89.8					89.8
0.7	119.0					119.0
1.00	149.4	147.2				148.3

RUN 3 T1STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	9.8					9.8
0.1	18.4					18.4
0.3	49.6					49.6
0.5	81.2					81.2
0.7	123.6					123.6
1.00	138.4	143.4				140.9

SAMPLE: BLOOD

GROUPS: PB + DMPS (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	8.8	3.1	4.2
0.05	10.0	9.0	9.8	12.9	10.5	11.8
0.10	20.0	22.5	18.4	20.3	18.0	19.0
0.30	84.4	49.8	49.8	49.7	48.0	48.8
0.50	85.2	89.8	81.2	70.1	77.9	78.8
0.70	115.8	119.0	123.8	108.5	107.9	108.3
1.00	143.2	148.3	140.9	182.8	182.8	183.0

Regression Output: RUN 1

Constant	5.5863404
Std Err of Y Est	6.9440102
R Squared	0.9888910
No. of Observations	7
Degrees of Freedom	5
X Coefficient(s)	147.05872
Std Err of Coef.	7.5787587

Regression Output: RUN 3

Constant	4.1586723
Std Err of Y Est	9.0275782
R Squared	0.9785461
No. of Observations	7
Degrees of Freedom	5
X Coefficient(s)	148.82297
Std Err of Coef.	9.8540859

Regression Output: RUN 2


Constant	3.0513181
Std Err of Y Est	7.0804102
R Squared	0.9888322
No. of Observations	7
Degrees of Freedom	5
X Coefficient(s)	149.78255
Std Err of Coef.	7.7068185

Regression Output: 3 STD RUNS
COMBINED

Constant	4.2591773
Std Err of Y Est	8.9151637
R Squared	0.9839102
No. of Observations	21
Degrees of Freedom	19
X Coefficient(s)	148.54808
Std Err of Coef.	4.3579870

SAMPLE: BLOOD

GROUPS: PB + DMPs (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE Tl CONC (ppm)
TC 1	23.8	34.0			28.8	0.17
TC 2	42.8	48.8			44.1	0.27
TC 3	52.2	53.2			52.7	0.33
TC 4	48.2	44.8			46.4	0.28
TC 5	48.0	48.8			48.4	0.30
TC 6	27.8	40.2			33.9	0.20
TC 7	31.8	38.0			34.8	0.21
TC 8	34.2	29.8			31.9	0.18
TC 9	28.8	27.8			28.2	0.18
TC 10	48.2	48.0			48.6	0.28
CC 1	131.8	129.8			130.7	0.85
CC 2	71.2	80.0			75.6	0.48
CC 3	80.0	85.8			82.8	0.53
CC 4	130.0	132.0			131.0	0.85
CC 5	138.4	140.4			139.9	0.91
CC 6	118.0	114.8			116.4	0.75
CC 7	108.8	101.4			105.1	0.88

$$Tl\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

FILE: A_C_BL2

THALLIUM ANTIDOTE STUDY
TI ANALYSIS WORKSHEET

DATE ANALYZED: 2/28/93

SAMPLE: BLOOD
PB + DMPS

SAMPLE	VOLUME BLOOD USED (ml)	VOLUME MIBK USED (ml)	INITIAL CONC FACTOR	DILUTION FACTOR	NET CONC FACTOR	TI CONC SAMPLE ANALYZED (ug/ml)	BLOOD TI CONC (ug/ml)	COMMENTS
FORMULA	(A)	(B)	(D)	(E)	(F)	(G)	(H)	
TC 1	7.5	1.5	5	-	5	0.17	0.039	
TC 2	7.5	1.5	5	-	5	0.27	0.054	
TC 3	7.5	1.5	5	-	5	0.33	0.065	
TC 4	7.5	1.5	5	-	5	0.28	0.057	
TC 5	7.5	1.5	5	-	5	0.30	0.059	
TC 6	7.5	1.5	5	-	5	0.20	0.040	
TC 7	7.5	1.5	5	-	5	0.21	0.041	
TC 8	7.5	1.5	5	-	5	0.19	0.037	
TC 9	7.5	1.5	5	-	5	0.16	0.032	
TC 10	7.5	1.5	5	-	5	0.28	0.056	
CC 1	2.0	4.0	-	2	0.50	0.65	1.70	
CC 2	2.0	4.0	-	2	0.50	0.48	0.96	
CC 3	2.0	4.0	-	2	0.50	0.53	1.06	
CC 4	2.0	4.0	-	2	0.50	0.85	1.71	
CC 5	2.0	4.0	-	2	0.50	0.91	1.63	
CC 6	2.0	4.0	-	2	0.50	0.75	1.51	
CC 7	2.0	4.0	-	2	0.50	0.68	1.36	DIED DAY 4

Column (D): TI content in 7.5 ml whole blood extracted into 1.5 ml MIBK. Applicable to TC group only.

Column (E): Dilution required to put sample in linear range of calibration curve (if necessary). Applicable to CC group only.

FECES

FILE A_A_F1

THALLIUM ANTIDOTE STUDY
PEAK HEIGHT WORKSHEET

DATE 3/1/83

SAMPLE: FECES

GROUPS: PB (TX & NO TX)

RUN 1 T1STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	7.0					7.0
0.10	18.8					18.8
0.30	58.8					58.8
0.50	88.0					88.0
0.70	108.6					108.6
1.00	148.4	148.2				148.3

RUN 2 T1STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	7.8					7.8
0.1	20.0					20.0
0.3	59.2					59.2
0.5	88.2					88.2
0.7	110.6					110.6
1.00	148.8	154.6				151.7

RUN 3 T1STDs (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	7.8					7.8
0.1	19.8					19.8
0.3	58.8					58.8
0.5	84.8					84.8
0.7	111.0					111.0
1.00	156.2	150.2				153.2

SAMPLE: FECES

GROUPS: PB (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	4.7	4.9	3.8
0.05	7.0	7.8	7.9	12.2	12.5	11.5
0.10	18.8	20.0	19.8	19.7	20.1	19.1
0.30	58.8	59.2	58.8	49.8	50.5	49.8
0.50	89.0	88.2	84.8	79.9	81.0	80.5
0.70	108.8	110.8	111.0	110.0	111.4	111.2
1.00	149.3	151.7	153.2	155.2	157.1	157.2

Regression Output: RUN 1

Constant	4.8570638
Std Err of Y Est	7.0597834
R Squared	0.9870654
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	150.52851
Std Err of Coef.	7.7061323

Regression Output: RUN 3

Constant	3.7868810
Std Err of Y Est	4.8976727
R Squared	0.9944418
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	153.30680
Std Err of Coef.	5.1277618

Regression Output: RUN 2

Constant	4.8788510
Std Err of Y Est	6.3646233
R Squared	0.9898905
No. of Observations	7
Degrees of Freedom	5

X Coefficient(s)	152.20680
Std Err of Coef.	6.9478552


Regression Output: 3 STD RUNS
COMBINED

Constant	4.4442553
Std Err of Y Est	5.4690926
R Squared	0.9903294
No. of Observations	21
Degrees of Freedom	19

X Coefficient(s)	152.03404
Std Err of Coef.	3.4486702

SAMPLE: FECES

GROUPS: PB (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TA 1	78.2	78.0			78.1	0.48
TA 2	68.4	69.4			68.9	0.42
TA 3	69.0	70.0			69.5	0.43
TA 4	49.4	50.2			49.8	0.30
TA 5	57.8	58.6			58.7	0.36
TA 6	57.2	59.8			58.4	0.35
TA 7	69.8	66.0			67.9	0.55
TA 8	57.2	60.4			58.8	0.36
TA 9	59.8	60.0			59.9	0.36
TA 10	59.4	57.8			58.6	0.36
CA 1	61.2	60.0			60.6	0.37
CA 2	48.2	43.8			46.0	0.27
CA 3	60.8	61.2			61.0	0.37
CA 4	62.6	62.0			62.3	0.38
CA 5	59.8	58.0			58.9	0.36
CA 6	45.0	50.0			47.5	0.28
CA 7	77.4	73.8			75.5	0.47

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE WET ASHED: 2/28/83 DATE ANALYZED: 3/1/83
 FILE: A_A_F2 PATH: c:\data\volus2.3
 THALLIUM ANTIDOTE STUDY TISSUE TYPE: FECES
 WET ASH DATA WORKSHEET PB

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TAPE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TIC CONC ug T/g tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C) A - B	(D)	(E)	(F) D x E	(G)	F x G / C	
TA 1	30.9492	30.4501	0.4991	5.0	2	10	0.48	9.71	
TA 2	30.5125	30.0266	0.4859	5.0	2	10	0.42	8.78	
TA 3	30.3922	29.8583	0.5339	5.0	2	10	0.43	8.49	
TA 4	31.6609	31.1415	0.5194	5.0	2	10	0.30	5.74	
TA 5	30.8983	30.3868	0.5085	5.0	2	10	0.36	7.02	
TA 6	30.4818	29.9926	0.4892	5.0	2	10	0.35	7.25	
TA 7	31.0584	30.5573	0.5021	5.0	2	10	0.55	10.93	
TA 8	30.8007	30.2883	0.5124	5.0	2	10	0.36	6.86	
TA 9	30.9711	30.4606	0.4805	5.0	2	10	0.36	7.59	
TA 10	30.3185	29.7989	0.5205	5.0	2	10	0.36	6.94	
CA 1	31.1237	30.6307	0.4930	5.0	1	5	0.37	3.75	
CA 2	29.2159	28.7024	0.5132	5.0	1	5	0.27	2.69	
CA 3	30.8248	30.3110	0.5138	5.0	1	5	0.37	3.82	
CA 4	30.7167	30.2424	0.4743	5.0	1	5	0.36	4.01	
CA 5	30.9395	30.4459	0.4936	5.0	1	5	0.36	3.63	
CA 6	30.9021	30.4070	0.4951	5.0	1	5	0.26	2.60	
CA 7	30.9158	30.3885	0.5263	5.0	1	5	0.27	4.44	DIED DAY 4
MEAN			0.5016						

FILE A_B_F1

THALLIUM ANTIDOTE STUDY
PEAK HEIGHT WORKSHEET

DATE 3/2/93

SAMPLE: FECES

GROUPS: DMPS (TX & NO TX)

RUN 1 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	7.6					7.6
0.10	19.4					19.4
0.30	54.8					54.8
0.50	86.0					86.0
0.70	110.0					110.0
1.00	150.8	149.0				149.9

RUN 2 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	6.6					6.6
0.1	17.8					17.8
0.3	53.0					53.0
0.5	85.0					85.0
0.7	106.2					106.2
1.00	148.0	141.0				144.5

RUN 3 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.2					5.2
0.1	17.0					17.0
0.3	47.8					47.8
0.5	80.4					80.4
0.7	103.4					103.4
1.00	140.2	139.2				139.7

SAMPLE: FECES

GROUPS: DMPS (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	3.9	3.9	2.2
0.05	7.6	6.6	5.2	11.5	10.9	9.4
0.10	19.4	17.8	17.0	19.0	18.2	16.5
0.30	54.8	53.0	47.6	49.2	47.5	45.0
0.50	89.0	85.0	80.4	79.4	76.8	73.5
0.70	110.0	106.2	103.4	109.6	106.1	102.0
1.00	149.9	144.5	139.7	154.9	150.1	144.8

Regression Output: RUN 1
 Constant 3.9299148
 Std Err of Y Est 5.1041820
 R Squared 0.9932403
 No. of Observations 7
 Degrees of Freedom 5

X Coefficient(s) 151.01531
 Std Err of Coef. 5.5714885

Regression Output: RUN 3
 Constant 2.2259148
 Std Err of Y Est 4.5732652
 R Squared 0.9939044
 No. of Observations 7
 Degrees of Freedom 5

X Coefficient(s) 142.53531
 Std Err of Coef. 4.9919643

Regression Output: RUN 2
 Constant 3.5505108
 Std Err of Y Est 5.6451834
 R Squared 0.9912328
 No. of Observations 7
 Degrees of Freedom 5


X Coefficient(s) 146.50808
 Std Err of Coef. 6.1620205

Regression Output: 3 STD RUNS
 Constant 3.2384488
 Std Err of Y Est 5.1787206
 R Squared 0.9906819
 No. of Observations 21
 Degrees of Freedom 19

X Coefficient(s) 146.68624
 Std Err of Coef. 3.2636752

SAMP_E: FECES

GROUPS: DMPS (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TB 1	57.4	56.8			57.1	0.37
TB 2	59.8	57.8			58.8	0.38
TB 3	52.0	50.2			51.1	0.33
TB 4	58.8	58.0			58.4	0.36
TB 5	44.2	41.2			42.7	0.27
TB 6	64.4	58.8			61.6	0.40
TB 7	58.0	55.8			55.8	0.38
TB 8	48.8	44.0			46.4	0.29
TB 9	33.4	35.8			34.6	0.21
TB 10	34.8	32.2			33.5	0.21
CB 1	49.8	53.8			51.7	0.33
CB 2	68.8	71.2			68.9	0.45
CB 3	48.8	51.8			49.3	0.31
CB 4	70.8	72.0			71.3	0.46
CB 5	41.2	46.2			43.7	0.28
CB 6	73.2	72.8			72.9	0.47
CB 7	72.8	72.2			72.5	0.47

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y-INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE WET ASHED: 3/1/83

FILE: A_B_F2

THALLIUM ANTIDOTE STUDY
WET ASH DATA WORKSHEETTISSUE TYPE: FECES
DMPS

DATE ANALYZED: 3/2/83

PATH: c:\data\lotus2.3
a:\lotus

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TARE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBQ)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TICONC ug TVg tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C) A - B	(D)	(E)	(F) D x E	(G)	(H) F x G / C	
TB 1	56.9016	56.3912	0.5104	5.0	1	5	0.37	3.60	
TB 2	53.4687	52.9490	0.5207	5.0	1	5	0.38	3.64	
TB 3	61.8246	61.2946	0.5300	5.0	1	5	0.33	3.08	
TB 4	56.9327	56.4031	0.4996	5.0	1	5	0.36	3.66	
TB 5	61.6938	61.1783	0.4855	5.0	1	5	0.27	2.77	
TB 6	72.5951	72.1182	0.4769	5.0	1	5	0.40	4.17	
TB 7	76.2085	77.7101	0.4984	5.0	1	5	0.36	3.61	
TB 8	18.8499	18.3298	0.5173	5.0	1	5	0.29	2.84	
TB 9	79.0937	78.5997	0.4940	5.0	1	5	0.21	2.18	
TB 10	81.9514	81.4733	0.4781	5.0	1	5	0.21	2.18	
CB 1	72.1988	71.7151	0.4837	5.0	1	5	0.33	3.42	
CB 2	72.3596	71.8404	0.5182	5.0	1	5	0.45	4.32	
CB 3	76.2983	77.8069	0.4904	5.0	1	5	0.31	3.20	
CB 4	81.2981	80.7721	0.5170	5.0	1	5	0.46	4.49	
CB 5	76.3095	77.8289	0.4908	5.0	1	5	0.28	2.87	
CB 6	61.5370	60.9862	0.5478	5.0	1	5	0.47	4.33	
CB 7	79.3104	78.8065	0.5039	5.0	1	5	0.47	4.69	
MEAN			0.5012						DIED DAY 5

SAMPLE: FECES

GROUPS: PB + DMPS (TX & NO TX)

RUN 1 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	6.0					6.0
0.10	14.2					14.2
0.30	37.6					37.6
0.50	85.0					85.0
0.70	106.8					106.8
1.00	135.4	135.8				137.1

RUN 2 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	5.2					5.2
0.1	12.2					12.2
0.3	47.4					47.4
0.5	77.4					77.4
0.7	99.0					99.0
1.00	133.8	129.6				131.7

RUN 3 TI STDS (ppm)	PEAK HEIGHT DATA					AVERAGE PEAK HT
BLK	0					0.0
0.05	2.4					2.4
0.1	13.2					13.2
0.3	46.8					46.8
0.5	82.0					82.0
0.7	104.6					104.6
1.00	133.0	135.4				134.2

SAMPLE: FECES

GROUPS: PB + DMPS (TX & NO TX)

TI STDS	PEAK HEIGHTS			DATA POINTS FOR LINEAR REGRESSION LINE		
	RUN 1	RUN 2	RUN 3	RUN 1	RUN 2	RUN 3
0	0	0	0	0.7	1.7	1.1
0.05	6.0	5.2	2.4	7.9	8.6	8.2
0.10	14.2	12.2	13.2	15.1	15.4	15.3
0.30	37.6	47.4	46.8	43.9	42.6	43.6
0.50	85.0	77.4	82.0	72.7	69.8	71.9
0.70	106.8	99.0	104.6	101.6	97.0	100.3
1.00	157.1	131.7	134.2	144.8	137.9	142.7

Regression Output:

RUN 1

Constant 0.6782785
 Std Err of Y Est 7.5062847
 R Squared 0.9840685
 No. of Observations 7
 Degrees of Freedom 5

X Coefficient(s) 144.13021
 Std Err of Coef. 8.1834606

Regression Output:

RUN 3

Constant 1.1422978
 Std Err of Y Est 6.9865628
 R Squared 0.9857821
 No. of Observations 7
 Degrees of Freedom 5

X Coefficient(s) 141.58638
 Std Err of Coef. 7.6043770

Regression Output:

RUN 2

Constant 1.7460851
 Std Err of Y Est 5.4229028
 R Squared 0.9906310
 No. of Observations 7
 Degrees of Freedom 5

X Coefficient(s) 136.10468
 Std Err of Coef. 5.9193893

Regression Output:


3 STD RUNS
COMBINED

Constant 1.1892198
 Std Err of Y Est 6.1317310
 R Squared 0.9858522
 No. of Observations 21
 Degrees of Freedom 19

X Coefficient(s) 140.80709
 Std Err of Coef. 3.8042706

SAMPLE: FECES

GROUPS: PB + DMP6 (TX & NO TX)



SAMPLE ID	PEAK HEIGHT DATA				AVERAGE PEAK HT	SAMPLE TI CONC (ppm)
TC 1	102.2	101.0			101.6	0.71
TC 2	99.0	99.6			99.3	0.70
TC 3	84.2	83.2			83.7	0.59
TC 4	105.2	105.6			105.4	0.74
TC 5	124.2	126.2			125.2	0.89
TC 6	126.0	124.4			125.2	0.88
TC 7	107.8	106.2			106.9	0.75
TC 8	95.0	94.4			94.7	0.67
TC 9	95.2	97.0			96.1	0.68
TC 10	95.6	90.8			93.7	0.66
CC 1	49.6	48.8			49.2	0.34
CC 2	45.4	43.8			44.6	0.31
CC 3	45.0	45.0			45.0	0.31
CC 4	72.0	71.4			71.7	0.50
CC 5	69.2	66.2			67.7	0.47
CC 6	48.2	44.0			46.1	0.32
CC 7	50.6	50.4			50.5	0.35

$$TI\ CONC = (y - b) / m$$

WHERE y = AVERAGE PEAK HEIGHT
 b = y - INTERCEPT, COMBINED RUNS
 m = SLOPE, COMBINED RUNS

DATE WET ASHED: 3/2/83

FILE: A_C_F2

THALLIUM ANTIDOTE STUDY
WET ASH DATA WORKSHEET

DATE ANALYZED: 3/3/83

PATH: c:\data\ltdat2.3
a:\ltdatTISSUE TYPE: FECES
PB + DMPs

SAMPLE	BEAKER+ SAMPLE WT (g)	BEAKER TARE WT (g)	NET WT SAMPLE (g)	DILUTION FACTOR (sample extracted into 5 ml MIBK)	ADDITIONAL DILUTION FACTOR (to put sample in linear range of cal curve)	TOTAL DILUTION FACTOR	SAMPLE CONC (ppm)	TI CONC ug TI/g tissue (wet wt)	COMMENTS
FORMULA	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H) $F \times G / C$	
TC 1	60.9017	60.4110	0.4907	5.0	1	5	0.71	7.28	
TC 2	49.5101	49.0231	0.4870	5.0	1	5	0.70	7.16	
TC 3	63.1214	62.6197	0.5017	5.0	1	5	0.59	5.65	
TC 4	62.4931	61.9942	0.5089	5.0	1	5	0.74	7.28	
TC 5	57.0624	56.5642	0.4982	5.0	1	5	0.86	9.11	
TC 6	60.5919	60.0879	0.5040	5.0	1	5	0.86	8.75	
TC 7	61.9792	61.4690	0.4902	5.0	1	5	0.75	7.67	
TC 8	50.5299	50.0128	0.5161	5.0	1	5	0.67	6.44	
TC 9	63.2488	62.7455	0.5033	5.0	1	5	0.88	8.69	
TC 10	59.3072	58.8266	0.4786	5.0	1	5	0.69	6.87	
CC 1	60.6436	60.1374	0.5062	5.0	1	5	0.34	3.37	
CC 2	49.2093	48.6773	0.5320	5.0	1	5	0.31	2.90	
CC 3	49.8745	49.4833	0.4912	5.0	1	5	0.31	3.17	
CC 4	60.2762	59.7826	0.4936	5.0	1	5	0.50	5.09	
CC 5	62.1355	61.6136	0.5218	5.0	1	5	0.47	4.53	DIED DAY 5
CC 6	61.9967	61.4760	0.5107	5.0	1	5	0.32	3.13	DIED DAY 4
CC 7	62.5014	61.9833	0.5181	5.0	1	5	0.35	3.38	
MEAN			0.5025						